<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S0223523419305197</prism:url><dc:identifier>doi:10.1016/j.ejmech.2019.06.002</dc:identifier><eid>1-s2.0-S0223523419305197</eid><prism:doi>10.1016/j.ejmech.2019.06.002</prism:doi><pii>S0223-5234(19)30519-7</pii><dc:title>Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade </dc:title><prism:publicationName>European Journal of Medicinal Chemistry</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>02235234</prism:issn><prism:volume>178</prism:volume><prism:startingPage>468</prism:startingpage><prism:endingPage>483</prism:endingpage><prism:pageRange>468-483</prism:pagerange><dc:format>text/xml</dc:format><prism:coverDate>2019-09-15</prism:coverdate><prism:coverDisplayDate>15 September 2019</prism:coverdisplaydate><prism:copyright>© 2019 Elsevier Masson SAS. All rights reserved.</prism:copyright><prism:publisher>Elsevier Masson SAS.</prism:publisher><dc:creator>Yuan, Ting</dc:creator><dc:creator>Qi, Baowen</dc:creator><dc:creator>Jiang, Zhongliang</dc:creator><dc:creator>Dong, Wenjuan</dc:creator><dc:creator>Zhong, Lei</dc:creator><dc:creator>Bai, Lan</dc:creator><dc:creator>Tong, Rongsheng</dc:creator><dc:creator>Yu, Jiying</dc:creator><dc:creator>Shi, Jianyou</dc:creator><dc:description>
                  Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells. Although the pathogenesis has not been fully elucidated, many specific gene mutations have been found in AML. Fms-like tyrosine kinase 3 (FLT3) is recognized as a drug target for the treatment of AML, and the activation mutations of FLT3 were found in about 30% of AML patients. Targeted inhibition of FLT3 receptor tyrosine kinase has shown promising results in the treatment of FLT3 mutation AML. Unfortunately, the therapeutic effects of FLT3 tyrosine kinase inhibitors used as AML monotherapy are usually accompanied by the high risk of resistance development within a few months after treatment. FLT3 dual inhibitors were generated with the co-inhibition of FLT3 and another target, such as CDK4, JAK2, MEK, Mer, Pim, etc., to solve the problems mentioned above. As a result, the therapeutic effect of the drug is significantly improved, while the toxic and side effects are reduced. Besides, the life quality of AML patients with FLT3 mutation has been effectively improved. In this paper, we reviewed the studies of dual FLT3 inhibitors that have been discovered in recent years for the treatment of AML.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><dcterms:subject>FLT3</dcterms:subject><dcterms:subject>Dual inhibitors</dcterms:subject><dcterms:subject>Acute myeloid leukemia</dcterms:subject><dcterms:subject>Drug resistance</dcterms:subject><link href="https://api.elsevier.com/content/article/pii/S0223523419305197" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S0223523419305197" rel="scidir"/></link></coredata><objects><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="148" size="22430">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2a" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="101" height="164" size="10425">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2a.sml?httpAccept=%2A%2F%2A</object><object ref="fx1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="155" height="164" size="19245">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-fx1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2b" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="100" height="164" size="9624">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2b.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="669" height="451" size="119317">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2a" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="866" size="90191">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2a.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="232" height="245" size="39947">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-fx1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2b" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="533" height="874" size="82344">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2b.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2961" height="1995" size="781946">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2a" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="3838" size="574232">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2a_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="fx1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1027" height="1085" size="197335">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-fx1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2b" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2362" height="3872" size="522513">https://api.elsevier.com/content/object/eid/1-s2.0-S0223523419305197-gr2b_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85067181890</scopus-id><scopus-eid>2-s2.0-85067181890</scopus-eid><pubmed-id>31207462</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85067181890" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271932</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291732</xocs:ssid>
         <xocs:ssid type="subj">291789</xocs:ssid>
         <xocs:ssid type="subj">291858</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>European Journal of Medicinal Chemistry</xocs:srctitle>
      <xocs:normalized-srctitle>EUROPEANJOURNALMEDICINALCHEMISTRY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20190605">2019-06-05</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20190605">2019-06-05</xocs:available-online-date>
      <xocs:vor-load-date yyyymmdd="20190614">2019-06-14</xocs:vor-load-date>
      <xocs:vor-available-online-date yyyymmdd="20190614">2019-06-14</xocs:vor-available-online-date>
      <xocs:ew-transaction-id>2019-07-31T04:44:58</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S0223523419305197</xocs:eid>
      <xocs:pii-formatted>S0223-5234(19)30519-7</xocs:pii-formatted>
      <xocs:pii-unformatted>S0223523419305197</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.ejmech.2019.06.002</xocs:doi>
      <xocs:item-stage>S300</xocs:item-stage>
      <xocs:item-version-number>S300.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:hub-eid>1-s2.0-S0223523419X0015X</xocs:hub-eid>
      <xocs:timestamp yyyymmdd="20190731">2019-07-31T05:21:38.697631Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20190915</xocs:date-search-begin>
      <xocs:year-nav>2019</xocs:year-nav>
      <xocs:indexeddate epoch="1559702196">2019-06-05T02:36:36.00581Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid hubeid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pg pgfirst pglast pii piinorm pubdatestart pubdatetxt pubyr sectiontitle sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings suppl tomb volfirst volissue volumelist webpdf webpdfpagecount yearnav figure table body acknowledge affil articletitle auth authfirstini authfull authkeywords authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>0223-5234</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>02235234</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="1">true</xocs:crossmark>
      <xocs:vol-first>178</xocs:vol-first>
      <xocs:volume-list>
         <xocs:volume>178</xocs:volume>
      </xocs:volume-list>
      <xocs:suppl>C</xocs:suppl>
      <xocs:vol-iss-suppl-text>Volume 178</xocs:vol-iss-suppl-text>
      <xocs:sort-order>6</xocs:sort-order>
      <xocs:first-fp>468</xocs:first-fp>
      <xocs:last-lp>483</xocs:last-lp>
      <xocs:pages>
         <xocs:first-page>468</xocs:first-page>
         <xocs:last-page>483</xocs:last-page>
      </xocs:pages>
      <xocs:cover-date-orig>
         <xocs:start-date>20190915</xocs:start-date>
      </xocs:cover-date-orig>
      <xocs:cover-date-text>15 September 2019</xocs:cover-date-text>
      <xocs:cover-date-start>2019-09-15</xocs:cover-date-start>
      <xocs:cover-date-year>2019</xocs:cover-date-year>
      <xocs:hub-sec>
         <xocs:hub-sec-title>Review articles</xocs:hub-sec-title>
      </xocs:hub-sec>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>© 2019 Elsevier Masson SAS. All rights reserved.</xocs:copyright-line>
      <xocs:normalized-article-title>DUALFLT3INHIBITORSAGAINSTDRUGRESISTANCEACUTEMYELOIDLEUKEMIAINRECENTDECADE</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>YUAN</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>T</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>1</xocs:item-toc-label>
            <xocs:item-toc-section-title>Introduction</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>2</xocs:item-toc-label>
            <xocs:item-toc-section-title>Dual inhibitors of FLT3</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.1</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/CDK4 dual Inhibitor:AMG 925 (FLX 925) (1)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.2</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/JAK2 dual inhibitor: pacritinib (SB1518) (3)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.3</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/MEK dual inhibitor: E6201 (4)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.4</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/Pim dual Inhibitor:SGI-1776 (6), SEL24-B489 (7) and EC-70124 (8)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.5</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/SYK dual Inhibitor:TAK-659 (9) and Midostaurin (PKC412) (10)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.6</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/Mer dual Inhibitor:UNC2025 (11)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.7</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/fes dual Inhibitor:TAE-684 (14), WZ4-49-1(15) and HG7-92-01 (16)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.8</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/AKT dual Inhibitor:A674563 (17)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.9</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/PDGFR dual Inhibitor:Crenolanib (CP-868–596) (18) and tandutinib (19)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.10</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/AXL dual Inhibitor:Gilteritinib (ASP2215) (20)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.11</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/Mnk2 dual inhibitor: N-phenylpyrimidin-2-amine derivative (21)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.12</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/Auroral B dual inhibitor: Acylureidoindolin-2-one derivative (22), CCT137690 (23) and CCT241736 (24)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.13</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/TOPK dual inhibitor: HSD1169 (25)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-label>2.14</xocs:item-toc-label>
               <xocs:item-toc-section-title>FLT3/IKK2 dual inhibitor: AS602868 (26)</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-label>3</xocs:item-toc-label>
            <xocs:item-toc-section-title>Perspective</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgements</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="sref1">
            <xocs:ref-normalized-surname>KHWAJA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>16010</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref2">
            <xocs:ref-normalized-surname>SMALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>178</xocs:ref-first-fp>
            <xocs:ref-last-lp>184</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref3">
            <xocs:ref-normalized-surname>GILLILAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>274</xocs:ref-first-fp>
            <xocs:ref-last-lp>281</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref4">
            <xocs:ref-normalized-surname>DU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1996</xocs:ref-pub-year>
            <xocs:ref-first-fp>261</xocs:ref-first-fp>
            <xocs:ref-last-lp>270</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sref5">
            <xocs:ref-normalized-surname>KADIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>770</xocs:ref-first-fp>
            <xocs:ref-last-lp>778</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref6">
            <xocs:ref-normalized-surname>KAYSER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>243</xocs:ref-first-fp>
            <xocs:ref-last-lp>255</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref7">
            <xocs:ref-normalized-surname>GILLILAND</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>1532</xocs:ref-first-fp>
            <xocs:ref-last-lp>1542</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref8">
            <xocs:ref-normalized-surname>MARCUCCI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>475</xocs:ref-first-fp>
            <xocs:ref-last-lp>486</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref9">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>184</xocs:ref-first-fp>
            <xocs:ref-last-lp>198</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref10">
            <xocs:ref-normalized-surname>OFARRELL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3597</xocs:ref-first-fp>
            <xocs:ref-last-lp>3605</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref11">
            <xocs:ref-normalized-surname>LOPESDEMENEZES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>5281</xocs:ref-first-fp>
            <xocs:ref-last-lp>5291</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref12">
            <xocs:ref-normalized-surname>SMITH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>3669</xocs:ref-first-fp>
            <xocs:ref-last-lp>3676</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref13">
            <xocs:ref-normalized-surname>WANDER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>65</xocs:ref-first-fp>
            <xocs:ref-last-lp>77</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref14">
            <xocs:ref-normalized-surname>ROLLIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref15">
            <xocs:ref-normalized-surname>KINDLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5089</xocs:ref-first-fp>
            <xocs:ref-last-lp>5102</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref16">
            <xocs:ref-normalized-surname>GRUNWALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>683</xocs:ref-first-fp>
            <xocs:ref-last-lp>694</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref17">
            <xocs:ref-normalized-surname>ELLIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>7471</xocs:ref-first-fp>
            <xocs:ref-last-lp>7478</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref18">
            <xocs:ref-normalized-surname>WOODCOCK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>985</xocs:ref-first-fp>
            <xocs:ref-last-lp>987</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref19">
            <xocs:ref-normalized-surname>JIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>111</xocs:ref-first-fp>
            <xocs:ref-last-lp>128</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref20">
            <xocs:ref-normalized-surname>BAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>658</xocs:ref-first-fp>
            <xocs:ref-last-lp>669</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref21">
            <xocs:ref-normalized-surname>KEEGAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>880</xocs:ref-first-fp>
            <xocs:ref-last-lp>889</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref22">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2075</xocs:ref-first-fp>
            <xocs:ref-last-lp>2083</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref23">
            <xocs:ref-normalized-surname>DREXLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>845</xocs:ref-first-fp>
            <xocs:ref-last-lp>859</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref24">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>3430</xocs:ref-first-fp>
            <xocs:ref-last-lp>3449</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref25">
            <xocs:ref-normalized-surname>PRATZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1425</xocs:ref-first-fp>
            <xocs:ref-last-lp>1432</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref26">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>375</xocs:ref-first-fp>
            <xocs:ref-last-lp>383</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref27">
            <xocs:ref-normalized-surname>FINN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>43</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref28">
            <xocs:ref-normalized-surname>RAWLINGS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1281</xocs:ref-first-fp>
            <xocs:ref-last-lp>1283</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref29">
            <xocs:ref-normalized-surname>BENNETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>41</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref30">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4052</xocs:ref-first-fp>
            <xocs:ref-last-lp>4062</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref31">
            <xocs:ref-normalized-surname>IKEZOE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>2512</xocs:ref-first-fp>
            <xocs:ref-last-lp>2521</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref32">
            <xocs:ref-normalized-surname>HART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>1751</xocs:ref-first-fp>
            <xocs:ref-last-lp>1759</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref33">
            <xocs:ref-normalized-surname>HART</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>e44</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref34">
            <xocs:ref-normalized-surname>LOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>212</xocs:ref-first-fp>
            <xocs:ref-last-lp>213</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref35">
            <xocs:ref-normalized-surname>VERSTOVSEK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>137</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref36">
            <xocs:ref-normalized-surname>LEE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>354</xocs:ref-first-fp>
            <xocs:ref-last-lp>372</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref37">
            <xocs:ref-normalized-surname>MCCUBREY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1068</xocs:ref-first-fp>
            <xocs:ref-last-lp>1111</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref38">
            <xocs:ref-normalized-surname>BORTHAKUR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>62</xocs:ref-first-fp>
            <xocs:ref-last-lp>68</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref39">
            <xocs:ref-normalized-surname>KONOPLEVA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>103</xocs:ref-first-fp>
            <xocs:ref-last-lp>113</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref40">
            <xocs:ref-normalized-surname>LEUENROTH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>171</xocs:ref-first-fp>
            <xocs:ref-last-lp>177</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref41">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>2363</xocs:ref-first-fp>
            <xocs:ref-last-lp>2374</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref42">
            <xocs:ref-normalized-surname>IKEMORIKAWADA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2059</xocs:ref-first-fp>
            <xocs:ref-last-lp>2068</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref43">
            <xocs:ref-normalized-surname>SHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>3155</xocs:ref-first-fp>
            <xocs:ref-last-lp>3157</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref44">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>1528</xocs:ref-first-fp>
            <xocs:ref-last-lp>1537</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref45">
            <xocs:ref-normalized-surname>BRAULT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1004</xocs:ref-first-fp>
            <xocs:ref-last-lp>1015</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref46">
            <xocs:ref-normalized-surname>NAWIJN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>23</xocs:ref-first-fp>
            <xocs:ref-last-lp>34</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref47">
            <xocs:ref-normalized-surname>LILLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>4022</xocs:ref-first-fp>
            <xocs:ref-last-lp>4031</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref48">
            <xocs:ref-normalized-surname>MIZUKI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>3164</xocs:ref-first-fp>
            <xocs:ref-last-lp>3173</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref49">
            <xocs:ref-normalized-surname>GREEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-article-number>e1500221</xocs:ref-article-number>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref50">
            <xocs:ref-normalized-surname>XIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>942</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref51">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>4150</xocs:ref-first-fp>
            <xocs:ref-last-lp>4157</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref52">
            <xocs:ref-normalized-surname>KAUFMANN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>991</xocs:ref-first-fp>
            <xocs:ref-last-lp>1000</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref53">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>693</xocs:ref-first-fp>
            <xocs:ref-last-lp>702</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref54">
            <xocs:ref-normalized-surname>CZARDYBON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>16917</xocs:ref-first-fp>
            <xocs:ref-last-lp>16931</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref55">
            <xocs:ref-normalized-surname>PUENTEMONCADA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>614</xocs:ref-first-fp>
            <xocs:ref-last-lp>624</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref56">
            <xocs:ref-normalized-surname>BU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>5106</xocs:ref-first-fp>
            <xocs:ref-last-lp>5110</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref57">
            <xocs:ref-normalized-surname>CORNALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1713</xocs:ref-first-fp>
            <xocs:ref-last-lp>1718</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref58">
            <xocs:ref-normalized-surname>TURNER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>298</xocs:ref-first-fp>
            <xocs:ref-last-lp>302</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref59">
            <xocs:ref-normalized-surname>CHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1995</xocs:ref-pub-year>
            <xocs:ref-first-fp>303</xocs:ref-first-fp>
            <xocs:ref-last-lp>306</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref60">
            <xocs:ref-normalized-surname>PUISSANT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>226</xocs:ref-first-fp>
            <xocs:ref-last-lp>242</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref61">
            <xocs:ref-normalized-surname>WEISBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>52026</xocs:ref-first-fp>
            <xocs:ref-last-lp>52044</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref62">
            <xocs:ref-normalized-surname>LAM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>5947</xocs:ref-first-fp>
            <xocs:ref-last-lp>5950</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref63">
            <xocs:ref-normalized-surname>WEISBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>433</xocs:ref-first-fp>
            <xocs:ref-last-lp>443</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref64">
            <xocs:ref-normalized-surname>FISCHER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>4339</xocs:ref-first-fp>
            <xocs:ref-last-lp>4345</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref65">
            <xocs:ref-normalized-surname>SCHLENK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>840</xocs:ref-first-fp>
            <xocs:ref-last-lp>851</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref66">
            <xocs:ref-normalized-surname>COOPER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>428</xocs:ref-first-fp>
            <xocs:ref-last-lp>432</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref67">
            <xocs:ref-normalized-surname>STRATI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>276</xocs:ref-first-fp>
            <xocs:ref-last-lp>281</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref68">
            <xocs:ref-normalized-surname>STONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>454</xocs:ref-first-fp>
            <xocs:ref-last-lp>464</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref69">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1997</xocs:ref-pub-year>
            <xocs:ref-first-fp>2033</xocs:ref-first-fp>
            <xocs:ref-last-lp>2039</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref70">
            <xocs:ref-normalized-surname>LINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1599</xocs:ref-first-fp>
            <xocs:ref-last-lp>1609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref71">
            <xocs:ref-normalized-surname>LEESHERICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>5359</xocs:ref-first-fp>
            <xocs:ref-last-lp>5368</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref72">
            <xocs:ref-normalized-surname>LEESHERICK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>6722</xocs:ref-first-fp>
            <xocs:ref-last-lp>6736</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref73">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>7031</xocs:ref-first-fp>
            <xocs:ref-last-lp>7041</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref74">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>129</xocs:ref-first-fp>
            <xocs:ref-last-lp>134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref75">
            <xocs:ref-normalized-surname>LIU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>83</xocs:ref-first-fp>
            <xocs:ref-last-lp>93</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref76">
            <xocs:ref-normalized-surname>WENGLOWSKY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>912</xocs:ref-first-fp>
            <xocs:ref-last-lp>915</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref77">
            <xocs:ref-normalized-surname>GP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>278</xocs:ref-first-fp>
            <xocs:ref-last-lp>289</xocs:ref-last-lp>
         </xocs:ref-info>
         <xocs:ref-info refid="sref78">
            <xocs:ref-normalized-surname>GREER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>489</xocs:ref-first-fp>
            <xocs:ref-last-lp>501</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref79">
            <xocs:ref-normalized-surname>HELLWIG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3146</xocs:ref-first-fp>
            <xocs:ref-last-lp>3155</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref80">
            <xocs:ref-normalized-surname>SMITHGALL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1998</xocs:ref-pub-year>
            <xocs:ref-first-fp>43</xocs:ref-first-fp>
            <xocs:ref-last-lp>62</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref81">
            <xocs:ref-normalized-surname>VOISSET</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>721</xocs:ref-first-fp>
            <xocs:ref-last-lp>728</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref82">
            <xocs:ref-normalized-surname>WEIR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-article-number>e0181178</xocs:ref-article-number>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref83">
            <xocs:ref-normalized-surname>SAGATYS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1526</xocs:ref-first-fp>
            <xocs:ref-last-lp>1531</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref84">
            <xocs:ref-normalized-surname>ENGELMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>606</xocs:ref-first-fp>
            <xocs:ref-last-lp>619</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref85">
            <xocs:ref-normalized-surname>SATO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>3286</xocs:ref-first-fp>
            <xocs:ref-last-lp>3293</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref86">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>S57</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref87">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>29131</xocs:ref-first-fp>
            <xocs:ref-last-lp>29142</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref88">
            <xocs:ref-normalized-surname>DEKEERSMAECKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>200</xocs:ref-first-fp>
            <xocs:ref-last-lp>205</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref89">
            <xocs:ref-normalized-surname>MAHBOOBI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>2187</xocs:ref-first-fp>
            <xocs:ref-last-lp>2197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref90">
            <xocs:ref-normalized-surname>HEINRICH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>4375</xocs:ref-first-fp>
            <xocs:ref-last-lp>4384</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref91">
            <xocs:ref-normalized-surname>LEWIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>5262</xocs:ref-first-fp>
            <xocs:ref-last-lp>5269</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref92">
            <xocs:ref-normalized-surname>SMITH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>5319</xocs:ref-first-fp>
            <xocs:ref-last-lp>5324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref93">
            <xocs:ref-normalized-surname>WEISBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5120</xocs:ref-first-fp>
            <xocs:ref-last-lp>5134</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref94">
            <xocs:ref-normalized-surname>KELLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2002</xocs:ref-pub-year>
            <xocs:ref-first-fp>421</xocs:ref-first-fp>
            <xocs:ref-last-lp>432</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref95">
            <xocs:ref-normalized-surname>DEANGELO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>3674</xocs:ref-first-fp>
            <xocs:ref-last-lp>3681</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref96">
            <xocs:ref-normalized-surname>SCHITTENHELM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>2621</xocs:ref-first-fp>
            <xocs:ref-last-lp>2630</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref97">
            <xocs:ref-normalized-surname>LINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>35</xocs:ref-first-fp>
            <xocs:ref-last-lp>83</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref98">
            <xocs:ref-normalized-surname>BENBATALLA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2443</xocs:ref-first-fp>
            <xocs:ref-last-lp>2452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref99">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>2064</xocs:ref-first-fp>
            <xocs:ref-last-lp>2073</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>I</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref100">
            <xocs:ref-normalized-surname>PERL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1061</xocs:ref-first-fp>
            <xocs:ref-last-lp>1075</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref101">
            <xocs:ref-normalized-surname>JANNING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>135</xocs:ref-first-fp>
            <xocs:ref-last-lp>138</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref102">
            <xocs:ref-normalized-surname>HONG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>314</xocs:ref-first-fp>
            <xocs:ref-last-lp>324</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref103">
            <xocs:ref-normalized-surname>MORI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>556</xocs:ref-first-fp>
            <xocs:ref-last-lp>565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref104">
            <xocs:ref-normalized-surname>MGORCEA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
            <xocs:ref-normalized-srctitle>ASP2215INTREATMENTRELAPSEDREFRACTORYACUTEMYELOIDLEUKEMIAFLT3MUTATIONBACKGROUNDDESIGNADMIRALTRIAL</xocs:ref-normalized-srctitle>
         </xocs:ref-info>
         <xocs:ref-info refid="sref105">
            <xocs:ref-normalized-surname>NAKAKURA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>1085</xocs:ref-first-fp>
            <xocs:ref-last-lp>1098</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref106">
            <xocs:ref-normalized-surname>ALTMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>510</xocs:ref-first-fp>
            <xocs:ref-last-lp>517</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref107">
            <xocs:ref-normalized-surname>DIAB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>441</xocs:ref-first-fp>
            <xocs:ref-last-lp>452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref108">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>56811</xocs:ref-first-fp>
            <xocs:ref-last-lp>56825</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref109">
            <xocs:ref-normalized-surname>TEO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>380</xocs:ref-first-fp>
            <xocs:ref-last-lp>389</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref110">
            <xocs:ref-normalized-surname>DIAB</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>762</xocs:ref-first-fp>
            <xocs:ref-last-lp>772</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref111">
            <xocs:ref-normalized-surname>CARMENA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>842</xocs:ref-first-fp>
            <xocs:ref-last-lp>854</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref112">
            <xocs:ref-normalized-surname>FU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>10</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref113">
            <xocs:ref-normalized-surname>JENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2065</xocs:ref-first-fp>
            <xocs:ref-last-lp>2071</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref114">
            <xocs:ref-normalized-surname>VISCHIONI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>2905</xocs:ref-first-fp>
            <xocs:ref-last-lp>2913</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref115">
            <xocs:ref-normalized-surname>NADLER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>4455</xocs:ref-first-fp>
            <xocs:ref-last-lp>4462</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref116">
            <xocs:ref-normalized-surname>IKEZOE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1851</xocs:ref-first-fp>
            <xocs:ref-last-lp>1857</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref117">
            <xocs:ref-normalized-surname>DAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>268</xocs:ref-first-fp>
            <xocs:ref-last-lp>278</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref118">
            <xocs:ref-normalized-surname>LOWENBERG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>6030</xocs:ref-first-fp>
            <xocs:ref-last-lp>6036</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref119">
            <xocs:ref-normalized-surname>ESTEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>1908</xocs:ref-first-fp>
            <xocs:ref-last-lp>1915</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref120">
            <xocs:ref-normalized-surname>BAVETSIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>8721</xocs:ref-first-fp>
            <xocs:ref-last-lp>8734</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref121">
            <xocs:ref-normalized-surname>JAGTAP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>268</xocs:ref-first-fp>
            <xocs:ref-last-lp>288</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref122">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>498</xocs:ref-first-fp>
            <xocs:ref-last-lp>511</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref123">
            <xocs:ref-normalized-surname>OTTONE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>533</xocs:ref-first-fp>
            <xocs:ref-last-lp>540</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref124">
            <xocs:ref-normalized-surname>MOORE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>1462</xocs:ref-first-fp>
            <xocs:ref-last-lp>1470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref125">
            <xocs:ref-normalized-surname>BAVETSIAS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>5213</xocs:ref-first-fp>
            <xocs:ref-last-lp>5228</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref126">
            <xocs:ref-normalized-surname>ABE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>21525</xocs:ref-first-fp>
            <xocs:ref-last-lp>21531</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref127">
            <xocs:ref-normalized-surname>WU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>6461</xocs:ref-first-fp>
            <xocs:ref-last-lp>6468</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref128">
            <xocs:ref-normalized-surname>AYLLON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>3451</xocs:ref-first-fp>
            <xocs:ref-last-lp>3461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref129">
            <xocs:ref-normalized-surname>PARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>9186</xocs:ref-first-fp>
            <xocs:ref-last-lp>9195</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref130">
            <xocs:ref-normalized-surname>BROWNCLAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>15594</xocs:ref-first-fp>
            <xocs:ref-last-lp>15609</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref131">
            <xocs:ref-normalized-surname>JOEL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>121</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref132">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>219</xocs:ref-first-fp>
            <xocs:ref-last-lp>231</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref133">
            <xocs:ref-normalized-surname>AKSAMITIENE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>1369</xocs:ref-first-fp>
            <xocs:ref-last-lp>1378</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref134">
            <xocs:ref-normalized-surname>NANDI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>240</xocs:ref-first-fp>
            <xocs:ref-last-lp>245</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref135">
            <xocs:ref-normalized-surname>ALACHKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>33410</xocs:ref-first-fp>
            <xocs:ref-last-lp>33425</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref136">
            <xocs:ref-normalized-surname>MATSUO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref137">
            <xocs:ref-normalized-surname>DAYAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>823</xocs:ref-first-fp>
            <xocs:ref-last-lp>835</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>N</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref138">
            <xocs:ref-normalized-surname>KARIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>17</xocs:ref-first-fp>
            <xocs:ref-last-lp>26</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref139">
            <xocs:ref-normalized-surname>HAYDEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>2195</xocs:ref-first-fp>
            <xocs:ref-last-lp>2224</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref140">
            <xocs:ref-normalized-surname>SCHMID</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>157</xocs:ref-first-fp>
            <xocs:ref-last-lp>165</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref141">
            <xocs:ref-normalized-surname>METTANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1916</xocs:ref-first-fp>
            <xocs:ref-last-lp>1932</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref142">
            <xocs:ref-normalized-surname>HAYDEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>203</xocs:ref-first-fp>
            <xocs:ref-last-lp>234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref143">
            <xocs:ref-normalized-surname>OECKINGHAUS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>695</xocs:ref-first-fp>
            <xocs:ref-last-lp>708</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref144">
            <xocs:ref-normalized-surname>BIRKENKAMP</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>103</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref145">
            <xocs:ref-normalized-surname>GUZMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2001</xocs:ref-pub-year>
            <xocs:ref-first-fp>2301</xocs:ref-first-fp>
            <xocs:ref-last-lp>2307</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref146">
            <xocs:ref-normalized-surname>GRIESSINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2007</xocs:ref-pub-year>
            <xocs:ref-first-fp>877</xocs:ref-first-fp>
            <xocs:ref-last-lp>885</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref147">
            <xocs:ref-normalized-surname>FRELIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>8187</xocs:ref-first-fp>
            <xocs:ref-last-lp>8194</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref148">
            <xocs:ref-normalized-surname>CHENG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2000</xocs:ref-pub-year>
            <xocs:ref-first-fp>4936</xocs:ref-first-fp>
            <xocs:ref-last-lp>4940</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="sref149">
            <xocs:ref-normalized-surname>GRIESSINGER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>1466</xocs:ref-first-fp>
            <xocs:ref-last-lp>1469</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys>
         <xocs:refkey3>YUANX2019X468</xocs:refkey3>
         <xocs:refkey4lp>YUANX2019X468X483</xocs:refkey4lp>
         <xocs:refkey4ai>YUANX2019X468XT</xocs:refkey4ai>
         <xocs:refkey5>YUANX2019X468X483XT</xocs:refkey5>
      </xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:open-research>
         <xocs:or-embargo-opening-date>2021-06-14T00:00:00.000Z</xocs:or-embargo-opening-date>
      </xocs:open-research>
      <xocs:self-archiving>
         <xocs:sa-start-date>2021-06-14T00:00:00.000Z</xocs:sa-start-date>
         <xocs:sa-user-license>http://creativecommons.org/licenses/by-nc-nd/4.0/</xocs:sa-user-license>
      </xocs:self-archiving>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">© 2019 Elsevier Masson SAS. All rights reserved.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2019-06-05T10:09:20.179Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/eoas</xocs:funding-addon-type>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S0223-5234(19)30519-7</xocs:pii-formatted>
         <xocs:pii-unformatted>S0223523419305197</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S0223523419305197</xocs:eid>
         <xocs:doi>10.1016/j.ejmech.2019.06.002</xocs:doi>
         <xocs:cid>271932</xocs:cid>
         <xocs:timestamp>2019-07-31T05:21:38.697631Z</xocs:timestamp>
         <xocs:cover-date-start>2019-09-15</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/MAIN/application/pdf/0f94389b7d8ed24d4cacb712c3d7a6d8/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1509741</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>16</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S0223523419305197-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/PREVIEW/image/png/4e2643a44b148326502792b00e299e0f/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>45177</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr1/THUMBNAIL/image/gif/e730f43ad1ac9af5725e348e9427d60f/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>22430</xocs:filesize>
               <xocs:pixel-height>148</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2a.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2a/THUMBNAIL/image/gif/17e7d50060ea1b6632dd75011f7e70b7/gr2a.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2a</xocs:file-basename>
               <xocs:filename>gr2a.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10425</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>101</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-fx1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/fx1/THUMBNAIL/image/gif/be88de2efbbe4756848b3ba717401210/fx1.sml</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>19245</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>155</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2b.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2b/THUMBNAIL/image/gif/64b91f1ad69d0b3c150d69cbfcf238b3/gr2b.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2b</xocs:file-basename>
               <xocs:filename>gr2b.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>9624</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>100</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr1/DOWNSAMPLED/image/jpeg/42f44d99578e10e75c0eaefe0a382fde/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>119317</xocs:filesize>
               <xocs:pixel-height>451</xocs:pixel-height>
               <xocs:pixel-width>669</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2a.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2a/DOWNSAMPLED/image/jpeg/bd735a99bc2078679502aa1dc95c7147/gr2a.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2a</xocs:file-basename>
               <xocs:filename>gr2a.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>90191</xocs:filesize>
               <xocs:pixel-height>866</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-fx1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/fx1/DOWNSAMPLED/image/jpeg/740780d0c7491b096e928c0d96937440/fx1.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>39947</xocs:filesize>
               <xocs:pixel-height>245</xocs:pixel-height>
               <xocs:pixel-width>232</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2b.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2b/DOWNSAMPLED/image/jpeg/68cfc59f5882fcdd1d5af29716a6ed34/gr2b.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2b</xocs:file-basename>
               <xocs:filename>gr2b.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>82344</xocs:filesize>
               <xocs:pixel-height>874</xocs:pixel-height>
               <xocs:pixel-width>533</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr1/HIGHRES/image/jpeg/8ab9be1464d7b8e6f8875eed1f1e0339/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>781946</xocs:filesize>
               <xocs:pixel-height>1995</xocs:pixel-height>
               <xocs:pixel-width>2961</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2a_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2a/HIGHRES/image/jpeg/1e83b0a4cac495ba184c8498b025ced4/gr2a_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2a</xocs:file-basename>
               <xocs:filename>gr2a_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>574232</xocs:filesize>
               <xocs:pixel-height>3838</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-fx1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/fx1/HIGHRES/image/jpeg/f7f3cdfe237f53fa5ef1c4a9c5912942/fx1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>fx1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>fx1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>197335</xocs:filesize>
               <xocs:pixel-height>1085</xocs:pixel-height>
               <xocs:pixel-width>1027</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S0223523419305197-gr2b_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3.amazonaws.com/prod-ucs-content-store-us-east/content/pii:S0223523419305197/gr2b/HIGHRES/image/jpeg/029182ffeb79cfa90412aebec476b888/gr2b_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2b</xocs:file-basename>
               <xocs:filename>gr2b_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>522513</xocs:filesize>
               <xocs:pixel-height>3872</xocs:pixel-height>
               <xocs:pixel-width>2362</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>EJMECH</jid>
            <aid>11405</aid>
            <ce:pii>S0223-5234(19)30519-7</ce:pii>
            <ce:doi>10.1016/j.ejmech.2019.06.002</ce:doi>
            <ce:copyright type="full-transfer" year="2019">Elsevier Masson SAS</ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="fig1">
               <ce:label>Fig. 1</ce:label>
               <ce:caption id="cap0010">
                  <ce:simple-para id="fspara0010" view="all">Relationship of signaling pathways covered in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0015">Fig. 1</ce:alt-text>
               <ce:link locator="gr1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419305197/gr1"/></ce:link>
            </ce:figure>
            <ce:figure id="fig2">
               <ce:label>Fig. 2</ce:label>
               <ce:caption id="cap0015">
                  <ce:simple-para id="fspara0015" view="all">The Chemical structures of dual inhibitors in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0020">Fig. 2</ce:alt-text>
               <ce:link locator="gr2a" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419305197/gr2a"/></ce:link>
               <ce:link locator="gr2b" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419305197/gr2b"/></ce:link>
            </ce:figure>
            <ce:table xmlns="http://www.elsevier.com/xml/common/cals/dtd" id="tbl1" frame="topbot" colsep="0" rowsep="0">
               <ce:label>Table 1</ce:label>
               <ce:caption id="cap0020">
                  <ce:simple-para id="tspara0010" view="all">Clinical trials of dual target inhibitors used in this review.</ce:simple-para>
               </ce:caption>
               <ce:alt-text role="short" id="alttext0025">Table 1</ce:alt-text>
               <tgroup cols="6">
                  <colspec colnum="1" colname="col1"/></colspec>
                  <colspec colnum="2" colname="col2"/></colspec>
                  <colspec colnum="3" colname="col3"/></colspec>
                  <colspec colnum="4" colname="col4"/></colspec>
                  <colspec colnum="5" colname="col5"/></colspec>
                  <colspec colnum="6" colname="col6"/></colspec>
                  <thead>
                     <row rowsep="1" valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Drug</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Targets</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Sponsor</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Disease</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Phase</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd">Identifier</entry>
                     </row>
                  </thead>
                  <tbody>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AMG925 (FLX925)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3/CDK4</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLX Bio, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02335814</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">Pacritinib (SB1518)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">FLT3/JAK2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">S*BIO.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myelogenous Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="4" align="left">NCT00719836</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic Myelogenous Leukemia</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic MyelomonocytIc Leukemia</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelodysplastic Syndromes</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelofibrosis</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">E6201</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">FLT3/MEK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">Strategia Therapeutics.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">NCT02418000</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Myelodysplastic Syndrome</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Chronic Myelomonocytic Leukemia</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">SEL24-B489</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3/Pim</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Selvita S.A.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03008187</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">TAK-659</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3/SYK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Millennium Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myelogenous Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02323113</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="17" align="left">Midostaurin (PKC412)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="17" align="left">FLT3/SYK</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">University of Kansas</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01130662</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">OHSU Knight Cancer Institute</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03900949</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00093600</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Brenda Cooper, MD</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Untreated Adult Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01093573</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT00866281</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Lymphoblastic Leukemia</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03280030</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">University of Florida</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03207334</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Stanford University</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia With Gene Mutations</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT02723435</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Adult Acute Myeloid Leukemia in Remission</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01883362</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3-mutated Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03591510</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">University of Ulm</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01477606</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Technische Universität Dresden</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01830361</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Washington University School of Medicine</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02756962</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Newly Diagnosed FLT3 Mutated AML</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03258931</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03379727</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Novartis Pharmaceuticals</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03512197</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="15" align="left">Crenolanib (CP-868–596)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="15" align="left">FLT3/PDGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">St. Jude Children's Research Hospital.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02270788</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">AbbVie.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03625505</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02400281</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed/Refractory Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02626338</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed/Refractory FLT3-mutated AML</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03324243</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02400255</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01657682</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT01522469</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Newly Diagnosed AML With FLT3 Activating Mutations</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02283177</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">University of Ulm.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02298166</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Newly Diagnosed FLT3 Mutated AML</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03258931</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03250338</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="3" align="left">Arog Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3-ITD Mutation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="3" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="3" align="left">NCT03620318</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FLT3/TKD Mutation</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFR-Alpha D842V</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">PDGFRA Gene Amplification</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">Tandutinib (MLN518 or CT53518)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="2" align="left">FLT3/PDGFR</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Millennium Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myelogenous Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00274248</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Millennium Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myelogenous Leukemia<br/></br>Myelodysplastic Syndrome</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00064584</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Millennium Pharmaceuticals, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myelogenous Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT00297921</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="14" align="left">Gilteritinib (ASP2215)</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="14" align="left">FLT3/AXL</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02181660</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02310321</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02236013</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 1<br/></br>Phase 2</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02014558</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 2<br/></br>Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT02752035</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT03070093</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FMS-like Tyrosine Kinase-3 (FLT3) Mutations</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT03182244</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02421939</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">NCT02997202</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT03409081</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">FMS-like Tyrosine Kinase-3 (FLT3) Mutations</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Astellas Pharma Global Development, Inc.</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">Phase 3</entry>
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" morerows="1" align="left">NCT02927262</entry>
                     </row>
                     <row valign="top">
                        <entry xmlns="http://www.elsevier.com/xml/common/dtd" align="left">Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3)/Internal Tandem Duplication (ITD) Mutation</entry>
                     </row>
                  </tbody>
               </tgroup>
            </ce:table>
         </ce:floats>
         <head>
            <ce:dochead id="dhead0010">
               <ce:textfn>Review article</ce:textfn>
            </ce:dochead>
            <ce:title id="title0010">Dual FLT3 inhibitors: Against the drug resistance of acute myeloid leukemia in recent decade</ce:title>
            <ce:author-group id="augrp0010">
               <ce:author id="au1" author-id="S0223523419305197-013d151102ebb71026628dde623f3b8f">
                  <ce:given-name>Ting</ce:given-name>
                  <ce:surname>Yuan</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0010">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0015">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au2" author-id="S0223523419305197-b6b3c84201b86df34f61d89029de1def">
                  <ce:given-name>Baowen</ce:given-name>
                  <ce:surname>Qi</ce:surname>
                  <ce:cross-ref refid="aff2" id="crosref0020">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0025">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au3" author-id="S0223523419305197-11cbe9cbcc631e7983639b8f1a49086c">
                  <ce:given-name>Zhongliang</ce:given-name>
                  <ce:surname>Jiang</ce:surname>
                  <ce:cross-ref refid="aff3" id="crosref0030">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="fn1" id="crosref0035">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au4" author-id="S0223523419305197-5aa1fbd327b0665258e55defe2bf7dd9">
                  <ce:given-name>Wenjuan</ce:given-name>
                  <ce:surname>Dong</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0040">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au5" author-id="S0223523419305197-4109b2096d541189ea4cb53baabd0f37">
                  <ce:given-name>Lei</ce:given-name>
                  <ce:surname>Zhong</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0045">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au6" author-id="S0223523419305197-305f3c85d7b3f060234b3faf22978e17">
                  <ce:given-name>Lan</ce:given-name>
                  <ce:surname>Bai</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0050">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au7" author-id="S0223523419305197-b7c784c14b54ed9c0dca650b5f7cba97">
                  <ce:given-name>Rongsheng</ce:given-name>
                  <ce:surname>Tong</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0055">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au8" author-id="S0223523419305197-51230cf4b7843fe0166d2b3e5aecbd79">
                  <ce:given-name>Jiying</ce:given-name>
                  <ce:surname>Yu</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0060">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor2" id="crosref0065">
                     <ce:sup loc="post">∗∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au9" author-id="S0223523419305197-8c103013b97afe6d52b94528ba258493">
                  <ce:given-name>Jianyou</ce:given-name>
                  <ce:surname>Shi</ce:surname>
                  <ce:cross-ref refid="aff1" id="crosref0070">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref refid="cor1" id="crosref0075">
                     <ce:sup loc="post">∗</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="aff1" affiliation-id="S0223523419305197-a02ce1e0dccd5b16bc7b447820f8ef58">
                  <ce:label>a</ce:label>
                  <ce:textfn>Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Personalized Drug Therapy Key Laboratory of Sichuan Province</sa:organization>
                     <sa:organization>Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital</sa:organization>
                     <sa:organization>School of Medicine of University of Electronic Science and Technology of China</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610072</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0010">Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine of University of Electronic Science and Technology of China, Chengdu, 610072, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff2" affiliation-id="S0223523419305197-2cebaac6f27feda50d2d540b05fc70db">
                  <ce:label>b</ce:label>
                  <ce:textfn>College of Pharmacy and Biological Engineering, Chengdu University, Chengdu, 610106, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>College of Pharmacy and Biological Engineering</sa:organization>
                     <sa:organization>Chengdu University</sa:organization>
                     <sa:city>Chengdu</sa:city>
                     <sa:postal-code>610106</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0015">College of Pharmacy and Biological Engineering, Chengdu University, Chengdu, 610106, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="aff3" affiliation-id="S0223523419305197-7353fe2660c24dcc54ef93ef10b882d6">
                  <ce:label>c</ce:label>
                  <ce:textfn>Miller School of Medicine, University of Miami, Miami, Florida, 33136, USA</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Miller School of Medicine</sa:organization>
                     <sa:organization>University of Miami</sa:organization>
                     <sa:city>Miami</sa:city>
                     <sa:state>Florida</sa:state>
                     <sa:postal-code>33136</sa:postal-code>
                     <sa:country>USA</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="srct0020">Miller School of Medicine, University of Miami, Miami, 33136, America</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:correspondence id="cor2">
                  <ce:label>∗∗</ce:label>
                  <ce:text>Corresponding author.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="ntpara0010" view="all">Ting Yuan, Baowen Qi and Zhongliang Jiang contributed equally to this work.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:date-received day="2" month="3" year="2019"/></ce:date-received>
            <ce:date-revised day="16" month="5" year="2019"/></ce:date-revised>
            <ce:date-accepted day="2" month="6" year="2019"/></ce:date-accepted>
            <ce:abstract xml:lang="en" id="abs0010" view="all" class="author"><ce:abstract-sec id="abssec0010" view="all">
                  <ce:simple-para id="abspara0010" view="all">Acute myeloid leukemia (AML) is a malignant disease characterized by abnormal growth and differentiation of hematopoietic stem cells. Although the pathogenesis has not been fully elucidated, many specific gene mutations have been found in AML. Fms-like tyrosine kinase 3 (FLT3) is recognized as a drug target for the treatment of AML, and the activation mutations of FLT3 were found in about 30% of AML patients. Targeted inhibition of FLT3 receptor tyrosine kinase has shown promising results in the treatment of FLT3 mutation AML. Unfortunately, the therapeutic effects of FLT3 tyrosine kinase inhibitors used as AML monotherapy are usually accompanied by the high risk of resistance development within a few months after treatment. FLT3 dual inhibitors were generated with the co-inhibition of FLT3 and another target, such as CDK4, JAK2, MEK, Mer, Pim, etc., to solve the problems mentioned above. As a result, the therapeutic effect of the drug is significantly improved, while the toxic and side effects are reduced. Besides, the life quality of AML patients with FLT3 mutation has been effectively improved. In this paper, we reviewed the studies of dual FLT3 inhibitors that have been discovered in recent years for the treatment of AML.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
            <ce:abstract class="graphical" id="abs0015" view="all">
               <ce:section-title id="sectitle0015">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="abssec0015" view="all">
                  <ce:simple-para id="abspara0015" view="all">
                     <ce:display>
                        <ce:figure id="undfig1">
                           <ce:alt-text role="short" id="alttext0010">Image 1</ce:alt-text>
                           <ce:link locator="fx1" xlink:type="simple" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S0223523419305197/fx1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:keywords xml:lang="en" id="kwrds0010" view="all" class="keyword">
               <ce:section-title id="sectitle0025">Keywords</ce:section-title>
               <ce:keyword id="kwrd0010">
                  <ce:text>FLT3</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0015">
                  <ce:text>Dual inhibitors</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0020">
                  <ce:text>Acute myeloid leukemia</ce:text>
               </ce:keyword>
               <ce:keyword id="kwrd0025">
                  <ce:text>Drug resistance</ce:text>
               </ce:keyword>
            </ce:keywords>
         </head>
         <body view="all">
            <ce:sections>
               <ce:section id="sec1" role="introduction" view="all">
                  <ce:label>1</ce:label>
                  <ce:section-title id="sectitle0030">Introduction</ce:section-title>
                  <ce:para id="p0025" view="all">Acute myeloid leukemia (AML) is a malignant disease due to abnormal growth and differentiation of hematopoietic stem cells, mainly characterized by abnormal proliferation of primitive and immature myeloblasts in bone marrow and peripheral blood [<ce:cross-ref refid="bib1" id="crosref0080">1</ce:cross-ref>]. Clinical manifestations of AML include anemia, hemorrhage, fever, viscera infiltration, abnormal metabolism, etc., accounting for about 25% of adult leukemia with the lowest survival rate. The annual incidence of AML is about 23 per 1,000,000, slightly more in men than women, and significantly associated with the age over 65 years old (about 10 times higher than those under 65). Up to now, the etiology of AML is still unclear. It may relate to the regional environmental factors, ionizing radiation, chemical exposure, alcoholism, smoking, as well as certain viral infections. Besides, the occurrence and development of AML is a complex process. The mutations in specific genes have been found in many cases of AML, although the pathogenesis has not yet been fully elucidated.</ce:para>
                  <ce:para id="p0030" view="all">Fms-like tyrosine kinase 3 (FLT3) is a type III receptor tyrosine kinase and one of the most commonly mutated genes in AML [<ce:cross-ref refid="bib2" id="crosref0090">2</ce:cross-ref>,<ce:cross-ref refid="bib3" id="crosref0095">3</ce:cross-ref>]. The structure of FLT3 consists of five immunoglobulin-like extracellular domains, transmembrane domains, and intracellular tyrosine kinase domains [<ce:cross-ref refid="bib4" id="crosref0100">4</ce:cross-ref>]. FLT3 plays a crucial role in the proliferation, differentiation, and apoptosis of hematopoietic cells and lymphocytes. FLT3 mutations usually lead to abnormal activation, in the absence of binding to ligands, autophosphorylation activates downstream signaling pathways, resulting to abnormal proliferation of hematopoietic cells and lymphocytes, as well as leading to a variety of hematological malignancies, including AML. There are two main types of activating mutations in FLT3: internal tandem duplication (ITD) mutations in the juxta-membrane domain and point mutations in the activation loop in the tyrosine kinase domain (TKD). Compared with other forms of AML, the FLT3-ITD mutation is particularly associated with poor prognosis [<ce:cross-ref refid="bib5" id="crosref0105">5</ce:cross-ref>,<ce:cross-ref refid="bib6" id="crosref0110">6</ce:cross-ref>]. Some studies have shown that more than a third of patients with AML are accompanied by abnormal activation of FLT3 [<ce:cross-ref refid="bib7" id="crosref0115">7</ce:cross-ref>,<ce:cross-ref refid="bib8" id="crosref0120">8</ce:cross-ref>].</ce:para>
                  <ce:para id="p0035" view="all">Currently, several <ce:italic>anti</ce:italic>-AML inhibitors have emerged into the market, such as the first generation FLT3 inhibitor Sorafenib [<ce:cross-ref refid="bib9" id="crosref0125">9</ce:cross-ref>], Sunitinib [<ce:cross-ref refid="bib10" id="crosref0130">10</ce:cross-ref>], Dovitinib [<ce:cross-ref refid="bib11" id="crosref0135">11</ce:cross-ref>], Lestaurtinib [<ce:cross-ref refid="bib12" id="crosref0140">12</ce:cross-ref>] and so on. However, the results of the first generation of FLT3 inhibitors have been disappointing [<ce:cross-ref refid="bib13" id="crosref0145">13</ce:cross-ref>]. The tyrosine kinase inhibitors of FLT3 used as AML monotherapy will result to the reduction in peripheral blood and bone marrow blasts only in a minority of AML patients, and these effects are usually transient [<ce:cross-ref refid="bib14" id="crosref0150">14</ce:cross-ref>]. The secondary mutations in FLT3 interfere with the ability of small molecule inhibitors binding to FLT3 [<ce:cross-ref refid="bib15" id="crosref0155">15</ce:cross-ref>,<ce:cross-ref refid="bib16" id="crosref0160">16</ce:cross-ref>]. The main issue is that drug resistance occurs within a few months after the initial therapy, which severely affected the therapeutic effect in the clinic [<ce:cross-ref refid="bib17" id="crosref0165">17</ce:cross-ref>]. Combination therapy is one of the most effective ways to overcome this resistance [<ce:cross-ref refid="bib18" id="crosref0170">18</ce:cross-ref>]. However, drug-drug interactions need also be considered in clinical efficacy for the inclusion of other drugs. To minimize these problems, rational control of multi-target monotherapy is essential [<ce:cross-ref refid="bib19" id="crosref0175">19</ce:cross-ref>]. Multi-target antitumor drugs have better effects than currently available single-target medicines, which can reduce drug resistance and toxic side effects. The relationship of signaling pathways was summarized in the <ce:cross-ref refid="fig1" id="crosref0930">Fig. 1</ce:cross-ref>.<ce:float-anchor refid="fig1"/></ce:float-anchor> In this review, we summarize some of the research findings of FLT3 dual inhibitors for the treatment of AML in the past decade. The chemical structures of dual inhibitors were described in the <ce:cross-ref refid="fig2" id="crosref0935">Fig. 2</ce:cross-ref>
                     <ce:float-anchor refid="fig2"/></ce:float-anchor>.</ce:para>
                  <ce:para id="p0040" view="all">FLT3: fms-like tyrosine kinase 3; PDGFR: platelet-derived growth factor receptor; JAK: the Janus kinase; CDK4: cyclin-dependent kinase 4; MEK: Mitogen-activated extracellular signal-regulated kinase; Pim: provirus integration site for moloney murine leukemia virus; SYK: spleen tyrosine kinase; Fes: FEline sarcoma; AKT (also known as PKB): Protein kinase B; Mnk2: MAPK-interacting kinase-2; TOPK: T-lymphokine-activated killer cell-originated protein kinase; NF-κB: the nuclear factor kappaB.</ce:para>
               </ce:section>
               <ce:section id="sec2" view="all">
                  <ce:label>2</ce:label>
                  <ce:section-title id="sectitle0035">Dual inhibitors of FLT3</ce:section-title>
                  <ce:section id="sec2.1" view="all">
                     <ce:label>2.1</ce:label>
                     <ce:section-title id="sectitle0040">FLT3/CDK4 dual Inhibitor:AMG 925 (FLX 925) (1)</ce:section-title>
                     <ce:para id="p0045" view="all">Cyclin-dependent kinase 4 (CDK4) is a cyclin D-dependent kinase, which plays an essential role in integrating external growth factors to promote G1-S transition in mammalian cells. It could function as a critical downstream effector of growth factor activation [<ce:cross-ref refid="bib20" id="crosref0180">20</ce:cross-ref>,<ce:cross-ref refid="bib21" id="crosref0185">21</ce:cross-ref>]. CDK4, located downstream of FLT3 signaling transduction, is essential for FLT3-activated cell proliferative responses. It is also up-regulated in AML by activating tyrosine kinase-growth signaling pathways that overexpress cyclin D and suppress the loss of p15 function [<ce:cross-ref refid="bib22" id="crosref0190">22</ce:cross-ref>,<ce:cross-ref refid="bib23" id="crosref0195">23</ce:cross-ref>]. When FLT3 and CDK4 are co-inhibited simultaneously in the AML cell line, synergistic activity has been observed in the preclinical study. Besides, CDK4 inhibition has been shown to enhance the apoptosis of FLT3 inhibitors in the AML cell lines [<ce:cross-ref refid="bib22" id="crosref0200">22</ce:cross-ref>].</ce:para>
                     <ce:para id="p0050" view="all">AMG 925(1) is a novel potent and selective FLT3/CDK4 dual kinase inhibitor (IC<ce:inf loc="post">50</ce:inf> values of 1 and 3 nmol/L, respectively) [<ce:cross-ref refid="bib24" id="crosref0205">24</ce:cross-ref>]. AMG025 was discovered by structural optimization of lead compound (<ce:bold>2</ce:bold>) (pyrido-[4′,3’:4,5]pyrrolo[2,3-<ce:italic>d</ce:italic>]pyrimidine) accompanied by SAR analysis using cell-based analysis. The addition of a methyl group at the 4-position of the cyclohexyl moiety can result in a significant decrease in CYP3A4 inhibition (CYP3A4 IC<ce:inf loc="post">50</ce:inf> = 90 μM), as the ligation of the heme iron could be disfavored by a remote steric interaction with a sterically bulky cycloalkane. In the coordination mode of the pyridine moiety of the lead compound <ce:bold>2</ce:bold> with the heme iron, when the cycloalkane was appropriately substituted, the cycloalkane created a spatial interaction with the critical residue of the CYP active site, and these destabilizing interactions grew more pronounced as the substituent was made longer and bulkier. Thus, trans-4-methylcyclohexyl could eliminate CYP3A4 inhibition without reducing the potency of FLT3 or CDK4 or inducing any other known load. Bioavailability and FLT3 potency could be improved by appropriate modification of the distal amine functional group (i.e., the piperazine ring of <ce:bold>2</ce:bold>) and the heteroaromatic ring attached to the tricyclic core. The resulting derivatives of the heteroaromatic and distal amine modification strategies exhibited good to moderate pharmacokinetics in the three species studied (rats, mice, and dogs). Thus, a series of derivatives were obtained to replace the basic amine with an effective non-basic polar substitute. Glycolamides, sulfones, and various spiro-lactams substituent significantly improved pharmacokinetic properties at the expense of a modest reduction in potency. Among these derivatives, AMG925 has been emerged as the most suitable candidate for clinical development by virtue of its excellent pharmacokinetic properties (in rat, CL = 0.39L/h/kg, F% = 75), well-balanced inhibitory activities on FLT3 and CDK4, potent anti-proliferation efficacy against MOLM13 cells, and superior safety profile and <ce:italic>in vitro</ce:italic> ADME properties [<ce:cross-ref refid="bib24" id="crosref0210">24</ce:cross-ref>].</ce:para>
                     <ce:para id="p0055" view="all">AMG 925 can effectively inhibit the growth of AML cell line MOLM13 (FLT3-ITD; IC<ce:inf loc="post">50</ce:inf> = 0.019 μmol/L) and MV4-11 (FLT3-ITD; IC<ce:inf loc="post">50</ce:inf> = 0.018μmol/L). AMG 925 overcomes the problem of selective FLT3 inhibitor resistance and improves clinical performances by inhibiting the two kinases FLT3 and CDK4, which are both necessary for the proliferation and survival of FLT3 mutant AML cells [<ce:cross-ref refid="bib21" id="crosref0215">21</ce:cross-ref>,<ce:cross-ref refid="bib24" id="crosref0220">24</ce:cross-ref>]. Compared to the single FLT3 selective inhibitor, the AMG 925 has the following advantages for the treatment of AML. First, AMG 925 inhibited the proliferation of wild-type FLT3 on Rb<ce:sup loc="post">+</ce:sup> AML cells. The clinical response to treatment of AML is less dependent on the ITD allele load [<ce:cross-ref refid="bib25" id="crosref0225">25</ce:cross-ref>]. Second, AMG 925 targeted two kinases do not fully overlap but are essential for the growth of AML cells. In addition, AMG 925 can reduce the chance of FLT3 resistance mutations and lead to a longer lasting clinical response than FLT3 inhibitor alone [<ce:cross-ref refid="bib26" id="crosref0230">26</ce:cross-ref>]. Therefore, AMG925 combining FLT3 with CDK4 inhibitory activity may exhibit better clinical toxicity characteristics, which will be a better method for treating elderly AML patients [<ce:cross-ref refid="bib27" id="crosref0235">27</ce:cross-ref>]. AMG 925 is a potent, selective, and orally bioavailable FLT3/CDK4 dual kinase inhibitor in preclinical studies, moreover, this compound shows well <ce:italic>in vivo</ce:italic> activity and tolerability in the AML tumor model. At present, AMG925 is in the late stage of preclinical research. Currently, AMG925 is in the phase 1/1b of clinical trials to evaluate the safety, PK, PD, and anti-tumor activity in patients with relapsed or refractory AML. The clinical trials of dual target inhibitors were shown in the <ce:cross-ref refid="tbl1" id="crosref0925">Table 1</ce:cross-ref>
                        <ce:float-anchor refid="tbl1"/></ce:float-anchor>.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.2" view="all">
                     <ce:label>2.2</ce:label>
                     <ce:section-title id="sectitle0045">FLT3/JAK2 dual inhibitor: pacritinib (SB1518) (3)</ce:section-title>
                     <ce:para id="p0060" view="all">The Janus Kinase (JAK) family consists of four cytoplasmic protein tyrosine kinases, including JAK1, JAK2, JAK3, and TYK2, which controls cell proliferation, differentiation, and death [<ce:cross-ref refid="bib28" id="crosref0240">28</ce:cross-ref>]. The genetic lesions and aberrations involving JAK2 are associated with a wide range of hematological malignancies, including myelofibrosis, lymphoma, and some rare leukemia [<ce:cross-ref refid="bib29" id="crosref0245">29</ce:cross-ref>]. The phospho-JAK2 is elevated in the original sample of AML. Besides, a negative regulator of JAK2 signaling was found to down-regulate in AML cells carrying FLT3-ITD mutations [<ce:cross-ref refid="bib30" id="crosref0250">30</ce:cross-ref>,<ce:cross-ref refid="bib31" id="crosref0255">31</ce:cross-ref>]. In AML cells, up-regulation of JAK2 is identified as a potential resistant to FLT3 inhibition. Therefore, Pacritinib could simultaneously inhibit FLT3 and JAK2 activities. In addition, co-blocking of FLT3 and JAK2 signal can increase the clinical benefit of AML patients with FLT3-ITD mutations.</ce:para>
                     <ce:para id="p0065" view="all">Pacritinib (SB1518) (3) is a selective dual inhibitor of FLT3 and JAK2 (IC<ce:inf loc="post">50</ce:inf> values of 23 and 22 nmol/L, respectively) [<ce:cross-ref refid="bib32" id="crosref0260">32</ce:cross-ref>]. Pacritinib inhibited FLT3-ITD, FLT3 phosphorylation in primary AML blasts, and downstream signaling transduction of STAT, MAPK, and PI3K. Notably, the FLT3-ITD mutating cells have the highest inhibition efficacy [<ce:cross-ref refid="bib33" id="crosref0265">33</ce:cross-ref>]. Pacritinib inhibits intracellular FLT3 signaling with antiproliferative effects on the FLT3-ITD cell lines MOLM13 and MV4-11 (IC<ce:inf loc="post">50</ce:inf> values of 47 and 67 nmol/L, respectively) [<ce:cross-ref refid="bib32" id="crosref0270">32</ce:cross-ref>]. Pacritinib is highly effective in blocking tumor growth in mouse subcutaneous xenograft models produced by MOLM13 and MV4-11. In the MOLM13 model, Pacritinib reduced FLT3 phosphorylation and downstream STAT5 signaling in tumor tissues resulted in 83% inhibition of tumor growth after 7 days of dosing. In the MV4-11 model, Pacritinib blocked tumor growth dose-dependently. The highest dose resulted in complete regression of tumors in all mice [<ce:cross-ref refid="bib34" id="crosref0275">34</ce:cross-ref>]. Pacritinib demonstrated a favorable safety and a pharmacological activity profile in preclinical hematologic malignancy models [<ce:cross-ref refid="bib33" id="crosref0280">33</ce:cross-ref>]. Pacritinib was used in the phase 1/2 study for the treatment of advanced myeloid malignancies. On phase 1, the dose was escalated to determine the maximum tolerated dose, and the dose is limited to minimize the toxicities of Pacritinib. On phase 2, Pacritinib was defined with the recommended dose in subjects with chronic idiopathic myelofibrosis. The good preclinical profile and the emergence of new clinical data provides a strong basis for the clinical evaluation of Pacritinib in the treatment of AML [<ce:cross-ref refid="bib35" id="crosref0285">35</ce:cross-ref>], which brings new hope to patients who are resistant to FLT3-TKI therapy.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.3" view="all">
                     <ce:label>2.3</ce:label>
                     <ce:section-title id="sectitle0050">FLT3/MEK dual inhibitor: E6201 (4)</ce:section-title>
                     <ce:para id="p0070" view="all">The mitogen-activated extracellular signal-regulated kinase (MEK) is a dual-specificity kinase, which can phosphorylate serine/threonine and tyrosine residues on target proteins, while it is also a significant component of RAS-RAF-MEK-ERK/MAPK signal pathway [<ce:cross-ref refid="bib36" id="crosref0290">36</ce:cross-ref>]. This signaling pathway controls many cellular processes, including proliferation, differentiation, apoptosis, and metabolism. MEK is one of the critical target overexpressed or mutated in many tumors [<ce:cross-ref refid="bib37" id="crosref0295">37</ce:cross-ref>]. The up-regulation of phosphorylated ERK was observed in the cells of patients with recurrent AML, suggesting that MAPK activation occurs when FLT3 phosphorylation remains suppressed [<ce:cross-ref refid="bib38" id="crosref0300">38</ce:cross-ref>]. Bone marrow microenvironment plays another critical role in AML chemotherapy resistance [<ce:cross-ref refid="bib39" id="crosref0305">39</ce:cross-ref>]. Studies have shown that hypoxia significantly increased the level of phosphorylated FLT3 and MSCs, completely up-regulated ERK activation, suggesting that the up-regulation of MEK/ERK and FLT3 signaling pathway is the crucial factor for AML cells to resist chemotherapy in microenvironment [<ce:cross-ref refid="bib40" id="crosref0310">40</ce:cross-ref>]. Besides, some <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> studies have simultaneously demonstrated synergistic anti-leukemia effects by inhibiting both FLT3 and MEK signaling pathways [<ce:cross-ref refid="bib41" id="crosref0315">41</ce:cross-ref>].</ce:para>
                     <ce:para id="p0075" view="all">E6201(4) is another selective dual inhibitor of FLT3 and MEK (IC<ce:inf loc="post">50</ce:inf> values of 5 and 50 nmol/L, respectively) [<ce:cross-ref refid="bib42" id="crosref0320">42</ce:cross-ref>]. Inspired by natural product LL-Z1640-2(5), E6201 was through total synthesis method. C14 region of LL-Z1640-2 could tolerate substitutions, and among the C14-substituted analogs, the ethyl-substituted analog E6201 demonstrated excellent bioavailability and <ce:italic>in vitro</ce:italic> potency in mice [<ce:cross-ref refid="bib43" id="crosref0325">43</ce:cross-ref>]. E6201 significantly inhibited cell growth and induced apoptosis in FLL3-ITD mutant AML cells MOLM13 and MV4-11 [<ce:cross-ref refid="bib44" id="crosref0330">44</ce:cross-ref>]. E6201 exerted significant pro-apoptotic effects not only in FLT3-ITD mutant cells but also in FLT3 inhibitor-resistant cells. It is noteworthy that E6201 showed no pro-apoptotic effect on normal myeloid cells. Besides, E6201 also inhibited the proliferation of FLT3-TKD mutant cells Ba/F3-D835G and Ba/F3-D835Y (IC<ce:inf loc="post">50</ce:inf> values of 0.0046 and 0.026 mmol/L, respectively) [<ce:cross-ref refid="bib44" id="crosref0335">44</ce:cross-ref>]. These TKD mutations are usually more clinically resistant to FLT3-targeted therapies, in particular, E6201 showed more potent anti-proliferative effects in leukemia cells containing these TKD mutations than clinically useful FLT3 inhibitors. The use of dual FLT3/MEK inhibitor E6201 provided the best outcome of apoptotic synergy and reduced potential side effects caused by the use of multiple drug combinations. E6201 is an attractive clinical compound which can effectively target leukemia cells with abnormal FLT3 and MAPK signaling pathway activation, especially for FLT3 inhibitor-resistant. Therefore, E6201 significantly improved the efficacy of targeted therapy with FLT3 by overcoming bone marrow-mediated MAPK activation, providing new therapeutic approaches for the treatment of patients with relapsed and refractory AML. A Phase I/IIa clinical trial is currently under investigation at the MD Anderson Cancer Center (Houston, TX) to evaluate the anti-leukemia efficacy of E6201 against relapsed/refractory FLT3 mutant AML.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.4" view="all">
                     <ce:label>2.4</ce:label>
                     <ce:section-title id="sectitle0055">FLT3/Pim dual Inhibitor:SGI-1776 (6), SEL24-B489 (7) and EC-70124 (8)</ce:section-title>
                     <ce:para id="p0080" view="all">Pim (provirus integration site for Moloney murine leukemia virus) is a serine/threonine protein kinase in the family of the calcium/calmodulin regulatory kinases, demonstrated as three isoforms, Pim1, Pim2, and Pim3 [<ce:cross-ref refid="bib45" id="crosref0340">45</ce:cross-ref>,<ce:cross-ref refid="bib46" id="crosref0345">46</ce:cross-ref>]. It has been found that Pim kinase plays a vital role in enhancing cell survival and inhibiting hematopoietic cell apoptosis [<ce:cross-ref refid="bib47" id="crosref0350">47</ce:cross-ref>]. The expression of Pim1 and Pim2 is up-regulated by STAT5, mainly overexpressed in primary AML samples [<ce:cross-ref refid="bib48" id="crosref0355">48</ce:cross-ref>]. One of the challenges of FLT3 inhibition therapy is the drug resistance, while Pim1 reduced the resistance to a certain level. Pim kinase controls FLT3-ITD signaling because its pharmacological actions or genetic inhibition can restore the sensitivity of cells to FLT3 inhibitors [<ce:cross-ref refid="bib49" id="crosref0360">49</ce:cross-ref>]. Also, Pim phosphorylates FLT3 in the feedback loop [<ce:cross-ref refid="bib50" id="crosref0365">50</ce:cross-ref>], indicating Pim kinase inhibition is an alternative strategy for FLT3 activated mutations.</ce:para>
                     <ce:para id="p0085" view="all">SGI-1776 (6) is a selective dual inhibitor of FLT3 and Pim (FLT3 has an IC<ce:inf loc="post">50</ce:inf> value of 44 nmol/L; Pim1, Pim2, and Pim3 have IC<ce:inf loc="post">50</ce:inf> values of 7, 363 and 69 nmol/L, respectively) [<ce:cross-ref refid="bib51" id="crosref0370">51</ce:cross-ref>]. SGI-1776 is an imidazo [1,2-b] pyridazine small molecule. Pim kinase signaling involves multiple pathways, especially the biological role of SGI-1776 in AML cells is manifold. Myeloid cell leukemia-1(Mcl-1) is a signaling molecule downstream of Pim and has found that Mcl-1 is overexpressed in cells after the recurrence of AML [<ce:cross-ref refid="bib52" id="crosref0375">52</ce:cross-ref>]. In AML primary cell lines, Mcl-1 transcript and Mcl-1 protein levels significantly decreased after treatment with SGI-1776 [<ce:cross-ref refid="bib53" id="crosref0380">53</ce:cross-ref>]. SGI-1776 is effective in cells with the highest efficacy in cells with FLT3-ITD. Besides, in the AML xenograft model, the tumor volume was reduced, and the animal body weight was not significantly changed after SGI-1776 treatment. Although in earlier studies with preclinical AML models, SGI-1776 exhibited promising activity. However, the compound failed the clinical testing due to a narrow therapeutic window and cardiac toxicity (related to off-target effects of the inhibitor and its metabolites-inhibition of the potassium channel hERG) (NCT 01239108).</ce:para>
                     <ce:para id="p0090" view="all">SEL24-B489(7) is a potent, type I, dual Pim/FLT3 inhibitor, with a Kd of 2 nM for Pim1, 2 nM for Pim2, 3 nM for Pim3 and 16 nM for FLT3-ITD [<ce:cross-ref refid="bib54" id="crosref0385">54</ce:cross-ref>]. SEL24-B489 exhibited significantly broader on-target activity in AML cell lines and primary AML blasts than selective FLT3-ITD or Pim inhibitors. SEL24-B489 also showed a marked activity in cells bearing FLT3-TKD mutations that lead to FLT3 inhibitor resistance. Besides, SEL24-B489 inhibited the growth of a wide range of AML cell lines in the xenograft models with significant pharmacodynamics/pharmacokinetic relationships. The results as mentioned above highlighted the unique dual activity of the SEL24-B489, which eliminated the activity of signaling circuits involved in proliferation, inhibition of apoptosis, and protein translation/metabolism. These results also underscore the therapeutic potential of the dual Pim/FLT3-ITD inhibitor for the treatment of AML, having confirmed the favorable pharmacokinetics, good bioavailability, and metabolic stability of the compound. Researchers determined SEL24-B489 single-agent activity in the animal xenograft models. In SCID/beige mice bearing MV-4-11 tumors (FLT3-ITD+) treated with SEL24-B489, researchers noted a significant dose-dependent tumor reduction (67%, 74% and 82% tumor growth inhibition (TGI) for 50, 75 and 100 mg/kg daily doses, respectively). Given the favorable pharmacokinetics and safety profile, SEL24-B489 has been recently cleared for the phase I/II trial in AML patients. Therefore, further clinical development of the dual Pim/FLT3-ITD inhibition strategy with SEL24-B489 is ongoing (NCT03008187).</ce:para>
                     <ce:para id="p0095" view="all">EC-70124 (8), an indolocarbazole analog, is a multi-kinase inhibitor with K<ce:inf loc="post">d</ce:inf> values of 3.2, 2.9, 3.1, 0.4 nM for FLT3, Pim1, Pim2, and Pim3, respectively [<ce:cross-ref refid="bib55" id="crosref0390">55</ce:cross-ref>]. EC-70124 has anti-proliferative activity in several AML cell lines. Among them, it has significant anti-proliferative effects in FLT3 mutant cells expressing a high level of Pim kinases, whereas moderate effects in FLT3 wild-type cells not expressing Pim kinases. EC-70124 is also potent against monocytes obtained from bone marrow aspirate of newly diagnosed AML patients. EC-70124 could induce cell cycle arrest and cell apoptosis. Cell-cycle analyses showed a dose-dependent increase in the G0/G1 phase in AML cells treated with EC-70124. Besides, EC-70124 has oral bioavailability, higher metabolic stability, and lower human protein plasma binding than Midostaurin. In the MV4-11 xenograft model, the inhibition of tumor growth was observed by intravenous or oral administration of EC-70124, and no significant weight loss was detected, indicating that all mice were well tolerated for both routes of administration. It is worth noting that one mice from the high dose group was permanently cured (tumor free > 6 months) [<ce:cross-ref refid="bib55" id="crosref0395">55</ce:cross-ref>]. Taking together, EC-70124 is a promising new candidate for the treatment of AML.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.5" view="all">
                     <ce:label>2.5</ce:label>
                     <ce:section-title id="sectitle0060">FLT3/SYK dual Inhibitor:TAK-659 (9) and Midostaurin (PKC412) (10)</ce:section-title>
                     <ce:para id="p0100" view="all">Spleen tyrosine kinase (SYK) is a member of the non-receptor tyrosine kinase SYK/ZAP-70 family [<ce:cross-ref refid="bib56" id="crosref0400">56</ce:cross-ref>,<ce:cross-ref refid="bib57" id="crosref0405">57</ce:cross-ref>]. It is expressed in most hematopoietic cells as an essential signaling partner for FLT3 [<ce:cross-ref refid="bib58" id="crosref0410">58</ce:cross-ref>,<ce:cross-ref refid="bib59" id="crosref0415">59</ce:cross-ref>]. SYK has shown to be important in FLT3 mutant positive AML because it transactivates FLT3-ITD in AML transformation through overexpression [<ce:cross-ref refid="bib60" id="crosref0420">60</ce:cross-ref>]. Besides, overexpression of constitutively activated SYK leads to resistance to highly selective FLT3 tyrosine kinase inhibitors [<ce:cross-ref refid="bib61" id="crosref0425">61</ce:cross-ref>]. Given the importance of SYK in the transformation and maintenance of AML, it is of great significance to using SYK as a potentially important target as FLT3 kinase inhibitors for AML therapy.</ce:para>
                     <ce:para id="p0105" view="all">TAK-659(9) is a potent and selective dual inhibitor of FLT3 and SYK (IC<ce:inf loc="post">50</ce:inf> values of 40.6 and 3.2 nmol/L, respectively) [<ce:cross-ref refid="bib62" id="crosref0430">62</ce:cross-ref>]. In the cell proliferation assay, TAK-659 showed significant inhibition of the SYK-dependent cell line (OCI-LY10). In cell viability assays, TAK-659 was shown to be sensitive to the FLT3-ITD-dependent cell lines MV4-11 and MOLM-13. In the MV4-11 xenograft model, TAK-659 showed tumor regression at 60 mg/kg every day after 20 days of drug administration [<ce:cross-ref refid="bib62" id="crosref0435">62</ce:cross-ref>]. TAK-659 is currently undergoing the Ib/II trial for relapsed/refractory AML (NCT02323113). The purpose of the Phase 1b dose is to determine the safety, tolerability, and maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of TAK-659 in relapsed or refractory AML patients. The further Phase 2 study will evaluate preliminary efficacy of TAK-659 in relapsed or refractory AML as measured by overall response rate (ORR).</ce:para>
                     <ce:para id="p0110" view="all">Midostaurin (10), also known as PKC412, (N-[(2S,3R,4R,6R)-3-Methoxy-2-methyl-16-oxo-29-oxa-1,7,17-triazaoctacyclo [12.12.2.12, 6.07, 28.08, 13.015, 19.020, 27.021, 26] nonacosa 8, 10, 12, 14, 19, 21, 23, 25, 27-nonaen-4-yl]-N-methylbenzamide) is a multi-kinase inhibitor with significant inhibition of FLT3 and SYK (K<ce:inf loc="post">d</ce:inf> values of 11 and 88 nmol/L, respectively) [<ce:cross-ref refid="bib61" id="crosref0440">61</ce:cross-ref>,<ce:cross-ref refid="bib63" id="crosref0445">63</ce:cross-ref>]. Dual FLT3/SYK inhibitor could effectively inhibit proliferation of both Ba/F3-ITD and Ba/F3-D835Y cells with an IC<ce:inf loc="post">50</ce:inf> of less than 10 nM [<ce:cross-ref refid="bib63" id="crosref0450">63</ce:cross-ref>]. Compared with targeted FLT3 inhibitors such as Crenolanib and Quizartinib, Midostaurin had better anti-proliferative activity against co-expressing FLT3-ITD and constitutively activated SYK-TEL cells. Interestingly, additional SYK inhibition enhanced the effect of dual FLT3/SYK inhibitors on FLT3-ITD-driven leukemia, whether in the absence or absence of activated SYK [<ce:cross-ref refid="bib61" id="crosref0455">61</ce:cross-ref>]. At present, there are many ongoing clinical trials on the effect of Midostaurin in the treatment of AML [<ce:cross-refs refid="bib64 bib65 bib66 bib67" id="crosrefs0015">64–67</ce:cross-refs>]. For example, a multi-institutional, multinational, randomized, double-blind, placebo-controlled trial was conducted to determine the effect of adding Midostaurin on standard chemotherapy in FLT3-mutated AML patients (NCT00651261) [<ce:cross-ref refid="bib68" id="crosref0460">68</ce:cross-ref>]. In this trial, a total of 717 patients between 18 and 59 years of age with newly diagnosed FLT3-mutated AML were included. Patients were randomly assigned to Midostaurin group (cytarabine + daunorubicin + Midostaurin) and placebo group (cytarabine + daunorubicin + placebo). After a minimum follow-up of 3.5 years after randomization, the overall survival (OS) of the Midostaurin group was significantly longer than that in the placebo group (OS, 74.7 months vs. 25.6 months; p = 0.009). The 4-year median OS rate was 51.4% in the Midostaurin group and 44.3% in the placebo group. The median disease-free survival (DFS) was also improved in the Midostaurin group (26.7 months vs. 15.5 months; p = 0.01) [<ce:cross-ref refid="bib68" id="crosref0465">68</ce:cross-ref>]. Importantly, Midostaurin has been approved by the FDA for the treatment of adult patients with newly diagnosed FLT3 mutation-positive AML in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. But, Midostaurin is not indicated as a single-agent induction therapy for the treatment of patients with AML.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.6" view="all">
                     <ce:label>2.6</ce:label>
                     <ce:section-title id="sectitle0065">FLT3/Mer dual Inhibitor:UNC2025 (11)</ce:section-title>
                     <ce:para id="p0115" view="all">Mer receptor tyrosine kinase is a member of Tyro3, Axl and Mer families [<ce:cross-ref refid="bib69" id="crosref0470">69</ce:cross-ref>]. Aberrant expression of the Mer receptor tyrosine kinase has found in 80–100% of AML patients, while Mer expression has rarely expressed in normal bone marrow precursor cells [<ce:cross-ref refid="bib70" id="crosref0475">70</ce:cross-ref>]. Activation of Mer in AML cell lines leads to pro-survival signaling, including phosphorylation of Erkl/2, Akt, and Stat6. Inhibition of Mer in AML by RNA interference resulted in a significant increase in myeloid cell apoptosis and reduced colony formation of methylcellulose in the murine xenograft model [<ce:cross-ref refid="bib71" id="crosref0480">71</ce:cross-ref>]. These findings corroborate that abnormal expression of Mer may be the cause of leukemia. The inhibition of Mer kinase selectively targets AML cells while retaining normal myeloid progenitors [<ce:cross-ref refid="bib72" id="crosref0485">72</ce:cross-ref>]. As a result, the combined inhibition of FLT3 and Mer may be an effective strategy for treating the widespread applicability of AML.</ce:para>
                     <ce:para id="p0120" view="all">UNC2025(11) is a highly selective FLT3 and tyrosine kinase small molecule inhibitor (IC<ce:inf loc="post">50</ce:inf> values of 0.80 and 0.74 nmol/L, respectively) [<ce:cross-ref refid="bib73" id="crosref0490">73</ce:cross-ref>]. To decrease the metabolic clearance of lead compound (12), the modifications at each substituent position to either reduce log P, increase solubility, or decrease cytochrome P450 oxidation while retaining Mer/Flt3 potency. Re-examination of the SAR of the pyrazolopyrimidine scaffold showed that a trans-4-hydroxycyclohexyl group at the N1 position was optimal, while alternative substitutions at this position either compromised the Mer potency or introduced undesired hERG activity [<ce:cross-ref refid="bib74" id="crosref0495">74</ce:cross-ref>,<ce:cross-ref refid="bib75" id="crosref0500">75</ce:cross-ref>]. However, SAR analysis in pyrazolopyrimidines demonstrates that the butylamine group at the C6 position could be substituted with other aliphatic groups while Mer potency retained. Besides, substituents at the C3 position were positioned toward the solvent front in X-ray cocrystal structures, and researchers reasoned that different solubilizing groups might be well-tolerated at this position [<ce:cross-ref refid="bib75" id="crosref0505">75</ce:cross-ref>]. Therefore, the C3 and C6 positions were simultaneously changed to quickly explore their combined effects on DMPK properties in a feasible fashion. This modification strategy yielded a series of analogs that were effective for both Mer and FLT3 had some selectivity over Axl and Tyro3. In addition to the 3-fluoro substituent, the introduction of a basic soluble N-methylpiperazine group on the phenyl ring on compound (13) leads to an increase of oral bioavailability, although the clearance was still high. Removal of the sulfonamide group in compound (13) might be another strategy to increase its solubility further and improve the PK properties since sulfonamides were known to have a high melting point relative to the corresponding amine [<ce:cross-ref refid="bib76" id="crosref0510">76</ce:cross-ref>]. As a result, analog UNC2025 was demonstrated excellent PK properties: low clearance (9.2 mL/min/kg), longer half-life (3.8 h), and high oral exposure (100%). In addition, the HCl salt of UNC2025 was highly soluble in normal saline (kinetic solubility: 38 μg/mL, pH = 7.4) [<ce:cross-ref refid="bib73" id="crosref0515">73</ce:cross-ref>].</ce:para>
                     <ce:para id="p0125" view="all">This ATP binding site-competent small molecule compound selectively inhibits phosphorylation of Mer and FLT3 kinases of downstream signal transduction, resulting in growth inhibition and apoptosis of AML cell lines and primary myeloblasts cells [<ce:cross-ref refid="bib72" id="crosref0520">72</ce:cross-ref>]. Besides, UNC2025 has good pharmacological selectivity and oral bioavailability, while its solubility and pharmacokinetic properties are also significantly improved compared to the previous compound UNC1666 [<ce:cross-ref refid="bib72" id="crosref0525">72</ce:cross-ref>]. Importantly, in acute leukemia mice model, oral treatment with UNC2025 can effectively inhibit myeloid leukemia cells, showing excellent stability and pharmacokinetic properties and inhibitory activity [<ce:cross-ref refid="bib73" id="crosref0530">73</ce:cross-ref>]. Therefore, this novel FLT3 and Mer dual-targeted small molecule tyrosine kinase inhibitor has significant therapeutic potential in AML. It may lead to better outcomes for high-risk patients and a promising treatment option for patients who cannot tolerate high-intensity chemotherapy.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.7" view="all">
                     <ce:label>2.7</ce:label>
                     <ce:section-title id="sectitle0070">FLT3/fes dual Inhibitor:TAE-684 (14), WZ4-49-1(15) and HG7-92-01 (16)</ce:section-title>
                     <ce:para id="p0130" view="all">FEline sarcoma (Fes) is a member of the non-receptor tyrosine kinase family homologous to the viral v-fes cat and the v-fps avian oncogene, which mainly expressed in myeloid hematopoietic cells [<ce:cross-ref refid="bib77" id="crosref0535">77</ce:cross-ref>,<ce:cross-ref refid="bib78" id="crosref0540">78</ce:cross-ref>]. Fes kinase activity is tightly regulated within cells [<ce:cross-ref refid="bib79" id="crosref0545">79</ce:cross-ref>]. Fes functions as a downstream signaling mediator of growth factors, cytokines, immune cell receptors, and participates. It regulates hematopoietic cell growth, survival, and differentiation, as well as innate immune responses [<ce:cross-ref refid="bib80" id="crosref0550">80</ce:cross-ref>]. Studies by Voisset et al. showed that Fes played an essential role in downstream signal transduction of FLT3-ITD in AML as well [<ce:cross-ref refid="bib81" id="crosref0555">81</ce:cross-ref>]. Fes is expressed and constitutively activated in FLT3-ITD<ce:sup loc="post">+</ce:sup> AML cell lines, including MV4-11 and MOLM13, or primary AML bone marrow samples. These data suggest that inhibition of Fes kinase activity may be therapeutically beneficial in AML.</ce:para>
                     <ce:para id="p0135" view="all">TAE-684 (14), WZ4-49-1(15) and HG7-92-01 (16) are dual inhibitors of FLT3 and Fes. TAE-684 is a diaminopyrimidine inhibitor, and the IC<ce:inf loc="post">50</ce:inf> value for Fes, FLT3-WT, FLT3-ITD and FLT3-D835Y are 569, 536, 120 and 218 nmol/L, respectively. WZ4-49-1 is a pyrazolopyrimidine inhibitor, and the IC<ce:inf loc="post">50</ce:inf> value for Fes, FLT3-WT, FLT3-ITD and FLT3-D835Y are 494, 3138, 1390 and 642 nmol/L, respectively. HG7-92-01 is a pyrrolopyridine inhibitor, and the IC<ce:inf loc="post">50</ce:inf> value for Fes, FLT3-WT, FLT3-ITD and FLT3-D835Y are 527, 536, 149 and 3646 nmol/L, respectively [<ce:cross-ref refid="bib82" id="crosref0560">82</ce:cross-ref>]. All three inhibitors can inhibit the growth and induce apoptosis of Flt3-ITD<ce:sup loc="post">+</ce:sup> AML cells. Among them, WZ4-49-1 is less effective, while HG7-92-01 is a more effective compound to block the activities of Fes and FLT3-ITD kinases. HG7-92-01 can induce growth arrest and apoptosis in three FLT3-ITD cell lines MV4-11, MOLM-13 and MOLM-14 with the IC<ce:inf loc="post">50</ce:inf> value of 19, 93 and 34 nM, respectively [<ce:cross-ref refid="bib82" id="crosref0565">82</ce:cross-ref>]. Additionally, HG7-92-01 only induces apoptosis in FLT3-ITD<ce:sup loc="post">+</ce:sup> AML bone marrow cells from patients, but not in normal donor bone marrow cells. In the case of FLT3-ITD<ce:sup loc="post">+</ce:sup> AML, dual inhibitors targeting FLT3 and Fes may provide therapeutic advantages for the treatment of FLT3-ITD<ce:sup loc="post">+</ce:sup> AML.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.8" view="all">
                     <ce:label>2.8</ce:label>
                     <ce:section-title id="sectitle0075">FLT3/AKT dual Inhibitor:A674563 (17)</ce:section-title>
                     <ce:para id="p0140" view="all">Protein kinase B (PKB, also known as AKT) is a serine/threonine protein kinase whose C-terminus is a proline-rich hydrophobic region, while its pleckstrin homology domain is highly conserved in evolution [<ce:cross-ref refid="bib83" id="crosref0570">83</ce:cross-ref>]. The PI3K/AKT signaling pathway is extensively present in various cell types, connecting extracellular signals and cellular responses, interacting with downstream signaling molecules and participating in cell growth, proliferation, and differentiation [<ce:cross-ref refid="bib84" id="crosref0575">84</ce:cross-ref>]. In the AML refractory patients, drug treatment-induced elevation of FLT3 ligand levels may cause resistance and hence lead to the persistent activation of downstream mediators, such as AKT [<ce:cross-ref refid="bib85" id="crosref0580">85</ce:cross-ref>,<ce:cross-ref refid="bib86" id="crosref0585">86</ce:cross-ref>].</ce:para>
                     <ce:para id="p0145" view="all">A674563 (17) is an effective dual inhibitor of FLT3 and AKT (IC<ce:inf loc="post">50</ce:inf> values of 134 and 180 nmol/L, respectively). The EC<ce:inf loc="post">50</ce:inf> values of A674563 against the FLT3-ITD positive AML cell lines are 0.092, 0.17, 0.061 μmol/L, for MV4-11, MOLM13, and MOLM14, respectively [<ce:cross-ref refid="bib87" id="crosref0590">87</ce:cross-ref>]. A674563 exhibits potent activity against FLT3-ITD positive AML cancer cells <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> through dual inhibition of AKT and FLT3 kinases, such as in the FLT3-ITD positive AML patient primary cells and the FLT3-ITD positive xenograft model, while A674563 shows excellent anti-tumor activity. More importantly, A674563 can overcome FLT3 ligand-induced drug resistance by simultaneously inhibiting FLT3-ITD and AKT-mediated signaling compared to other single FLT3 inhibitors. Due to the stimulatory effects of FLT3 ligand, AML patients co-stimulating FLT3-ITD and FLT3 WT can produce clinical drug resistance via subsequent over-activation of AKT signaling. Therefore, A674563 may serve as a novel drug for the effective treatment of FLT3-ITD positive AML.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.9" view="all">
                     <ce:label>2.9</ce:label>
                     <ce:section-title id="sectitle0080">FLT3/PDGFR dual Inhibitor:Crenolanib (CP-868–596) (18) and tandutinib (19)</ce:section-title>
                     <ce:para id="p0150" view="all">Similar to the FLT3, the platelet-derived growth factor receptor (PDGFR) kinase is also a member of the class III receptor tyrosine kinase (RTK) family. The aberrant activation of PDGFR was observed in various myeloid malignancies [<ce:cross-ref refid="bib88" id="crosref0595">88</ce:cross-ref>]. FLT3 and PDGFR tyrosine kinases are both critical targets for the treatment of different types of leukemia. Given the structural similarity between FLT3 and PDGFR, it is not surprising that most of the small molecule inhibitors targeting one kinase could also be active against the other [<ce:cross-ref refid="bib89" id="crosref0600">89</ce:cross-ref>]. Therefore, simultaneous inhibition of FLT3 and PDGFR tyrosine kinase may provide a new option for the treatment of leukemia.</ce:para>
                     <ce:para id="p0155" view="all">Crenolanib (CP-868-596) (18) is a novel dual FLT3/PDGFR inhibitor, initially developed as the selective inhibitor of PDGFR. It has a high affinity to other III receptor tyrosine kinase (RTKs), such as FLT3 [<ce:cross-ref refid="bib90" id="crosref0605">90</ce:cross-ref>]. Crenolanib is a benzamidine quinolone derivative (crenolanib besylate, 4-piperidinamine, 1-[2-[5-[(3-methyl-3-oxetanyl)methoxy]-1H-benzimidazol-1-yl]-8-quinolinyl]-, monobenzenesulfonate) [<ce:cross-ref refid="bib91" id="crosref0610">91</ce:cross-ref>]. Crenolanib effectively reduced the viability of MV4-11 and MOLM-13 cells expressing FLT3-ITD, with IC<ce:inf loc="post">50</ce:inf> values of 1.3 and 4.9 nM, respectively. Crenolanib potently inhibited the viability of cells expressing single FLT3 D835H or D835Y mutations (IC<ce:inf loc="post">50</ce:inf> values of 0.3 and 0.06 nM, respectively) and moderately inhibited double FLT3 mutants containing the ITD and D835H/Y or F691L (IC<ce:inf loc="post">50</ce:inf> range, 35–62 nM). The decrease of Ba/F3 cell viability was related to the decrease of FLT 3 phosphorylation level. <ce:italic>In vivo</ce:italic>, Crenolanib delayed tumor infiltration and prolonged survival in a mouse xenograft model of FLT3-ITD positive AML [<ce:cross-ref refid="bib91" id="crosref0615">91</ce:cross-ref>]. These preclinical data indicate that Crenolanib is effective against FLT3-ITD with secondary KD mutation, which suggests that Crenolanib may be a useful therapeutic agent for TKI initial treatment and drug-resistant FLT3-ITD positive AML.</ce:para>
                     <ce:para id="p0160" view="all">Crenolanib represents the first TKI to exhibit both kinase selectivity and invulnerability to resistance-conferring KD mutations [<ce:cross-ref refid="bib92" id="crosref0620">92</ce:cross-ref>]. Although initial responses to FLT3 TKI are observed in FLT3-ITD positive patients, subsequent relapses usually occur upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691 [<ce:cross-ref refid="bib92" id="crosref0625">92</ce:cross-ref>]. Data from preclinical studies suggest that one mechanism of FLT3 TKI resistance is to obtain secondary point mutations in FLT3 KD, which may alter drug binding and convert kinases to a self-activated conformation [<ce:cross-ref refid="bib93" id="crosref0630">93</ce:cross-ref>]. Type II FLT3 inhibitors, such as Quizartinib, Sorafenib, Midostaurin, binding to the inactive conformation of the kinase and prevent its activation. In contrast, type I TKIs can bind to the active or inactive conformation of a receptor tyrosine kinase and can be effective against FLT3-ITD, with point mutations conferring resistance to type II FLT3 inhibitors. Studies have shown that type I TKI can be active and selective to resistance-conferring KD mutation as a mechanism of resistance [<ce:cross-ref refid="bib93" id="crosref0635">93</ce:cross-ref>]. Furthermore, the combination of Crenolanib and the type II inhibitor Sorafenib produced tumor regression and prolonged survival compared to TKI alone. Simultaneous treatment with both type I and type II inhibitors may result in complete inhibition of multiple FLT3-ITD conformations (e.g., active and inactive), which may be an effective therapeutic strategy for FLT3-ITD positive AML.</ce:para>
                     <ce:para id="p0165" view="all">In a word, Crenolanib is a novel FLT3 inhibitor with type I properties and potent activity against FLT3-ITD and FLT3 D835 mutations, which are resistant to currently available FLT3 inhibitors. Currently, many clinical studies of Crenolanib for the treatment of AML with relapsed/refractory AML and FLT3 activating mutations are ongoing, such as a phase II study of Crenolanib in relapsed/refractory acute myeloid leukemia patients with FLT3 activating mutations (NCT01657682). This phase II study is designed to evaluate the effectiveness and tolerability of Crenolanib in two cohorts of AML patients with FLT3 activation mutations. Moreover, the study investigating the efficacy of Crenolanib with chemotherapy versus chemotherapy alone in R/R FLT3 mutated AML (NCT03250338). It was designed to evaluate the efficacy of Crenolanib administered following salvage chemotherapy, consolidation chemotherapy, the post bone marrow transplantation and as maintenance in relapsed/refractory AML subjects with FLT3 activating mutation. As the first effective FLT3 TKI retains the activity of <ce:italic>anti</ce:italic>-D835 mutants and other FLT3 mutant isoforms, the concentration is much lower than the safely achieved level in clinical trial experience, and Crenolanib has great promise to produce a long-lasting clinical response, which may represent a significant advance in the treatment of FLT3-mutant AML.</ce:para>
                     <ce:para id="p0170" view="all">Tandutinib (19) (also known as MLN518 or CT53518), a novel piperazinyl quinazoline, selectively inhibits FLT3 and PDGFR with IC<ce:inf loc="post">50</ce:inf> values of 0.22 and 0.20 μM, respectively [<ce:cross-ref refid="bib94" id="crosref0640">94</ce:cross-ref>]. Tandutinib selectively blocks FLT3-ITD phosphorylation, inhibits cell proliferation and induces apoptosis in FLT3-ITD-positive human leukemia cell lines. Tandutinib treatment results in a significant reduction in disease progression and increased survival in a mouse model of FLT3-ITD-mediated AML. Pharmacokinetic studies in dog and monkey have shown that Tandutinib has an oral bioavailability ranging from 50% to 100% and the terminal plasma half-life of 7–16 h [<ce:cross-ref refid="bib94" id="crosref0645">94</ce:cross-ref>]. Due to the suitable pharmacokinetic and toxic characteristics of Tandutinib for clinical applications, several clinical trials of Tandutinib for the treatment of AML have been conducted. Although Tandutinib has shown good <ce:italic>anti</ce:italic>-AML effects both <ce:italic>in vivo</ce:italic> and <ce:italic>in vitro</ce:italic> in preclinical studies, it has limited activity as a single drug in phase I and phase II clinical trials of AML and myelodysplastic syndrome patients [<ce:cross-ref refid="bib95" id="crosref0650">95</ce:cross-ref>]. However, I/II trials in combination with cytarabine and daunorubicin showed promising antileukemic activity (90% complete remission) in newly diagnosed AML patients [<ce:cross-ref refid="bib96" id="crosref0655">96</ce:cross-ref>].</ce:para>
                  </ce:section>
                  <ce:section id="sec2.10" view="all">
                     <ce:label>2.10</ce:label>
                     <ce:section-title id="sectitle0085">FLT3/AXL dual Inhibitor:Gilteritinib (ASP2215) (20)</ce:section-title>
                     <ce:para id="p0175" view="all">AXL is a receptor tyrosine kinase belonging to the TAM family. It is overexpressed in many cancers, including AML [<ce:cross-ref refid="bib97" id="crosref0660">97</ce:cross-ref>]. Similar to FLT3, AXL has transforming properties, identified as a potential therapeutic target for AML [<ce:cross-ref refid="bib98" id="crosref0665">98</ce:cross-ref>,<ce:cross-ref refid="bib99" id="crosref0670">99</ce:cross-ref>]. Activated by FLT3, AXL is involved in the pathogenesis of AML through its ability to enhance proliferation of leukemic blasts in the FLT3-mutated AML and wild-type FLT3 AML [<ce:cross-ref refid="bib100" id="crosref0675">100</ce:cross-ref>]. Preclinical studies have shown that inhibition of AXL blocks proliferation of FLT3 AML mutants and FLT3 wild-type AML cells, inhibiting the leukemic burden of FLT3-ITD<ce:sup loc="post">+</ce:sup> AML in both a subcutaneous xenograft model and a leukemia engraftment model [<ce:cross-ref refid="bib98" id="crosref0680">98</ce:cross-ref>,<ce:cross-ref refid="bib101" id="crosref0685">101</ce:cross-ref>]. Overexpression of AXL has been associated with poor prognosis in AML and resistance to standard chemotherapy [<ce:cross-ref refid="bib98" id="crosref0690">98</ce:cross-ref>,<ce:cross-ref refid="bib102" id="crosref0695">102</ce:cross-ref>]. Therefore, a new chemical entity that targets both FLT3 and AXL may provide a novel option for AML treatment.</ce:para>
                     <ce:para id="p0180" view="all">Gilteritinib (ASP2215) (20) is a FLT3/AXL small-molecule inhibitor with a structure based on a pyrazine carboxamide scaffold. To date, Gilteritinib is also a type I TKI to exhibit dual and highly selective tyrosine kinase inhibition for FLT3 and AXL. (IC<ce:inf loc="post">50</ce:inf> values of 0.29 and 0.73 nM, respectively). These data suggest that Gilteritinib has less off-target effects and therefore may reduce the toxicity of the drug to patients [<ce:cross-ref refid="bib103" id="crosref0700">103</ce:cross-ref>]. Gilteritinib also demonstrated potent inhibitory activity against the FLT3-ITD and FLT3-D835Y point mutations in cellular assays using MV4–11 and MOLM-13 cells as well as Ba/F3 cells expressing mutated FLT3. Gilteritinib also inhibited FLT3-F691 mutations, although to a lesser degree, in these assays. Furthermore, Gilteritinib decreased the phosphorylation levels of FLT3 in both cellular and animal models. <ce:italic>In vivo</ce:italic>, Gilteritinib was distributed at the high levels in tumors after single administration orally, showing antitumor activity against FLT3-driven tumors in a mouse xenograft model. This antitumor activity was associated with a strong inhibition of phospho-FLT3 and phospho-STAT5, demonstrating the <ce:italic>in vivo</ce:italic> inhibitory effect of Gilteritinib. The decreased FLT3 activity and high intratumor distribution of Gilteritinib translated to tumor regression and improved survival in xenograft and intra-bone marrow transplantation models of FLT3-driven AML. No obvious toxicity was seen in mouse models treated with Gilteritinib. These data suggest that Gilteritinib blocks FLT3 phosphorylation, impairs downstream signal transduction, and consequently inhibits AML cell proliferation in both <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> models. These results also indicate that Gilteritinib may be an important next-generation FLT3 inhibitor for the use in the treatment of FLT3 mutation-positive AML.</ce:para>
                     <ce:para id="p0185" view="all">At present, a number of Gilteritinib clinical studies are underway, such as promising preclinical data in AML cell lines and mouse models led to a Phase I/II dose-escalation study in relapsed/refractory AML with/without FLT3 mutations (NCT02014558). This trial is designed to investigate the safety, tolerability, anti-leukemic effects and pharmacokinetics of ASP2215. Besides, ADMIRAL (NCT02421939) is a Phase III, open-label, multicenter, randomized trial that is conducted at approximately 144 centers worldwide from October 2015 to October 2019 [<ce:cross-ref refid="bib104" id="crosref0705">104</ce:cross-ref>]. The purpose of this study is to determine the clinical benefit of ASP2215 therapy in patients with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML), who are refractory to or have relapsed after first-line AML therapy. Compared to salvage chemotherapy, the efficacy of ASP2215 treatment was assessed by the rate of complete remission and complete remission with partial hematological recovery (CR/CRh) in these patients. This study will also determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy. Further studies for evaluating the role of Gilteritinib will be conducted in different clinical settings, such as maintenance after conventional chemotherapy in newly diagnosed FLT3-mutated AML (GOSSAMER trial, NCT 02927262) or following HSCT (MORPHO trial, NCT02997202) may provide further insight into the best use of such therapies in AML. Excitingly, Gilteritinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients who have relapsed or refractory AML with an FLT3 mutation.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.11" view="all">
                     <ce:label>2.11</ce:label>
                     <ce:section-title id="sectitle0090">FLT3/Mnk2 dual inhibitor: N-phenylpyrimidin-2-amine derivative (21)</ce:section-title>
                     <ce:para id="p0190" view="all">MAPK-interacting kinase-2 (Mnk2) is one of the MAPK-activated protein kinases, which is considered as an essential marker involved in tumorigenesis and development. MAPK cell signaling pathway is associated with many physiological processes of tumor cells, such as gene expression, cell survival, proliferation and apoptosis [<ce:cross-ref refid="bib105" id="crosref0710">105</ce:cross-ref>]. As an initiation actor of translation, eIF4E has been widely used as an <ce:italic>anti</ce:italic>-AML therapy [<ce:cross-ref refid="bib106" id="crosref0715">106</ce:cross-ref>], blocking the activity of eIF4E down-regulates Mcl-1 in AML cells, which leads to the death of apoptotic cells [<ce:cross-ref refid="bib107" id="crosref0720">107</ce:cross-ref>,<ce:cross-ref refid="bib108" id="crosref0725">108</ce:cross-ref>]. It has been demonstrated that Mnk inhibitors down-regulated eIF4E phosphorylation, which induced cell cycle arrest in G1 phase and apoptosis in MV4-11 cells [<ce:cross-ref refid="bib109" id="crosref0730">109</ce:cross-ref>]. The inhibition of eIF4E's translational function may interrupt the mechanism of drug resistance after FLT3 suppression via the MAPK and mTOR pathway.</ce:para>
                     <ce:para id="p0195" view="all">The development of FLT3 and Mnks dual inhibitors was based on the N-(2,4-dimethoxyphenyl)-pyrimidin-2-amine scaffold, bearing either a thiazole or an indole system at the C4 position of pyrimidine. N-phenylpyrimidin-2-amine derivative (21) is the dual inhibitor of FLT3 and Mnk2 (Ki values of 0.34 and 0.11 μmol/L, respectively), which blocks cell cycle G1 phase in a dose-dependent manner [<ce:cross-ref refid="bib110" id="crosref0735">110</ce:cross-ref>]. Compared to single inhibition of FLT3 or Mnk2, the dual inhibition of FLT3 and Mnk2 caused an increase in the number of apoptotic cells in MV4-11 cells. However, the down-regulation of Mcl-1 protein is pronounced dose-dependently, indicating that the combined blockade of Mnk2 and FLT3 exerts an additive effect on AML cells [<ce:cross-ref refid="bib110" id="crosref0740">110</ce:cross-ref>]. As a new approach, the combination of dual inhibitors of FLT3 and Mnk2 have shown an accumulative impact, most likely through induction of apoptosis and down-regulation of viable Mcl-1 protein. These combined effects are precious for the treatment of AML patients, especially those who cannot tolerate the side effects of chemotherapy drugs.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.12" view="all">
                     <ce:label>2.12</ce:label>
                     <ce:section-title id="sectitle0095">FLT3/Auroral B dual inhibitor: Acylureidoindolin-2-one derivative (22), CCT137690 (23) and CCT241736 (24)</ce:section-title>
                     <ce:para id="p0200" view="all">Aurora kinase is a serine/threonine protein kinase which plays a crucial role in mammalian cell cycle regulation, including Aurora A, Aurora B, and Aurora C family members [<ce:cross-ref refid="bib111" id="crosref0745">111</ce:cross-ref>]. The three Aurora kinases have different subcellular locations and functions during mitosis [<ce:cross-ref refid="bib112" id="crosref0750">112</ce:cross-ref>]. Aurora A and Aurora B are overexpressed in various solid tumors [<ce:cross-refs refid="bib113 bib114 bib115" id="crosrefs0020">113–115</ce:cross-refs>] and the hematological malignancies [<ce:cross-ref refid="bib116" id="crosref0755">116</ce:cross-ref>], highlighting their potential as drug targets [<ce:cross-ref refid="bib117" id="crosref0760">117</ce:cross-ref>]. Recent studies have shown that the survival of Aurora B in AML cells is more functional than Aurora A. In addition, in the Phase I-II clinical trial, the efficacy of the Aurora B inhibitor AZD1152 was 25% effective in the relapse or standard treatment resistance of elderly patients with AML (52–75 years old) [<ce:cross-ref refid="bib118" id="crosref0765">118</ce:cross-ref>]. In contrast, the effective rate for patients over 65 years of age who received standard treatment was 10% [<ce:cross-ref refid="bib119" id="crosref0770">119</ce:cross-ref>]. Recent studies have demonstrated that dual Aurora B/FLT3 inhibitors have better therapeutic efficacy than selective FLT3 inhibitors on FLT3 mutant-associated AML [<ce:cross-ref refid="bib120" id="crosref0775">120</ce:cross-ref>].</ce:para>
                     <ce:para id="p0205" view="all">A series of 6-acylureido derivatives including a 3-(pyrrol-2-ylmethylidene)indolin-2-one scaffold were synthesized as possible dual Aurora B/FLT3 inhibitors by replacing the 6-arylureido moiety in 6-arylureidoindolin-2-one-based multi-kinase inhibitors. (Z)-N-(2-(pyrrolidin-1-yl) ethyl)-5-((6-(3-(2-fluoro-4-methoxybenzoyl)ureido)-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (22) was identified as a dual Aurora B/FLT3 inhibitor (IC<ce:inf loc="post">50</ce:inf> = 0.4 nM and 0.5 nM, respectively). Structure-activity relationship studies demonstrated the significance of the 6-acylureido and 3-pyrrolemethylidene moieties attached to the indolin-2-one scaffold concerning potent kinase inhibitory activity and cytotoxicity. This compound has potent cytotoxicity against the FLT3 mutant-associated AML cell lines, MV4-11 and MOLM13 (IC<ce:inf loc="post">50</ce:inf> values of 2.4 and 0.7 nmol/L, respectively) [<ce:cross-ref refid="bib121" id="crosref0780">121</ce:cross-ref>]. Induction of extrinsic apoptosis inhibited phosphorylation specifically of Aurora B and FLT3 pathways in MOLM-13 cells [<ce:cross-ref refid="bib122" id="crosref0785">122</ce:cross-ref>]. Cell cycle arrest in the G2/M phase was observed in MOLM13 cells treated with this compound, while no cell cycle arrest was observed in MOLM13 cells treated with sunitinib. The compound effectively inhibits tumor growth and reduce mortality of BALB/c nude mice (subcutaneous xenograft models), which have been implanted with MOLM13 cells. It inhibits not only FLT3-WT AML cells but also has activity against sunitinib-resistant FLT3-ITD AML cells [<ce:cross-ref refid="bib123" id="crosref0790">123</ce:cross-ref>]. Besides, the compound has good solubility and permeability, exhibits good pharmacological and safety characteristics <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic> (therapeutic index LD50/ED50 is greater than 10). It is also acceptable <ce:italic>in vivo</ce:italic> pharmacokinetic profile when administered intravenously [<ce:cross-ref refid="bib121" id="crosref0795">121</ce:cross-ref>]. In sum, dual FLT3/Aurora B inhibitors have great potential in the treatment of AML with activating mutations in FLT3, which may be particularly useful in those elderly AML patients.</ce:para>
                     <ce:para id="p0210" view="all">CCT137690 (23), a derivative based on the imidazo[4,5-<ce:italic>b</ce:italic>]pyridine scaffold, is an orally bioavailable, potent FLT3 and pan-Aurora inhibitor (IC<ce:inf loc="post">50</ce:inf> values of Aurora A, Aurora B, Aurora C, and FLT3 are 15, 25, 19, and <0.5 nmol/L, respectively) [<ce:cross-ref refid="bib124" id="crosref0800">124</ce:cross-ref>]. CCT137690 effectively inhibited the viability of FLT3-ITD positive human AML cell lines MOLM-13 and MV4-11 <ce:italic>in vitro</ce:italic> (IC<ce:inf loc="post">50</ce:inf> values were 23 and 62 nmol/L, respectively). CCT137690 inhibited autophosphorylation of FLT3 and phosphorylation of its downstream targets STAT5 and p44/42 MAPK (Erk1/2). CCT137690 inhibited both Aurora and FLT3 kinase in FLT3-ITD positive AML to induce cell apoptosis and induce cell arrest in G2/M phase. In FLT3-ITD positive AML, FLT3 kinase is constitutively activated, and FLT3 inhibitory effect of CCT137690 is dominant, while Aurora inhibitory effect is dominant in FLT3-WT AML. In addition, FLT3-ITD positive AML cell lines carrying secondary D835Y mutation showed high relative resistance to FLT3 inhibitors AC220, MLN518 and Sorafenib, but no resistance to CCT137690 [<ce:cross-ref refid="bib124" id="crosref0805">124</ce:cross-ref>]. However, CCT137690 has a poor <ce:italic>in vitro</ce:italic> safety of hERG (IC<ce:inf loc="post">50</ce:inf> = 3.0 μM) and low human liver microsome stability (86% metabolized after 30 min of incubation), which limits its preclinical development [<ce:cross-ref refid="bib125" id="crosref0810">125</ce:cross-ref>].</ce:para>
                     <ce:para id="p0215" view="all">CCT241736 (24), an imidazo[4,5-<ce:italic>b</ce:italic>]pyridine derivative optimized on the basis of CCT137690 (6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-<ce:italic>b</ce:italic>]pyridine), is a novel, effective FLT3 and pan-Aurora inhibitors (IC<ce:inf loc="post">50</ce:inf> values for FLT3, Aurora A and Aurora B are 35, 15 and 100 nmol/L, respectively) [<ce:cross-ref refid="bib120" id="crosref0815">120</ce:cross-ref>]. The emergence of CCT241736 addresses the problems with CCT137690 - hERG inhibition and human liver microsome instability. The conversion of the N-methylpiperazine moiety to the m-position in the 6-Cl counterpart compound of CCT137690 is advantageous for reducing the affinity for hERG and significantly increasing the stability of human liver microsomes. Substitution of the R<ce:sup loc="post">2</ce:sup> (4-methylpiperazin-1-yl)phenyl substituent with a five-membered heteroaromatic led to the identification of the 1,3-dimethyl-1<ce:italic>H</ce:italic>-pyrazol-4-yl group as the preferred R<ce:sup loc="post">2</ce:sup> substituent. Subsequent improvements in the properties of the R<ce:sup loc="post">3</ce:sup> substituent modification resulted in CCT241736, a highly bioavailable dual FLT3/Aurora kinase inhibitor with high selectivity within the tested kinome [<ce:cross-ref refid="bib120" id="crosref0820">120</ce:cross-ref>]. CCT241736 inhibits a wide range of FLT3 mutants, including FLT3-ITD, -D835Y, -D835H, -K663Q and -N841I. In the cellular assay, CCT241736 inhibited the viability of human FLT3-ITD positive AML cell lines MOLM-13 and MV4-11 with EC<ce:inf loc="post">50</ce:inf> values of 0.1 and 0.27 M, respectively. In vivo, CCT241736 has a strong tumor growth inhibitory effect on mouse tumor xenograft models of MOLM-13 and MV4-11. Moreover, the pharmacokinetic studies of CCT241736 in mouse and rats showed moderate (48 ml/min/kg) and low (4.57 ml/min/kg) clearance, respectively, and high oral bioavailability (79–100%) [<ce:cross-ref refid="bib120" id="crosref0825">120</ce:cross-ref>]. CCT241736 has been selected as a preclinical development candidate for the treatment of human malignancies, especially for the treatment of AML in adults and children.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.13" view="all">
                     <ce:label>2.13</ce:label>
                     <ce:section-title id="sectitle0100">FLT3/TOPK dual inhibitor: HSD1169 (25)</ce:section-title>
                     <ce:para id="p0220" view="all">T-lymphokine-activated killer cell-originated protein kinase (TOPK), also known as PDZ-binding kinase (PBK), is a dual specificity serine/threonine kinase, which belongs to the mitogen-activated protein kinase kinase (MAPKK) family [<ce:cross-ref refid="bib126" id="crosref0830">126</ce:cross-ref>,<ce:cross-ref refid="bib127" id="crosref0835">127</ce:cross-ref>]. TOPK is reported to be related to cancer cell proliferation, apoptosis, metastasis and cell-cycle regulation [<ce:cross-refs refid="bib128 bib129 bib130 bib131" id="crosrefs0025">128–131</ce:cross-refs>]. TOPK is hardly detected in normal cells except for testis and fetal tissues, but highly expressed in multiple solid tumors and hematological malignancies [<ce:cross-refs refid="bib132 bib133 bib134" id="crosrefs0030">132–134</ce:cross-refs>]. Previous studies had shown that TOPK was highly expressed in most AML cell lines from different cytogenetic and molecular subpopulations. TOPK knock-down resulted in a significant decrease in the cell viability and strong induction of apoptosis in MV4-11 cells and MOLM13 cells [<ce:cross-ref refid="bib10" id="crosref0840">10</ce:cross-ref>]. Furthermore, TOPK inhibitor OTS514 resulted in a dose-dependent decrease in cell viability in MV4-11, MOLM13 cell lines and blasts obtained from patients who relapse after treatment with FLT3 inhibitors [<ce:cross-ref refid="bib135" id="crosref0845">135</ce:cross-ref>,<ce:cross-ref refid="bib136" id="crosref0850">136</ce:cross-ref>]. Importantly, OTS514 showed prominent anti-leukemia activity and significantly prolonged survival compared to the control group in MV4-11 engrafted mouse model [<ce:cross-ref refid="bib135" id="crosref0855">135</ce:cross-ref>]. Therefore, TOPK can be considered as a promising target for AML drug development.</ce:para>
                     <ce:para id="p0225" view="all">HSD1169 (25) is a novel and potent FLT3/TOPK dual inhibitor (IC<ce:inf loc="post">50</ce:inf> values of 5 and 21 nmol/L, respectively). Compound HSD1169 includes five rings, labeled A, B, C, D and E. Structural-activity relationships show that the ring A, C and E in HSD1169 play a key role in FLT3 kinase inhibition and proliferation inhibition. Compounds lacking ring C are weak inhibitors of FLT3 and do not inhibit the growth of MV4-11. Compounds with hydrogen, methyl or trifluoromethyl at the 3-position of ring A are effective inhibitors of AML proliferation, of which trifluoromethyl is the best one (HSD1169) [<ce:cross-ref refid="bib137" id="crosref0860">137</ce:cross-ref>]. The D835 and F691 mutations are two common mutations that occur at relapse. HSD1169 is active against FLT3-ITD (D835 or F691), and the IC<ce:inf loc="post">50</ce:inf> value of HSD1169 for FLT3-ITD and FLT3-D835Y is 2 and 1 nmol/L, respectively. Additionally, a dose-dependent increased cell ratio in G0/G1 phase was observed after treated with HSD1169 at different concentrations after 24 h [<ce:cross-ref refid="bib137" id="crosref0865">137</ce:cross-ref>]. HSD1169 or a close analog could be a promising therapeutic agent for AML patients with relapse.</ce:para>
                  </ce:section>
                  <ce:section id="sec2.14" view="all">
                     <ce:label>2.14</ce:label>
                     <ce:section-title id="sectitle0105">FLT3/IKK2 dual inhibitor: AS602868 (26)</ce:section-title>
                     <ce:para id="p0230" view="all">The nuclear factor kappaB (NF-κB), a transcription factor, is often activated in neoplasia [<ce:cross-ref refid="bib138" id="crosref0870">138</ce:cross-ref>]. Through transcription of a broad array of genes, NF-κB plays a critical role in cancer cell proliferation, anti-apoptosis, invasion, and sustaining angiogenesis [<ce:cross-ref refid="bib139" id="crosref0875">139</ce:cross-ref>]. IκB molecules are the repressors of NF-κB transcription factors [<ce:cross-ref refid="bib140" id="crosref0880">140</ce:cross-ref>]. Phosphorylation of the IκB protein by the inhibitor of NF-κB kinase (IKK) complex is a critical step in NF-κB activation, which leads to the degradation of the proteasome. This process induces nuclear translocation and transcriptional regulation of target genes. IKK complex contains two kinds of protein kinases, IKK1 (IKKα) and IKK2 (IKKβ), as well as the regulatory protein NF-κB essential modulator (IKKγ). IKK2 is a crucial kinase subunit that induces classical signaling pathways and involves in the regulation of cell apoptotic and survival [<ce:cross-refs refid="bib141 bib142 bib143" id="crosrefs0035">141–143</ce:cross-refs>]. Recently, it has been reported that NF-κB can be activated via the Ras/phosphatidylinositol-3-kinase (PI3K)/protein kinase B pathway in AML [<ce:cross-ref refid="bib144" id="crosref0885">144</ce:cross-ref>]. Therefore, IKK2 is an attractive potential therapeutical target as NF-κB is found aberrantly activated in most of AML [<ce:cross-ref refid="bib145" id="crosref0890">145</ce:cross-ref>].</ce:para>
                     <ce:para id="p0235" view="all">AS602868 (26), an anilino-pyrimidine derivative and adenosine triphosphate competitor, is an FLT3/IKK2 dual inhibitor (IC<ce:inf loc="post">50</ce:inf> values of 618 and 70 nmol/L, respectively) [<ce:cross-ref refid="bib146" id="crosref0895">146</ce:cross-ref>]. AS602868 blocked the activation of NF-κB by targeting the active form of IKK2 [<ce:cross-ref refid="bib147" id="crosref0900">147</ce:cross-ref>]. AS602868 not only affected the activation of IKK2, but also directly interfered with the activation of FLT3. AS602868 can inhibit FLT3-WT and FLT3-ITD, FLT3-D835V and FLT3-D835Y mutants [<ce:cross-ref refid="bib146" id="crosref0905">146</ce:cross-ref>]. In addition, it was also observed that AS602868 decreased the expression of Bcl-xL, an anti-apoptotic member of Bcl-2 mitochondrial protein family, which is very important for controlling the pathway of mitochondrial cell death [<ce:cross-ref refid="bib148" id="crosref0910">148</ce:cross-ref>]. AS602868 had no significant effect on the growth of HT-29 xenografts in nude mice, while AS602868 could enhance the anti-tumor effect of irinotecan (topoisomerase 1 inhibitor) in a dose-dependent manner. The combination of AS602868 and irinotecan reduced the dose of irinotecan and did not decrease the anti-tumor activity. Ex vivo tumor analysis and <ce:italic>in vitro</ce:italic> studies on HT-29 cells showed that AS602868 damaged the activation of NF-κB induced by irinotecan, enhanced cell cycle arrest and apoptosis, and reduced the tumor cell proliferation and tumor angiogenesis [<ce:cross-ref refid="bib146" id="crosref0915">146</ce:cross-ref>]. Importantly, AS602868 was given to NMRI nude or C57BL/6 mice at a dose of 100 mg/kg (5 days a week). After 3 weeks of treatment, AS602868 did not affect the number or size of colony-forming cells colonies, indicating that AS602868 did not exert significant toxicity on normal hematopoiesis <ce:italic>in vivo</ce:italic> [<ce:cross-ref refid="bib149" id="crosref0920">149</ce:cross-ref>]. Since FLT3 and NF-κB are vital participants in the proliferation, survival and differentiation of normal hematopoietic or leukemia cells, the inhibitor AS602868, which has dual inhibitory effects on these pathways, is a promising molecule for the treatment of AML.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="sec3" view="all">
                  <ce:label>3</ce:label>
                  <ce:section-title id="sectitle0110">Perspective</ce:section-title>
                  <ce:para id="p0240" view="all">At present, there is an urgent need for effective treatment of cancer cells with minimal cytotoxicity to improve the prognosis and long-term life quality of patients. Thus, from a clinical point of view, dual target inhibitors are of vital importance. The resistant to target therapy could be possibly reversed by simultaneously blocking two or more signaling pathways. It indicates a new strategy for agent screening as an effective targeted cancer therapy. In AML, the activity of these series of dual-inhibition compounds provides additional efficacy is related to inhibition of either kinase alone, reducing drug resistance and improving drug efficacy. However, most of the dual-target inhibitors only demonstrate their activities in preclinical studies at present. There are also some problems after entering clinical trials, such as toxicity, selectivity, PD, PK, etc. Its mechanism of action, the scope of application, and adverse effects of long-term require to be further researched. Moreover, it is foreseeable that dual-target drugs will be maturely and rationally evaluated, with the deepening of research on the mechanism of targeted therapeutic drug actions and abundant clinical data accumulations.</ce:para>
               </ce:section>
            </ce:sections>
            <ce:acknowledgment id="ack0010" view="all">
               <ce:section-title id="sectitle0115">Acknowledgements</ce:section-title>
               <ce:para id="p0245" view="all">The financial support of this study was from the <ce:grant-sponsor id="gs1" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Key project of clinical research and transformation fund of Sichuan people's hospital</ce:grant-sponsor> (No. <ce:grant-number refid="gs1">2016LZ03</ce:grant-number>) and <ce:grant-sponsor id="gs2" sponsor-id="https://doi.org/10.13039/501100001809" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Natural Science Foundation of China</ce:grant-sponsor> (No. <ce:grant-number refid="gs2">81302643</ce:grant-number>, <ce:grant-number refid="gs2">81703457</ce:grant-number>). The project of <ce:grant-sponsor id="gs3" sponsor-id="https://doi.org/10.13039/501100010822" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Chengdu Science and Technology, Bureau</ce:grant-sponsor> (No. <ce:grant-number refid="gs3">2015-HM01-00463-SF</ce:grant-number>), <ce:grant-sponsor id="gs4" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">Special research project on TCM science and technology in Sichuan province</ce:grant-sponsor> (No. <ce:grant-number refid="gs4">2016Q001</ce:grant-number>) and the <ce:grant-sponsor id="gs5" xlink:type="simple" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor">National Key Specialty Construction Project of Clinical Pharmacy</ce:grant-sponsor> (<ce:grant-number refid="gs5">30305030698</ce:grant-number>) is gratefully acknowledged.</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="cebib0010" view="all">
               <ce:section-title id="sectitle0120">References</ce:section-title>
               <ce:bibliography-sec id="cebibsec0010" view="all">
                  <ce:bib-reference id="bib1">
                     <ce:label>[1]</ce:label>
                     <sb:reference id="sref1">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Khwaja</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bjorkholm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Gale</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Jordan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ehninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Bloomfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Estey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Burnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Cornelissen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Scheinberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bouscary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Linch</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acute myeloid leukaemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Dis. Prim.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16010</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0025">A. Khwaja, M. Bjorkholm, R.E. Gale, R.L. Levine, C.T. Jordan, G. Ehninger, C.D. Bloomfield, E. Estey, A. Burnett, J.J. Cornelissen, D.A. Scheinberg, D. Bouscary, D.C. Linch, Acute myeloid leukaemia, Nature Reviews Disease Primers, 2 (2016) 16010.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib2">
                     <ce:label>[2]</ce:label>
                     <sb:reference id="sref2">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3 mutations biology and treatment</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hematol. Am. Soc. Hematol. Educ. Progr.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>178</sb:first-page>
                              <sb:last-page>184</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0030">D. Small, FLT3 Mutations Biology and Treatment, Hematology Am Soc Hematol Educ Program, 1 (2006) 178-184.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib3">
                     <ce:label>[3]</ce:label>
                     <sb:reference id="sref3">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of FLT3 in leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Curr. Opin. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>274</sb:first-page>
                              <sb:last-page>281</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0035">D.G. Gilliland, J.D. Griffin, Role of FLT3 in leukemia, Current Opinion in Hematology, 9 (2002) 274-281.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib4">
                     <ce:label>[4]</ce:label>
                     <sb:reference id="sref4">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>D. U</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Z. M</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>M. G</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>R. O</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>B. D</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>L. W D</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>Q. H</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>D. H G</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>1996</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>261</sb:first-page>
                              <sb:last-page>270</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0040">D. U, Z. M, M. G, R. O, B. D, L. W D, Q. H, D. H G, Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells, Leukemia, 2 (1996) 261-270.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib5">
                     <ce:label>[5]</ce:label>
                     <sb:reference id="sref5">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Kadia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ravandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>New drugs in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ann. Oncol. : Off. J. Eur. Soc. Med. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>770</sb:first-page>
                              <sb:last-page>778</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0045">T.M. Kadia, F. Ravandi, J. Cortes, H. Kantarjian, New drugs in acute myeloid leukemia, Annals of oncology : official journal of the European Society for Medical Oncology, 27 (2016) 770-778.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib6">
                     <ce:label>[6]</ce:label>
                     <sb:reference id="sref6">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kayser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leuk. Lymphoma</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>243</sb:first-page>
                              <sb:last-page>255</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0050">S. Kayser, M.J. Levis, FLT3tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations, Leukemia & Lymphoma, 55 (2013) 243-255.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib7">
                     <ce:label>[7]</ce:label>
                     <sb:reference id="sref7">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The roles of FLT3 in hematopoiesis and leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1532</sb:first-page>
                              <sb:last-page>1542</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0055">D.G. Gilliland, J.D. Griffin, The roles of FLT3 in hematopoiesis and leukemia, Blood, 100 (2002) 1532-1542.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib8">
                     <ce:label>[8]</ce:label>
                     <sb:reference id="sref8">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Marcucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Haferlach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dohner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>475</sb:first-page>
                              <sb:last-page>486</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0060">G. Marcucci, T. Haferlach, H. Dohner, Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 (2011) 475-486.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib9">
                     <ce:label>[9]</ce:label>
                     <sb:reference id="sref9">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>McQueen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Harris</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Estrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Quintas-Cardama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Natl. Cancer Inst.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>184</sb:first-page>
                              <sb:last-page>198</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0065">W. Zhang, M. Konopleva, Y.X. Shi, T. McQueen, D. Harris, X. Ling, Z. Estrov, A. Quintas-Cardama, D. Small, J. Cortes, M. Andreeff, Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia, Journal of the National Cancer Institute, 100 (2008) 184-198.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib10">
                     <ce:label>[10]</ce:label>
                     <sb:reference id="sref10">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>O'Farrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Abrams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.A.</ce:given-name>
                                 <ce:surname>Yuen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Ngai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Louie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Yee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.B.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Town</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smolich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Manning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Murray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Cherrington</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3597</sb:first-page>
                              <sb:last-page>3605</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0070">A.M. O'Farrell, T.J. Abrams, H.A. Yuen, T.J. Ngai, S.G. Louie, K.W. Yee, L.M. Wong, W. Hong, L.B. Lee, A. Town, B.D. Smolich, W.C. Manning, L.J. Murray, M.C. Heinrich, J.M. Cherrington, SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, 101 (2003) 3597-3605.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib11">
                     <ce:label>[11]</ce:label>
                     <sb:reference id="sref11">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Lopes de Menezes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.N.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.G.</ce:given-name>
                                 <ce:surname>Louie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wiesmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shephard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Goldbeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Oei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Aukerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Heise</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5281</sb:first-page>
                              <sb:last-page>5291</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0075">D.E. Lopes de Menezes, J. Peng, E.N. Garrett, S.G. Louie, S.H. Lee, M. Wiesmann, Y. Tang, L. Shephard, C. Goldbeck, Y. Oei, H. Ye, S.L. Aukerman, C. Heise, CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia, Clinical cancer research : an official journal of the American Association for Cancer Research, 11 (2005) 5281-5291.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib12">
                     <ce:label>[12]</ce:label>
                     <sb:reference id="sref12">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Beran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Dauses</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Allebach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>103</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3669</sb:first-page>
                              <sb:last-page>3676</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0080">B.D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K.M. Murphy, T. Dauses, J. Allebach, D. Small, Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia, Blood, 103 (2004) 3669-3676.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib13">
                     <ce:label>[13]</ce:label>
                     <sb:reference id="sref13">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Wander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:surname>F.A.T.</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Ther. Adv. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>65</sb:first-page>
                              <sb:last-page>77</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0085">Wander SA, Levis MJ, F. AT., The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond, Ther Adv Hematol, 5 (2014) 65-77.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib14">
                     <ce:label>[14]</ce:label>
                     <sb:reference id="sref14">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Röllig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Müller-Tidow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hüttmann</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>124</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>(abstract)</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0090">C. Rollig, C. Muller-Tidow, A. Huttmann, Sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosed acute myeloid leukemia: Results from 267 Patients Treated in the Randomized Placebo-Controlled SAL-Soraml Trial, Blood, 124 (2014) abstract.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib15">
                     <ce:label>[15]</ce:label>
                     <sb:reference id="sref15">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kindler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.B.</ce:given-name>
                                 <ce:surname>Lipka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3 as a therapeutic target in AML: still challenging after all these years</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>116</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5089</sb:first-page>
                              <sb:last-page>5102</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0095">T. Kindler, D.B. Lipka, T. Fischer, FLT3 as a therapeutic target in AML: still challenging after all these years, Blood, 116 (2010) 5089-5102.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib16">
                     <ce:label>[16]</ce:label>
                     <sb:reference id="sref16">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Grunwald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>683</sb:first-page>
                              <sb:last-page>694</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0100">M.R. Grunwald, M.J. Levis, FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance, International journal of hematology, 97 (2013) 683-694.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib17">
                     <ce:label>[17]</ce:label>
                     <sb:reference id="sref17">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Ellis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Hicklin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Resistance to targeted therapies: refining anticancer therapy in the era of molecular oncology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7471</sb:first-page>
                              <sb:last-page>7478</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0105">L.M. Ellis, D.J. Hicklin, Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology, Clinical cancer research : an official journal of the American Association for Cancer Research, 15 (2009) 7471-7478.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib18">
                     <ce:label>[18]</ce:label>
                     <sb:reference id="sref18">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Woodcock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.E.</ce:given-name>
                                 <ce:surname>Behrman</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development of novel combination therapies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>364</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>985</sb:first-page>
                              <sb:last-page>987</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0110">J. Woodcock, J.P. Griffin, R.E. Behrman, Development of novel combination therapies, The New England journal of medicine, 364 (2011) 985-987.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib19">
                     <ce:label>[19]</ce:label>
                     <sb:reference id="sref19">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.W.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Z.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of drug combinations: interaction and network perspectives</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>111</sb:first-page>
                              <sb:last-page>128</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0115">J. Jia, F. Zhu, X. Ma, Z. Cao, Z.W. Cao, Y. Li, Y.X. Li, Y.Z. Chen, Mechanisms of drug combinations: interaction and network perspectives, Nature reviews. Drug discovery, 8 (2009) 111-128.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib20">
                     <ce:label>[20]</ce:label>
                     <sb:reference id="sref20">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Baker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.P.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CDK4: a key player in the cell cycle, development, and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>658</sb:first-page>
                              <sb:last-page>669</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0120">S. Baker, E.P. Reddy, CDK4: A Key Player in the Cell Cycle, Development, and Cancer, Genes Cancer, 3 (2012) 658-669.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib21">
                     <ce:label>[21]</ce:label>
                     <sb:reference id="sref21">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Keegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ragains</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Coberly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hollenback</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Eksterowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Weidner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Huard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Alba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Orf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ngo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Carlson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Queva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Medina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wickramasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>13</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>880</sb:first-page>
                              <sb:last-page>889</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0125">K. Keegan, C. Li, Z. Li, J. Ma, M. Ragains, S. Coberly, D. Hollenback, J. Eksterowicz, L. Liang, M. Weidner, J. Huard, X. Wang, G. Alba, J. Orf, M.C. Lo, S. Zhao, R. Ngo, A. Chen, L. Liu, T. Carlson, C. Queva, L.R. McGee, J. Medina, A. Kamb, D. Wickramasinghe, K. Dai, Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia, Molecular cancer therapeutics, 13 (2014) 880-889.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib22">
                     <ce:label>[22]</ce:label>
                     <sb:reference id="sref22">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Blaser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Duchemin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Kusewitt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Caligiuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Briesewitz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2075</sb:first-page>
                              <sb:last-page>2083</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0130">L. Wang, J. Wang, B.W. Blaser, A.M. Duchemin, D.F. Kusewitt, T. Liu, M.A. Caligiuri, R. Briesewitz, Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia, Blood, 110 (2007) 2075-2083.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib23">
                     <ce:label>[23]</ce:label>
                     <sb:reference id="sref23">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.G.</ce:given-name>
                                 <ce:surname>Drexler</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>845</sb:first-page>
                              <sb:last-page>859</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0135">H.G. Drexler, Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells, Leukemia, 12 (1998) 845-859.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib24">
                     <ce:label>[24]</ce:label>
                     <sb:reference id="sref24">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Eksterowicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Gribble</ce:surname>
                                 <ce:suffix>Jr.</ce:suffix>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.Q.</ce:given-name>
                                 <ce:surname>Alba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ayres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Carlson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.V.</ce:given-name>
                                 <ce:surname>Connors</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>DeGraffenreid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Deignan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Duquette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fisher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.N.</ce:given-name>
                                 <ce:surname>Huard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kaizerman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Keegan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Lively</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Lo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>McMinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.T.</ce:given-name>
                                 <ce:surname>Mihalic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Modi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ngo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pattabiraman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Piper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Queva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Ragains</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Suchomel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Thibault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Walker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wanska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Wehn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.F.</ce:given-name>
                                 <ce:surname>Weidner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wickramasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Medina</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3430</sb:first-page>
                              <sb:last-page>3449</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0140">Z. Li, X. Wang, J. Eksterowicz, M.W. Gribble, Jr., G.Q. Alba, M. Ayres, T.J. Carlson, A. Chen, X. Chen, R. Cho, R.V. Connors, M. DeGraffenreid, J.T. Deignan, J. Duquette, P. Fan, B. Fisher, J. Fu, J.N. Huard, J. Kaizerman, K.S. Keegan, C. Li, K. Li, Y. Li, L. Liang, W. Liu, S.E. Lively, M.C. Lo, J. Ma, D.L. McMinn, J.T. Mihalic, K. Modi, R. Ngo, K. Pattabiraman, D.E. Piper, C. Queva, M.L. Ragains, J. Suchomel, S. Thibault, N. Walker, X. Wang, Z. Wang, M. Wanska, P.M. Wehn, M.F. Weidner, A.J. Zhang, X. Zhao, A. Kamb, D. Wickramasinghe, K. Dai, L.R. McGee, J.C. Medina, Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3, Journal of Medicinal Chemistry 57 (2014) 3430-3449.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib25">
                     <ce:label>[25]</ce:label>
                     <sb:reference id="sref25">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Pratz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Stine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rajkhowa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>115</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1425</sb:first-page>
                              <sb:last-page>1432</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0145">K.W. Pratz, T. Sato, K.M. Murphy, A. Stine, T. Rajkhowa, M. Levis, FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML, Blood, 115 (2010) 1425-1432.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib26">
                     <ce:label>[26]</ce:label>
                     <sb:reference id="sref26">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.R.</ce:given-name>
                                 <ce:surname>McGee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Newhall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sinclair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kamb</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wickramasinghe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>375</sb:first-page>
                              <sb:last-page>383</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0150">C. Li, L. Liu, L. Liang, Z. Xia, Z. Li, X. Wang, L.R. McGee, K. Newhall, A. Sinclair, A. Kamb, D. Wickramasinghe, K. Dai, AMG 925 is a dual FLT3/CDK4 inhibitor with the potential to overcome FLT3 inhibitor resistance in acute myeloid leukemia, Molecular cancer therapeutics, 14 (2015) 375-383.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib27">
                     <ce:label>[27]</ce:label>
                     <sb:reference id="sref27">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Finn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Crown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Boér</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Láng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Parikh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Breazna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Ho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.T.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Randolph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Slamon</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Results of a randomized phase 2 study of Pd 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of Er +/Her2-Advanced breast cancer (bc)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0155">R. S. Finn, J. P. Crown, K. Boer, I. Lang, R. J. Parikh, A. Breazna, S. N. Ho, S. T. Kim, S. Randolph, D. J. Slamon, Results of a Randomized Phase 2 Study of Pd 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination with Letrozole Vs Letrozole Alone for First-Line Treatment of Er +/Her2-Advanced Breast Cancer (Bc), Cancer research, 23 (2012) 43.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib28">
                     <ce:label>[28]</ce:label>
                     <sb:reference id="sref28">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Rawlings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Rosler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Harrison</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The JAK/STAT signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Cell Sci.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1281</sb:first-page>
                              <sb:last-page>1283</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0160">J.S. Rawlings, K.M. Rosler, D.A. Harrison, The JAK/STAT signaling pathway, Journal of cell science, 117 (2004) 1281-1283.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib29">
                     <ce:label>[29]</ce:label>
                     <sb:reference id="sref29">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bennett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.F.</ce:given-name>
                                 <ce:surname>Stroncek</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent advances in the bcr-abl negative chronic myeloproliferative diseases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Transl. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>41</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0165">M. Bennett, D.F. Stroncek, Recent advances in the bcr-abl negative chronic myeloproliferative diseases, Journal of translational medicine, 4 (2006) 41.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib30">
                     <ce:label>[30]</ce:label>
                     <sb:reference id="sref30">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.V.</ce:given-name>
                                 <ce:surname>Janakakumara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.G.</ce:given-name>
                                 <ce:surname>Tay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.F.</ce:given-name>
                                 <ce:surname>Poon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Palaniyandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Glaser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.H.</ce:given-name>
                                 <ce:surname>Albert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Davidsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>113</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4052</sb:first-page>
                              <sb:last-page>4062</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0170">J. Zhou, C. Bi, J.V. Janakakumara, S.C. Liu, W.J. Chng, K.G. Tay, L.F. Poon, Z. Xie, S. Palaniyandi, H. Yu, K.B. Glaser, D.H. Albert, S.K. Davidsen, C.S. Chen, Enhanced activation of STAT pathways and overexpression of survivin confer resistance to FLT3 inhibitors and could be therapeutic targets in AML, Blood, 113 (2009) 4052-4062.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib31">
                     <ce:label>[31]</ce:label>
                     <sb:reference id="sref31">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ikezoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kojima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Furihata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nishioka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Isaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Koeffler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Yokoyama</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Int. J. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>129</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2512</sb:first-page>
                              <sb:last-page>2521</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0175">T. Ikezoe, S. Kojima, M. Furihata, J. Yang, C. Nishioka, A. Takeuchi, M. Isaka, H.P. Koeffler, A. Yokoyama, Expression of p-JAK2 predicts clinical outcome and is a potential molecular target of acute myelogenous leukemia, International journal of cancer, 129 (2011) 2512-2521.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib32">
                     <ce:label>[32]</ce:label>
                     <sb:reference id="sref32">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Novotny-Diermayr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hentze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Madan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Amalini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.K.</ce:given-name>
                                 <ce:surname>Loh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>William</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Poulsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Jayaraman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.H.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ethirajulu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Dymock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1751</sb:first-page>
                              <sb:last-page>1759</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0180">S. Hart, K.C. Goh, V. Novotny-Diermayr, C.Y. Hu, H. Hentze, Y.C. Tan, B. Madan, C. Amalini, Y.K. Loh, L.C. Ong, A.D. William, A. Lee, A. Poulsen, R. Jayaraman, K.H. Ong, K. Ethirajulu, B.W. Dymock, J.W. Wood, SB1518, a novel macrocyclic pyrimidine-based JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies, Leukemia, 25 (2011) 1751-1759.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib33">
                     <ce:label>[33]</ce:label>
                     <sb:reference id="sref33">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Goh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Novotny-Diermayr</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Madan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Amalini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Ong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Cheong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.J.</ce:given-name>
                                 <ce:surname>Chng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wood</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood Canc. J.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>e44</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0185">S. Hart, K.C. Goh, V. Novotny-Diermayr, Y.C. Tan, B. Madan, C. Amalini, L.C. Ong, B. Kheng, A. Cheong, J. Zhou, W.J. Chng, J.M. Wood, Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia, Blood cancer journal, 1 (2011) e44.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib34">
                     <ce:label>[34]</ce:label>
                     <sb:reference id="sref34">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.-j.</ce:given-name>
                                 <ce:surname>Lou</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Pharmacol. Sin.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>212</sb:first-page>
                              <sb:last-page>213</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0190">Y.-j. Lou, Novel targeted therapy for acute myeloid leukemia with a dual FLT3 and JAK2 inhibitor, Acta Pharmacologica Sinica, 33 (2012) 212-213.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib35">
                     <ce:label>[35]</ce:label>
                     <sb:reference id="sref35">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Odenike</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Singer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Granston</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Al-Fayoumi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.J.</ce:given-name>
                                 <ce:surname>Deeg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Hematol. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>137</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0195">S. Verstovsek, O. Odenike, J.W. Singer, T. Granston, S. Al-Fayoumi, H.J. Deeg, Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies, Journal of hematology & oncology, 9 (2016) 137.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib36">
                     <ce:label>[36]</ce:label>
                     <sb:reference id="sref36">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Yen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.W.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.S.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Hsieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Schizandrin protects primary rat cortical cell cultures from glutamate-induced apoptosis by inhibiting activation of the MAPK family and the mitochondria dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Molecules</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>354</sb:first-page>
                              <sb:last-page>372</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0200">M.S. Lee, J. Chao, J.C. Yen, L.W. Lin, F.S. Tsai, M.T. Hsieh, W.H. Peng, H.Y. Cheng, Schizandrin protects primary rat cortical cell cultures from glutamate-induced apoptosis by inhibiting activation of the MAPK family and the mitochondria dependent pathway, Molecules (Basel, Switzerland), 18 (2012) 354-372.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib37">
                     <ce:label>[37]</ce:label>
                     <sb:reference id="sref37">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>McCubrey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Steelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.H.</ce:given-name>
                                 <ce:surname>Chappell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Abrams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Franklin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Montalto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cervello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Libra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Candido</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Malaponte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Mazzarino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Fagone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Nicoletti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Basecke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mijatovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Maksimovic-Ivanic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Milella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tafuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chiarini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Evangelisti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cocco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Martelli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1068</sb:first-page>
                              <sb:last-page>1111</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0205">J.A. McCubrey, L.S. Steelman, W.H. Chappell, S.L. Abrams, R.A. Franklin, G. Montalto, M. Cervello, M. Libra, S. Candido, G. Malaponte, M.C. Mazzarino, P. Fagone, F. Nicoletti, J. Basecke, S. Mijatovic, D. Maksimovic-Ivanic, M. Milella, A. Tafuri, F. Chiarini, C. Evangelisti, L. Cocco, A.M. Martelli, Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance, Oncotarget, 3 (2012) 1068-1111.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib38">
                     <ce:label>[38]</ce:label>
                     <sb:reference id="sref38">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Borthakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ravandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Faderl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Verstovsek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mathews</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I study of sorafenib in patients with refractory or relapsed acute leukemias</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>96</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>62</sb:first-page>
                              <sb:last-page>68</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0210">G. Borthakur, H. Kantarjian, F. Ravandi, W. Zhang, M. Konopleva, J.J. Wright, S. Faderl, S. Verstovsek, S. Mathews, M. Andreeff, J.E. Cortes, Phase I study of sorafenib in patients with refractory or relapsed acute leukemias, Haematologica, 96 (2011) 62-68.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib39">
                     <ce:label>[39]</ce:label>
                     <sb:reference id="sref39">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Tabe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Resist. Updates : Rev. Comment. Antimicrob. Anticancer Chemother.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>103</sb:first-page>
                              <sb:last-page>113</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0215">M. Konopleva, Y. Tabe, Z. Zeng, M. Andreeff, Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 12 (2009) 103-113.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib40">
                     <ce:label>[40]</ce:label>
                     <sb:reference id="sref40">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Leuenroth</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Grutkoski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ayala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Simms</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Surgery</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>128</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>171</sb:first-page>
                              <sb:last-page>177</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0220">S.J. Leuenroth, P.S. Grutkoski, A. Ayala, H.H. Simms, Suppression of PMN apoptosis by hypoxia is dependent on Mcl-1 and MAPK activity, Surgery, 128 (2000) 171-177.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib41">
                     <ce:label>[41]</ce:label>
                     <sb:reference id="sref41">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.O.</ce:given-name>
                                 <ce:surname>Jacamo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Borthakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ravandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ramachandran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2363</sb:first-page>
                              <sb:last-page>2374</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0225">W. Zhang, C. Gao, M. Konopleva, Y. Chen, R.O. Jacamo, G. Borthakur, J.E. Cortes, F. Ravandi, A. Ramachandran, M. Andreeff, Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies, Clinical cancer research : an official journal of the American Association for Cancer Research, 20 (2014) 2363-2374.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib42">
                     <ce:label>[42]</ce:label>
                     <sb:reference id="sref42">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ikemori-Kawada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Goto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kawakami</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Docking simulation study and kinase selectivity of f152A1 and its analogs</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Chem. Inf. Model.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>52</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2059</sb:first-page>
                              <sb:last-page>2068</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0230">M. Ikemori-Kawada, A. Inoue, M. Goto, Y.J. Wang, Y. Kawakami, Docking simulation study and kinase selectivity of f152A1 and its analogs, Journal of chemical information and modeling, 52 (2012) 2059-2068.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib43">
                     <ce:label>[43]</ce:label>
                     <sb:reference id="sref43">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Boivin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Yoneda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schiller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Matsushima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Goto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Shirota</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Gusovsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lemelin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Pelletier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ikemori-Kawada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kawakami</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Inoue</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Schnaderbeck</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3155</sb:first-page>
                              <sb:last-page>3157</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0235">Y. Shen, R. Boivin, N. Yoneda, H. Du, S. Schiller, T. Matsushima, M. Goto, H. Shirota, F. Gusovsky, C. Lemelin, Y. Jiang, Z. Zhang, R. Pelletier, M. Ikemori-Kawada, Y. Kawakami, A. Inoue, M. Schnaderbeck, Y. Wang, Discovery of anti-inflammatory clinical candidate E6201, inspired from resorcylic lactone LL-Z1640-2, III, Bioorganic & medicinal chemistry letters, 20 (2010) 3155-3157.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib44">
                     <ce:label>[44]</ce:label>
                     <sb:reference id="sref44">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Borthakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Mu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.R.</ce:given-name>
                                 <ce:surname>Ruvolo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Nomoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The dual MEK/FLT3 inhibitor E6201 exerts cytotoxic activity against acute myeloid leukemia cells harboring resistance-conferring FLT3 mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>76</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1528</sb:first-page>
                              <sb:last-page>1537</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0240">W. Zhang, G. Borthakur, C. Gao, Y. Chen, H. Mu, V.R. Ruvolo, K. Nomoto, N. Zhao, M. Konopleva, M. Andreeff, The Dual MEK/FLT3 Inhibitor E6201 Exerts Cytotoxic Activity against Acute Myeloid Leukemia Cells Harboring Resistance-Conferring FLT3 Mutations, Cancer research, 76 (2016) 1528-1537.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib45">
                     <ce:label>[45]</ce:label>
                     <sb:reference id="sref45">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Brault</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Gasser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Bracher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Huber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schwaller</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Haematologica</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>95</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1004</sb:first-page>
                              <sb:last-page>1015</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0245">L. Brault, C. Gasser, F. Bracher, K. Huber, S. Knapp, J. Schwaller, PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers, Haematologica, 95 (2010) 1004-1015.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib46">
                     <ce:label>[46]</ce:label>
                     <sb:reference id="sref46">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Nawijn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Alendar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Berns</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>For better or for worse: the role of Pim oncogenes in tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Canc.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>11</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>23</sb:first-page>
                              <sb:last-page>34</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0250">M.C. Nawijn, A. Alendar, A. Berns, For better or for worse: the role of Pim oncogenes in tumorigenesis, Nature reviews. Cancer, 11 (2011) 23-34.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib47">
                     <ce:label>[47]</ce:label>
                     <sb:reference id="sref47">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sandholm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Koskinen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kraft</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4022</sb:first-page>
                              <sb:last-page>4031</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0255">M. Lilly, J. Sandholm, J.J. Cooper, P.J. Koskinen, A. Kraft, The PIM-1 serine kinase prolongs survival and inhibits apoptosis-related mitochondrial dysfunction in part through a bcl-2-dependent pathway, Oncogene, 18 (1999) 4022-4031.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib48">
                     <ce:label>[48]</ce:label>
                     <sb:reference id="sref48">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mizuki</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schwable</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Steur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Choudhary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Agrawal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Sargin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Steffen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Matsumura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kanakura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.D.</ce:given-name>
                                 <ce:surname>Bohmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Muller-Tidow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.E.</ce:given-name>
                                 <ce:surname>Berdel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Serve</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>101</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3164</sb:first-page>
                              <sb:last-page>3173</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0260">M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F.D. Bohmer, C. Muller-Tidow, W.E. Berdel, H. Serve, Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations, Blood, 101 (2003) 3164-3173.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib49">
                     <ce:label>[49]</ce:label>
                     <sb:reference id="sref49">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Green</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.T.</ce:given-name>
                                 <ce:surname>Maciel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.-A.</ce:given-name>
                                 <ce:surname>Hospital</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mazed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Townsend</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pilorge</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lambert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Paubelle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jacquel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zylbersztejn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Decroocq</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Poulain</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sujobert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Jacque</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Adam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.C.</ce:given-name>
                                 <ce:surname>So</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Kosmider</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Auberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Hermine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Weinstock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lacombe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Mayeux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Vanasse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.Y.</ce:given-name>
                                 <ce:surname>Leung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.C.</ce:given-name>
                                 <ce:surname>Moura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bouscary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tamburini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Adv.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:article-number>e1500221</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0265">A.S. Green, T.T. Maciel, M.-A. Hospital, C. Yin, F. Mazed, E.C. Townsend, S. Pilorge, M. Lambert, E. Paubelle, A. Jacquel, F. Zylbersztejn, J. Decroocq, L. Poulain, P. Sujobert, N. Jacque, K. Adam, J.C.C. So, O. Kosmider, P. Auberger, O. Hermine, D.M. Weinstock, C. Lacombe, P. Mayeux, G.J. Vanasse, A.Y. Leung, I.C. Moura, D. Bouscary, J. Tamburini, Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia, Science Advances, 1 (2015) e1500221.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib50">
                     <ce:label>[50]</ce:label>
                     <sb:reference id="sref50">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Burcu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The serine/threonine kinase pim-1 stabilizes 130 kilodalton FLT3 and promotes aberrant signaling through STAT5 in acute myeloid leukemia cells with FLT3 internal tandem duplication: synergistic apoptosis induction by pim-1 and FLT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>942</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0270">Y. Xie, M. Burcu, M.R. Baer, The Serine/Threonine Kinase Pim-1 Stabilizes 130 Kilodalton FLT3 and Promotes Aberrant Signaling through STAT5 in Acute Myeloid Leukemia Cells with FLT3 Internal Tandem Duplication: Synergistic Apoptosis Induction by Pim-1 and FLT3 Inhibitors, Blood, 114 (2009) 942.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib51">
                     <ce:label>[51]</ce:label>
                     <sb:reference id="sref51">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Redkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Bearss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.G.</ce:given-name>
                                 <ce:surname>Wierda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gandhi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>114</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4150</sb:first-page>
                              <sb:last-page>4157</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0275">L.S. Chen, S. Redkar, D. Bearss, W.G. Wierda, V. Gandhi, Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells, Blood, 114 (2009) 4150-4157.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib52">
                     <ce:label>[52]</ce:label>
                     <sb:reference id="sref52">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Kaufmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Karp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Svingen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Krajewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Burke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Gore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Reed</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>91</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>991</sb:first-page>
                              <sb:last-page>1000</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0280">S.H. Kaufmann, J.E. Karp, P.A. Svingen, S. Krajewski, P.J. Burke, S.D. Gore, J.C. Reed, Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse, Blood, 91 (1998) 991-1000.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib53">
                     <ce:label>[53]</ce:label>
                     <sb:reference id="sref53">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Redkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Taverna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gandhi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>693</sb:first-page>
                              <sb:last-page>702</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0285">L.S. Chen, S. Redkar, P. Taverna, J.E. Cortes, V. Gandhi, Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia, Blood, 118 (2011) 693-702.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib54">
                     <ce:label>[54]</ce:label>
                     <sb:reference id="sref54">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Czardybon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Windak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Golas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Galezowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sabiniarz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Dolata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Salwinska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Guzik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zawadzka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Gabor-Worwa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Winnik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Zurawska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Kolasinska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Wincza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bugaj</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Danielewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Majewska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mazan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Dubin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Noyszewska-Kania</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jablonska</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Szydlowski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sewastianik</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Pula</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Szumera-Cieckiewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Prochorec-Sobieszek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Madro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Lech-Maranda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Warzocha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Tamburini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Juszczynski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Brzozka</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>16917</sb:first-page>
                              <sb:last-page>16931</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0290">W. Czardybon, R. Windak, A. Golas, M. Galezowski, A. Sabiniarz, I. Dolata, M. Salwinska, P. Guzik, M. Zawadzka, E. Gabor-Worwa, B. Winnik, M. Zurawska, E. Kolasinska, E. Wincza, M. Bugaj, M. Danielewicz, E. Majewska, M. Mazan, G. Dubin, M. Noyszewska-Kania, E. Jablonska, M. Szydlowski, T. Sewastianik, B. Pula, A. Szumera-Cieckiewicz, M. Prochorec-Sobieszek, E. Madro, E. Lech-Maranda, K. Warzocha, J. Tamburini, P. Juszczynski, K. Brzozka, A novel, dual pan-PIM/FLT3 inhibitor SEL24 exhibits broad therapeutic potential in acute myeloid leukemia, Oncotarget, 9 (2018) 16917-16931.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib55">
                     <ce:label>[55]</ce:label>
                     <sb:reference id="sref55">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Puente-Moncada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Costales</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Antolin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Nunez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Oro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Hermosilla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Perez-Escuredo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Rios-Lombardia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Sanchez-Sanchez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Luno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rodriguez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Martin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Moris</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>17</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>614</sb:first-page>
                              <sb:last-page>624</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0295">N. Puente-Moncada, P. Costales, I. Antolin, L.E. Nunez, P. Oro, M.A. Hermosilla, J. Perez-Escuredo, N. Rios-Lombardia, A.M. Sanchez-Sanchez, E. Luno, C. Rodriguez, V. Martin, F. Moris, Inhibition of FLT3 and PIM Kinases by EC-70124 Exerts Potent Activity in Preclinical Models of Acute Myeloid Leukemia, Molecular cancer therapeutics, 17 (2018) 614-624.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib56">
                     <ce:label>[56]</ce:label>
                     <sb:reference id="sref56">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Bu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Shaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Chan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Analysis of the interaction of ZAP-70 and syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>92</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5106</sb:first-page>
                              <sb:last-page>5110</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0300">J.Y. Bu, A.S. Shaw, A.C. Chan, Analysis of the interaction of ZAP-70 and syk protein-tyrosine kinases with the T-cell antigen receptor by plasmon resonance, Proceedings of the National Academy of Sciences of the United States of America, 92 (1995) 5106-5110.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib57">
                     <ce:label>[57]</ce:label>
                     <sb:reference id="sref57">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Cornall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pawson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Goodnow</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of Syk in B-cell development and antigen-receptor signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>97</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1713</sb:first-page>
                              <sb:last-page>1718</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0305">R.J. Cornall, A.M. Cheng, T. Pawson, C.C. Goodnow, Role of Syk in B-cell development and antigen-receptor signaling, Proc Natl Acad Sci U S A, 97 (2000) 1713-1718.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib58">
                     <ce:label>[58]</ce:label>
                     <sb:reference id="sref58">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Turner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Mee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.S.</ce:given-name>
                                 <ce:surname>Costello</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Price</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.P.</ce:given-name>
                                 <ce:surname>Duddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Furlong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Geahlen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.L.</ce:given-name>
                                 <ce:surname>Tybulewicz</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>378</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>298</sb:first-page>
                              <sb:last-page>302</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0310">M. Turner, P.J. Mee, P.S. Costello, O. Williams, A.A. Price, L.P. Duddy, M.T. Furlong, R.L. Geahlen, V.L. Tybulewicz, Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk, Nature, 378 (1995) 298-302.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib59">
                     <ce:label>[59]</ce:label>
                     <sb:reference id="sref59">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Rowley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Pao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hayday</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Bolen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Pawson</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Syk tyrosine kinase required for mouse viability and B-cell development</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>378</sb:volume-nr>
                              </sb:series>
                              <sb:date>1995</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>303</sb:first-page>
                              <sb:last-page>306</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0315">A.M. Cheng, B. Rowley, W. Pao, A. Hayday, J.B. Bolen, T. Pawson, Syk tyrosine kinase required for mouse viability and B-cell development, Nature, 378 (1995) 303-306.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib60">
                     <ce:label>[60]</ce:label>
                     <sb:reference id="sref60">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Puissant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fenouille</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Alexe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Pikman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.F.</ce:given-name>
                                 <ce:surname>Bassil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mehta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.U.</ce:given-name>
                                 <ce:surname>Kazi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Luciano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Ronnstrand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Kung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Aster</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Galinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>DeAngelo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Hemann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Stegmaier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>SYK is a critical regulator of FLT3 in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>226</sb:first-page>
                              <sb:last-page>242</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0320">A. Puissant, N. Fenouille, G. Alexe, Y. Pikman, C.F. Bassil, S. Mehta, J. Du, J.U. Kazi, F. Luciano, L. Ronnstrand, A.L. Kung, J.C. Aster, I. Galinsky, R.M. Stone, D.J. DeAngelo, M.T. Hemann, K. Stegmaier, SYK is a critical regulator of FLT3 in acute myeloid leukemia, Cancer cell, 25 (2014) 226-242.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib61">
                     <ce:label>[61]</ce:label>
                     <sb:reference id="sref61">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Weisberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Puissant</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sattler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Buhrlage</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Manley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Buonopane</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Daley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lazo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Wright</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.M.</ce:given-name>
                                 <ce:surname>Weinstock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Christie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Stegmaier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>52026</sb:first-page>
                              <sb:last-page>52044</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0325">E.L. Weisberg, A. Puissant, R. Stone, M. Sattler, S.J. Buhrlage, J. Yang, P.W. Manley, C. Meng, M. Buonopane, J.F. Daley, S. Lazo, R. Wright, D.M. Weinstock, A.L. Christie, K. Stegmaier, J.D. Griffin, Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase, Oncotarget, 8 (2017) 52026-52044.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib62">
                     <ce:label>[62]</ce:label>
                     <sb:reference id="sref62">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Lam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Arikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cramlett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>de Jong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Feher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.E.</ce:given-name>
                                 <ce:surname>Grimshaw</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Farrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.D.</ce:given-name>
                                 <ce:surname>Hoffman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Jennings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Jones</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Matuszkiewicz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Miura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Miyake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Natala</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Shi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Takahashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Taylor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wyrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zalevsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Nie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5947</sb:first-page>
                              <sb:last-page>5950</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0330">B. Lam, Y. Arikawa, J. Cramlett, Q. Dong, R. de Jong, V. Feher, C.E. Grimshaw, P.J. Farrell, I.D. Hoffman, A. Jennings, B. Jones, J. Matuszkiewicz, J. Miura, H. Miyake, S.R. Natala, L. Shi, M. Takahashi, E. Taylor, C. Wyrick, J. Yano, J. Zalevsky, Z. Nie, Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK), Bioorganic & medicinal chemistry letters, 26 (2016) 5947-5950.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib63">
                     <ce:label>[63]</ce:label>
                     <sb:reference id="sref63">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Weisberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Boulton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Manley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Fabbro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Meyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>433</sb:first-page>
                              <sb:last-page>443</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0335">E. Weisberg, C. Boulton, L.M. Kelly, P. Manley, D. Fabbro, T. Meyer, D.G. Gilliland, J.D. Griffin, Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412, Cancer cell, 1 (2002) 433-443.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib64">
                     <ce:label>[64]</ce:label>
                     <sb:reference id="sref64">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Fischer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Deangelo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Galinsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Estey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Lanza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fox</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ehninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Feldman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Schiller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.M.</ce:given-name>
                                 <ce:surname>Klimek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Nimer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dutreix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Huntsman-Labed</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Virkus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.J.</ce:given-name>
                                 <ce:surname>Giles</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>28</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4339</sb:first-page>
                              <sb:last-page>4345</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0340">T. Fischer, R.M. Stone, D.J. Deangelo, I. Galinsky, E. Estey, C. Lanza, E. Fox, G. Ehninger, E.J. Feldman, G.J. Schiller, V.M. Klimek, S.D. Nimer, D.G. Gilliland, C. Dutreix, A. Huntsman-Labed, J. Virkus, F.J. Giles, Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 (2010) 4339-4345.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib65">
                     <ce:label>[65]</ce:label>
                     <sb:reference id="sref65">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Schlenk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Weber</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fiedler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.R.</ce:given-name>
                                 <ce:surname>Salih</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Wulf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Salwender</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Schroeder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kindler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lubbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Wolf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Westermann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kraemer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Gotze</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ITD</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>840</sb:first-page>
                              <sb:last-page>851</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0345">R.F. Schlenk, D. Weber, W. Fiedler, H.R. Salih, G. Wulf, H. Salwender, T. Schroeder, T. Kindler, M. Lubbert, D. Wolf, J. Westermann, D. Kraemer, K.S. Gotze, Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD, 133 (2019) 840-851.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib66">
                     <ce:label>[66]</ce:label>
                     <sb:reference id="sref66">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.W.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Kindwall-Keller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Craig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Creger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hamadani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Tse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Lazarus</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients, Clinical lymphoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Myeloma & Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>428</sb:first-page>
                              <sb:last-page>432</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>e422</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0350">B.W. Cooper, T.L. Kindwall-Keller, M.D. Craig, R.J. Creger, M. Hamadani, W.W. Tse, H.M. Lazarus, A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients, Clinical lymphoma, myeloma & leukemia, 15 (2015) 428-432.e422.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib67">
                     <ce:label>[67]</ce:label>
                     <sb:reference id="sref67">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Strati</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Ravandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nazha</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Borthakur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Daver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kadia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Estrov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Garcia-Manero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Konopleva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Rajkhowa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Durand</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Andreeff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Am. J. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>90</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>276</sb:first-page>
                              <sb:last-page>281</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0355">P. Strati, H. Kantarjian, F. Ravandi, A. Nazha, G. Borthakur, N. Daver, T. Kadia, Z. Estrov, G. Garcia-Manero, M. Konopleva, T. Rajkhowa, M. Durand, M. Andreeff, M. Levis, J. Cortes, Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome, American journal of hematology, 90 (2015) 276-281.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib68">
                     <ce:label>[68]</ce:label>
                     <sb:reference id="sref68">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Mandrekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.L.</ce:given-name>
                                 <ce:surname>Sanford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Laumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Geyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.D.</ce:given-name>
                                 <ce:surname>Bloomfield</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Thiede</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.W.</ce:given-name>
                                 <ce:surname>Prior</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Dohner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Marcucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lo-Coco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Klisovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Sierra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Sanz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Brandwein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>de Witte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Niederwieser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.R.</ce:given-name>
                                 <ce:surname>Appelbaum</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.C.</ce:given-name>
                                 <ce:surname>Medeiros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Tallman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Krauter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.F.</ce:given-name>
                                 <ce:surname>Schlenk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ganser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Serve</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ehninger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Amadori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Larson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dohner</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>N. Engl. J. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>377</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>454</sb:first-page>
                              <sb:last-page>464</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0360">R.M. Stone, S.J. Mandrekar, B.L. Sanford, K. Laumann, S. Geyer, C.D. Bloomfield, C. Thiede, T.W. Prior, K. Dohner, G. Marcucci, F. Lo-Coco, R.B. Klisovic, A. Wei, J. Sierra, M.A. Sanz, J.M. Brandwein, T. de Witte, D. Niederwieser, F.R. Appelbaum, B.C. Medeiros, M.S. Tallman, J. Krauter, R.F. Schlenk, A. Ganser, H. Serve, G. Ehninger, S. Amadori, R.A. Larson, H. Dohner, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation, The New England journal of medicine, 377 (2017) 454-464.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib69">
                     <ce:label>[69]</ce:label>
                     <sb:reference id="sref69">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Carey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.J.</ce:given-name>
                                 <ce:surname>Godowski</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>1997</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2033</sb:first-page>
                              <sb:last-page>2039</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0365">J. Chen, K. Carey, P.J. Godowski, Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation, Oncogene, 14 (1997) 2033-2039.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib70">
                     <ce:label>[70]</ce:label>
                     <sb:reference id="sref70">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Linger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Lee-Sherick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Jacobsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>McGranahan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.N.</ce:given-name>
                                 <ce:surname>Brandao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Winges</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Sawczyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1599</sb:first-page>
                              <sb:last-page>1609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0370">R.M. Linger, A.B. Lee-Sherick, D. DeRyckere, R.A. Cohen, K.M. Jacobsen, A. McGranahan, L.N. Brandao, A. Winges, K.K. Sawczyn, X. Liang, A.K. Keating, A.C. Tan, H.S. Earp, D.K. Graham, Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia, Blood, 122 (2013) 1599-1609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib71">
                     <ce:label>[71]</ce:label>
                     <sb:reference id="sref71">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Lee-Sherick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Eisenman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sather</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>McGranahan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.M.</ce:given-name>
                                 <ce:surname>Armistead</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.S.</ce:given-name>
                                 <ce:surname>McGary</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Hunsucker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Schlegel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Martinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cannon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5359</sb:first-page>
                              <sb:last-page>5368</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0375">A.B. Lee-Sherick, K.M. Eisenman, S. Sather, A. McGranahan, P.M. Armistead, C.S. McGary, S.A. Hunsucker, J. Schlegel, H. Martinson, C. Cannon, A.K. Keating, H.S. Earp, X. Liang, D. DeRyckere, D.K. Graham, Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia, Oncogene, 32 (2013) 5359-5368.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib72">
                     <ce:label>[72]</ce:label>
                     <sb:reference id="sref72">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.B.</ce:given-name>
                                 <ce:surname>Lee-Sherick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.K.</ce:given-name>
                                 <ce:surname>Menachof</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Hill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rinella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kirkpatrick</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.S.</ce:given-name>
                                 <ce:surname>Page</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Stashko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Jordan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Frye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6722</sb:first-page>
                              <sb:last-page>6736</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0380">A.B. Lee-Sherick, W. Zhang, K.K. Menachof, A.A. Hill, S. Rinella, G. Kirkpatrick, L.S. Page, M.A. Stashko, C.T. Jordan, Q. Wei, J. Liu, D. Zhang, D. DeRyckere, X. Wang, S. Frye, H.S. Earp, D.K. Graham, Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia, Oncotarget, 6 (2015) 6722-6736.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib73">
                     <ce:label>[73]</ce:label>
                     <sb:reference id="sref73">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Stashko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Minson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Cummings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.G.</ce:given-name>
                                 <ce:surname>Glaros</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Newton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sather</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kireev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Janzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Frye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>57</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>7031</sb:first-page>
                              <sb:last-page>7041</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0385">W. Zhang, D. DeRyckere, D. Hunter, J. Liu, M.A. Stashko, K.A. Minson, C.T. Cummings, M. Lee, T.G. Glaros, D.L. Newton, S. Sather, D. Zhang, D. Kireev, W.P. Janzen, H.S. Earp, D.K. Graham, S.V. Frye, X. Wang, UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor, Journal of Medicinal Chemistry, 57 (2014) 7031-7041.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib74">
                     <ce:label>[74]</ce:label>
                     <sb:reference id="sref74">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Simpson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>DeRyckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Van Deusen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Miley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kireev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Norris-Drouin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sather</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.K.</ce:given-name>
                                 <ce:surname>Korboukh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Patel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Janzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Machius</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.L.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Frye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Med. Chem. Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>129</sb:first-page>
                              <sb:last-page>134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0390">J. Liu, C. Yang, C. Simpson, D. DeRyckere, A. Van Deusen, M.J. Miley, D. Kireev, J. Norris-Drouin, S. Sather, D. Hunter, V.K. Korboukh, H.S. Patel, W.P. Janzen, M. Machius, G.L. Johnson, H.S. Earp, D.K. Graham, S.V. Frye, X. Wang, Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia, ACS Medicinal Chemistry Letters, 3 (2012) 129-134.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib75">
                     <ce:label>[75]</ce:label>
                     <sb:reference id="sref75">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Stashko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Deryckere</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Cummings</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hunter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Jayakody</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Simpson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Norris-Drouin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sather</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Kireev</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.P.</ce:given-name>
                                 <ce:surname>Janzen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.V.</ce:given-name>
                                 <ce:surname>Frye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>UNC1062, a new and potent Mer inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>65</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>83</sb:first-page>
                              <sb:last-page>93</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0395">J. Liu, W. Zhang, M.A. Stashko, D. Deryckere, C.T. Cummings, D. Hunter, C. Yang, C.N. Jayakody, N. Cheng, C. Simpson, J. Norris-Drouin, S. Sather, D. Kireev, W.P. Janzen, H.S. Earp, D.K. Graham, S.V. Frye, X. Wang, UNC1062, a new and potent Mer inhibitor, Eur J Med Chem, 65 (2013) 83-93.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib76">
                     <ce:label>[76]</ce:label>
                     <sb:reference id="sref76">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wenglowsky</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Moreno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Rudolph</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Ahrendt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Arrigo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Colson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Gloor</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Hastings</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem. Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>912</sb:first-page>
                              <sb:last-page>915</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0400">S. Wenglowsky, D. Moreno, J. Rudolph, Y. Ran, K.A. Ahrendt, A. Arrigo, B. Colson, S.L. Gloor, G. Hastings, Pyrazolopyridine inhibitors of B-Raf(V600E). Part 3: an increase in aqueous solubility via the disruption of crystal packing, Bioorganic & medicinal chemistry letters, 22 (2012) 912-915.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib77">
                     <ce:label>[77]</ce:label>
                     <sb:reference id="sref77">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:surname>G.P.</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Closing in on the biological functions of fps/fes and fer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>278</sb:first-page>
                              <sb:last-page>289</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0405">G. P, Closing in on the biological functions of Fps/Fes and Fer, Nature Reviews. Molecular cell biology, 3 (2002) 278-289.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib78">
                     <ce:label>[78]</ce:label>
                     <sb:reference id="sref78">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.A.</ce:given-name>
                                 <ce:surname>Greer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kanda</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Smithgall</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The contrasting oncogenic and tumor suppressor roles of FES</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci. (Scholar edition)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>489</sb:first-page>
                              <sb:last-page>501</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0410">P. A Greer, S. Kanda, T. Smithgall, The contrasting oncogenic and tumor suppressor roles of FES, Frontiers in bioscience (Scholar edition), 4 (2012) 489-501.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib79">
                     <ce:label>[79]</ce:label>
                     <sb:reference id="sref79">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hellwig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Smithgall</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure and regulation of the c-Fes protein-tyrosine kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front. Biosci. (Scholar edition)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3146</sb:first-page>
                              <sb:last-page>3155</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0415">S. Hellwig, T. Smithgall, Structure and regulation of the c-Fes protein-tyrosine kinase, Frontiers in bioscience (Scholar edition), 16 (2011) 3146-3155.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib80">
                     <ce:label>[80]</ce:label>
                     <sb:reference id="sref80">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Smithgall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Rogers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Peters</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Briggs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Lionberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Shibata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Scholtz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Schreiner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dunham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The c-Fes family of protein-tyrosine kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Crit. Rev. Oncog.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>1998</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>43</sb:first-page>
                              <sb:last-page>62</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0420">T.E. Smithgall, J.A. Rogers, K.L. Peters, J. Li, S.D. Briggs, J.M. Lionberger, H. Cheng, A. Shibata, B. Scholtz, S. Schreiner, N. Dunham, The c-Fes family of protein-tyrosine kinases, Critical reviews in oncogenesis, 9 (1998) 43-62.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib81">
                     <ce:label>[81]</ce:label>
                     <sb:reference id="sref81">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Voisset</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lopez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Chaix</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Georges</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hanssens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Prebet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dubreuil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>De Sepulveda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FES kinases are required for oncogenic FLT3 signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>721</sb:first-page>
                              <sb:last-page>728</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0425">E. Voisset, S. Lopez, A. Chaix, C. Georges, K. Hanssens, T. Prebet, P. Dubreuil, P. De Sepulveda, FES kinases are required for oncogenic FLT3 signaling, Leukemia, 24 (2010) 721-728.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib82">
                     <ce:label>[82]</ce:label>
                     <sb:reference id="sref82">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Weir</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hellwig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Tan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.S.</ce:given-name>
                                 <ce:surname>Gray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.E.</ce:given-name>
                                 <ce:surname>Smithgall</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:article-number>e0181178</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0430">M.C. Weir, S. Hellwig, L. Tan, Y. Liu, N.S. Gray, T.E. Smithgall, Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth, 12 (2017) e0181178.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib83">
                     <ce:label>[83]</ce:label>
                     <sb:reference id="sref83">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sagatys</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.R.</ce:given-name>
                                 <ce:surname>Garrett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Boulware</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kelley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Malafa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sebti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hum. Pathol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>38</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1526</sb:first-page>
                              <sb:last-page>1531</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0435">E. Sagatys, C.R. Garrett, D. Boulware, S. Kelley, M. Malafa, J.Q. Cheng, S. Sebti, D. Coppola, Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia, Human pathology, 38 (2007) 1526-1531.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib84">
                     <ce:label>[84]</ce:label>
                     <sb:reference id="sref84">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Engelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Cantley</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Genet.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>606</sb:first-page>
                              <sb:last-page>619</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0440">J.A. Engelman, J. Luo, L.C. Cantley, The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism, Nature reviews. Genetics, 7 (2006) 606-619.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib85">
                     <ce:label>[85]</ce:label>
                     <sb:reference id="sref85">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Knapper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.D.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Galkin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Small</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Burnett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>117</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3286</sb:first-page>
                              <sb:last-page>3293</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0445">T. Sato, X. Yang, S. Knapper, P. White, B.D. Smith, S. Galkin, D. Small, A. Burnett, M. Levis, FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo, Blood, 117 (2011) 3286-3293.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib86">
                     <ce:label>[86]</ce:label>
                     <sb:reference id="sref86">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ishikawa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Kihara</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Naoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kiyoi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mechanism of FLT3 ligand dependent resistance to FLT3 inhibitors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>43</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>S57</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0450">F. Chen, Y. Ishikawa, R. Kihara, T. Naoe, H. Kiyoi, Mechanism of FLT3 Ligand Dependent Resistance to FLT3 Inhibitors, Blood, 43 (2015) S57.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib87">
                     <ce:label>[87]</ce:label>
                     <sb:reference id="sref87">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.A.</ce:given-name>
                                 <ce:surname>Galinksy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.L.</ce:given-name>
                                 <ce:surname>Weisberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>29131</sb:first-page>
                              <sb:last-page>29142</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0455">A. Wang, H. Wu, C. Chen, C. Hu, Z. Qi, W. Wang, K. Yu, X. Liu, F. Zou, Z. Zhao, J. Wu, J. Liu, F. Liu, L. Wang, R.M. Stone, I.A. Galinksy, J.D. Griffin, S. Zhang, E.L. Weisberg, J. Liu, Q. Liu, Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML, Oncotarget, 7 (2016) 29131-29142.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib88">
                     <ce:label>[88]</ce:label>
                     <sb:reference id="sref88">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>De Keersmaecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cools</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Chronic myeloproliferative disorders: a tyrosine kinase tale</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>200</sb:first-page>
                              <sb:last-page>205</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0460">K. De Keersmaecker, J. Cools, Chronic myeloproliferative disorders: a tyrosine kinase tale, Leukemia, 20 (2006) 200-205.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib89">
                     <ce:label>[89]</ce:label>
                     <sb:reference id="sref89">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Mahboobi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Uecker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Cenac</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sellmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Eichhorn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Elz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.D.</ce:given-name>
                                 <ce:surname>Bohmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Dove</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>15</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2187</sb:first-page>
                              <sb:last-page>2197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0465">S. Mahboobi, A. Uecker, C. Cenac, A. Sellmer, E. Eichhorn, S. Elz, F.D. Bohmer, S. Dove, Inhibition of FLT3 and PDGFR tyrosine kinase activity by bis(benzo[b]furan-2-yl)methanones, Bioorganic & medicinal chemistry, 15 (2007) 2187-2197.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib90">
                     <ce:label>[90]</ce:label>
                     <sb:reference id="sref90">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Griffith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>McKinley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Patterson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Presnell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ramachandran</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Debiec-Rychter</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4375</sb:first-page>
                              <sb:last-page>4384</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0470">M.C. Heinrich, D. Griffith, A. McKinley, J. Patterson, A. Presnell, A. Ramachandran, M. Debiec-Rychter, Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors, Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (2012) 4375-4384.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib91">
                     <ce:label>[91]</ce:label>
                     <sb:reference id="sref91">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.L.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.D.</ce:given-name>
                                 <ce:surname>Lewis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Eder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.J.</ce:given-name>
                                 <ce:surname>Reddy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.J.</ce:given-name>
                                 <ce:surname>Pierce</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Olszanski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>27</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5262</sb:first-page>
                              <sb:last-page>5269</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0475">N.L. Lewis, L.D. Lewis, J.P. Eder, N.J. Reddy, F. Guo, K.J. Pierce, A.J. Olszanski, R.B. Cohen, Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 27 (2009) 5262-5269.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib92">
                     <ce:label>[92]</ce:label>
                     <sb:reference id="sref92">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Lasater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.Q.</ce:given-name>
                                 <ce:surname>McCreery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.K.</ce:given-name>
                                 <ce:surname>Stewart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Damon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Perl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.R.</ce:given-name>
                                 <ce:surname>Jeschke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sugita</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carroll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Kogan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kuriyan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crenolanib is a selective type I pan-FLT3 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5319</sb:first-page>
                              <sb:last-page>5324</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0480">C.C. Smith, E.A. Lasater, K.C. Lin, Q. Wang, M.Q. McCreery, W.K. Stewart, L.E. Damon, A.E. Perl, G.R. Jeschke, M. Sugita, M. Carroll, S.C. Kogan, J. Kuriyan, N.P. Shah, Crenolanib is a selective type I pan-FLT3 inhibitor, Proc Natl Acad Sci U S A, 111 (2014) 5319-5324.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib93">
                     <ce:label>[93]</ce:label>
                     <sb:reference id="sref93">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Weisberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Sattler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ray</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Griffin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Drug resistance in mutant FLT3-positive AML</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>29</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5120</sb:first-page>
                              <sb:last-page>5134</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0485">E. Weisberg, M. Sattler, A. Ray, J.D. Griffin, Drug resistance in mutant FLT3-positive AML, Oncogene, 29 (2010) 5120-5134.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib94">
                     <ce:label>[94]</ce:label>
                     <sb:reference id="sref94">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Boulton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Apatira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Sullivan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Williams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Amaral</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.P.</ce:given-name>
                                 <ce:surname>Curley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Duclos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Neuberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Scarborough</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pandey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hollenbach</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Lokker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Gilliland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.A.</ce:given-name>
                                 <ce:surname>Giese</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML)</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>1</sb:volume-nr>
                              </sb:series>
                              <sb:date>2002</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>421</sb:first-page>
                              <sb:last-page>432</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0490">L.M. Kelly, J.C. Yu, C.L. Boulton, M. Apatira, J. Li, C.M. Sullivan, I. Williams, S.M. Amaral, D.P. Curley, N. Duclos, D. Neuberg, R.M. Scarborough, A. Pandey, S. Hollenbach, K. Abe, N.A. Lokker, D.G. Gilliland, N.A. Giese, CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML), Cancer cell, 1 (2002) 421-432.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib95">
                     <ce:label>[95]</ce:label>
                     <sb:reference id="sref95">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>DeAngelo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Stone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Heaney</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.D.</ce:given-name>
                                 <ce:surname>Nimer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Paquette</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.B.</ce:given-name>
                                 <ce:surname>Klisovic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Caligiuri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Lecerf</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Karol</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Holford</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Curtin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.J.</ce:given-name>
                                 <ce:surname>Druker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>108</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3674</sb:first-page>
                              <sb:last-page>3681</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0495">D.J. DeAngelo, R.M. Stone, M.L. Heaney, S.D. Nimer, R.L. Paquette, R.B. Klisovic, M.A. Caligiuri, M.R. Cooper, J.M. Lecerf, M.D. Karol, S. Sheng, N. Holford, P.T. Curtin, B.J. Druker, M.C. Heinrich, Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics, Blood, 108 (2006) 3674-3681.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib96">
                     <ce:label>[96]</ce:label>
                     <sb:reference id="sref96">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.M.</ce:given-name>
                                 <ce:surname>Schittenhelm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.M.</ce:given-name>
                                 <ce:surname>Kampa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Yee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Heinrich</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Cycle</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2621</sb:first-page>
                              <sb:last-page>2630</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0500">M.M. Schittenhelm, K.M. Kampa, K.W. Yee, M.C. Heinrich, The FLT3 inhibitor tandutinib (formerly MLN518) has sequence-independent synergistic effects with cytarabine and daunorubicin, Cell cycle (Georgetown, Tex.), 8 (2009) 2621-2630.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib97">
                     <ce:label>[97]</ce:label>
                     <sb:reference id="sref97">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.M.</ce:given-name>
                                 <ce:surname>Linger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Keating</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Earp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.K.</ce:given-name>
                                 <ce:surname>Graham</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Adv. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>100</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>35</sb:first-page>
                              <sb:last-page>83</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0505">R.M. Linger, A.K. Keating, H.S. Earp, D.K. Graham, TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer, Advances in cancer research, 100 (2008) 35-83.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib98">
                     <ce:label>[98]</ce:label>
                     <sb:reference id="sref98">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ben-Batalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Schultze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Wroblewski</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Erdmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Heuser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Waizenegger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Riecken</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Binder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Schewe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sawall</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Witzke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cubas-Cordova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Janning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wellbrock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fehse</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Hagel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Krauter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Ganser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Lorens</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Fiedler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Carmeliet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Pantel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Bokemeyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Loges</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>122</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2443</sb:first-page>
                              <sb:last-page>2452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0510">I. Ben-Batalla, A. Schultze, M. Wroblewski, R. Erdmann, M. Heuser, J.S. Waizenegger, K. Riecken, M. Binder, D. Schewe, S. Sawall, V. Witzke, M. Cubas-Cordova, M. Janning, J. Wellbrock, B. Fehse, C. Hagel, J. Krauter, A. Ganser, J.B. Lorens, W. Fiedler, P. Carmeliet, K. Pantel, C. Bokemeyer, S. Loges, Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma, Blood, 122 (2013) 2443-2452.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib99">
                     <ce:label>[99]</ce:label>
                     <sb:reference id="sref99">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>I.K.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mishra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chandler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.P.</ce:given-name>
                                 <ce:surname>Whitman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Marcucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Caligiuri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>121</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2064</sb:first-page>
                              <sb:last-page>2073</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0515">I.K. Park, A. Mishra, J. Chandler, S.P. Whitman, G. Marcucci, M.A. Caligiuri, Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target, Blood, 121 (2013) 2064-2073.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib100">
                     <ce:label>[100]</ce:label>
                     <sb:reference id="sref100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Perl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Altman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Cortes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Litzow</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.R.</ce:given-name>
                                 <ce:surname>Baer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Claxton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Erba</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Gill</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Goldberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.G.</ce:given-name>
                                 <ce:surname>Jurcic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Larson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ritchie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Schiller</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.I.</ce:given-name>
                                 <ce:surname>Spira</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Strickland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tibes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ustun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Stuart</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rollig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Neubauer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Martinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Bahceci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Levis</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study, the Lancet</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1061</sb:first-page>
                              <sb:last-page>1075</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0520">A.E. Perl, J.K. Altman, J. Cortes, C. Smith, M. Litzow, M.R. Baer, D. Claxton, H.P. Erba, S. Gill, S. Goldberg, J.G. Jurcic, R.A. Larson, C. Liu, E. Ritchie, G. Schiller, A.I. Spira, S.A. Strickland, R. Tibes, C. Ustun, E.S. Wang, R. Stuart, C. Rollig, A. Neubauer, G. Martinelli, E. Bahceci, M. Levis, Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study, The Lancet. Oncology, 18 (2017) 1061-1075.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib101">
                     <ce:label>[101]</ce:label>
                     <sb:reference id="sref101">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Janning</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Ben-Batalla</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Loges</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Expert Rev. Hematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>135</sb:first-page>
                              <sb:last-page>138</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0525">M. Janning, I. Ben-Batalla, S. Loges, Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?, Expert review of hematology, 8 (2015) 135-138.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib102">
                     <ce:label>[102]</ce:label>
                     <sb:reference id="sref102">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.C.</ce:given-name>
                                 <ce:surname>Hong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Lay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Huang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.L.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Chuang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>268</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>314</sb:first-page>
                              <sb:last-page>324</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0530">C.C. Hong, J.D. Lay, J.S. Huang, A.L. Cheng, J.L. Tang, M.T. Lin, G.M. Lai, S.E. Chuang, Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia, Cancer letters, 268 (2008) 314-324.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib103">
                     <ce:label>[103]</ce:label>
                     <sb:reference id="sref103">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kaneko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Ueno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Tanaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Saito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Shimada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Mori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kuromitsu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Investig. New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>556</sb:first-page>
                              <sb:last-page>565</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0535">M. Mori, N. Kaneko, Y. Ueno, M. Yamada, R. Tanaka, R. Saito, I. Shimada, K. Mori, S. Kuromitsu, Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia, Investigational new drugs, 35 (2017) 556-565.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib104">
                     <ce:label>[104]</ce:label>
                     <sb:reference id="sref104">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>M Gorcea</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Burthem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Tholouli</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>ASP2215 in the Treatment of Relapsed/refractory Acute Myeloid Leukemia with FLT3 Mutation: Background and Design of the ADMIRAL Trial</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:book>
                              <sb:date>2018</sb:date>
                           </sb:book>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0540">C. M Gorcea, J. Burthem, E. Tholouli, ASP2215 in the treatment of relapsed/refractory acute myeloid leukemia with FLT3 mutation: background and design of the ADMIRAL trial, 2018.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib105">
                     <ce:label>[105]</ce:label>
                     <sb:reference id="sref105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Nakakura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Choti</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Management of hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncology (Williston Park, N.Y.)</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1085</sb:first-page>
                              <sb:last-page>1098</sb:last-page>
                           </sb:pages>
                        </sb:host>
                        <sb:comment>discussion 1098-1102</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0545">E.K. Nakakura, M.A. Choti, Management of hepatocellular carcinoma, Oncology (Williston Park, N.Y.), 14 (2000) 1085-1098; discussion 1098-1102.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib106">
                     <ce:label>[106]</ce:label>
                     <sb:reference id="sref106">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.K.</ce:given-name>
                                 <ce:surname>Altman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Sassano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.C.</ce:given-name>
                                 <ce:surname>Platanias</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting mTOR for the treatment of AML. New agents and new directions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>510</sb:first-page>
                              <sb:last-page>517</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0550">J.K. Altman, A. Sassano, L.C. Platanias, Targeting mTOR for the treatment of AML. New agents and new directions, Oncotarget, 2 (2011) 510-517.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib107">
                     <ce:label>[107]</ce:label>
                     <sb:reference id="sref107">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Diab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kumarasiri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Proud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Milne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>MAP kinase-interacting kinases--emerging targets against cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Chem. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>441</sb:first-page>
                              <sb:last-page>452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0555">S. Diab, M. Kumarasiri, M. Yu, T. Teo, C. Proud, R. Milne, S. Wang, MAP kinase-interacting kinases--emerging targets against cancer, Chemistry & biology, 21 (2014) 441-452.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib108">
                     <ce:label>[108]</ce:label>
                     <sb:reference id="sref108">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Diab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Adams</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Islam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.C.</ce:given-name>
                                 <ce:surname>Basnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Albrecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Milne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>56811</sb:first-page>
                              <sb:last-page>56825</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0560">P. Li, S. Diab, M. Yu, J. Adams, S. Islam, S.K.C. Basnet, H. Albrecht, R. Milne, S. Wang, Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells, Oncotarget, 7 (2016) 56811-56825.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib109">
                     <ce:label>[109]</ce:label>
                     <sb:reference id="sref109">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lam</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Basnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Albrecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Sykes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pharmacologic inhibition of MNKs in acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Pharmacol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>88</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>380</sb:first-page>
                              <sb:last-page>389</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0565">T. Teo, F. Lam, M. Yu, Y. Yang, S.K. Basnet, H. Albrecht, M.J. Sykes, S. Wang, Pharmacologic Inhibition of MNKs in Acute Myeloid Leukemia, Molecular pharmacology, 88 (2015) 380-389.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib110">
                     <ce:label>[110]</ce:label>
                     <sb:reference id="sref110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Diab</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Abdelaziz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Teo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.C.</ce:given-name>
                                 <ce:surname>Basnet</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Noll</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Rahaman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.T.</ce:given-name>
                                 <ce:surname>Le</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Albrecht</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Milne</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>139</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>762</sb:first-page>
                              <sb:last-page>772</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0570">S. Diab, A.M. Abdelaziz, P. Li, T. Teo, S.K.C. Basnet, B. Noll, M.H. Rahaman, J. Lu, J. Hou, M. Yu, B.T. Le, H. Albrecht, R.W. Milne, S. Wang, Dual Inhibition of Mnk2 and FLT3 for potential treatment of acute myeloid leukaemia, Eur J Med Chem, 139 (2017) 762-772.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib111">
                     <ce:label>[111]</ce:label>
                     <sb:reference id="sref111">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Carmena</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.C.</ce:given-name>
                                 <ce:surname>Earnshaw</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cellular geography of aurora kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Rev. Mol. Cell Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>842</sb:first-page>
                              <sb:last-page>854</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0575">M. Carmena, W.C. Earnshaw, The cellular geography of aurora kinases, Nat Rev Mol Cell Biol, 4 (2003) 842-854.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib112">
                     <ce:label>[112]</ce:label>
                     <sb:reference id="sref112">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Roles of Aurora kinases in mitosis and tumorigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Res. : MCR</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>10</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0580">J. Fu, M. Bian, Q. Jiang, C. Zhang, Roles of Aurora kinases in mitosis and tumorigenesis, Molecular cancer research : MCR, 5 (2007) 1-10.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib113">
                     <ce:label>[113]</ce:label>
                     <sb:reference id="sref113">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Jeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Peng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Hsu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overexpression and amplification of Aurora-A in hepatocellular carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2065</sb:first-page>
                              <sb:last-page>2071</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0585">Y.M. Jeng, S.Y. Peng, C.Y. Lin, H.C. Hsu, Overexpression and amplification of Aurora-A in hepatocellular carcinoma, Clinical cancer research : an official journal of the American Association for Cancer Research, 10 (2004) 2065-2071.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib114">
                     <ce:label>[114]</ce:label>
                     <sb:reference id="sref114">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Vischioni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Oudejans</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Vos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Rodriguez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Giaccone</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2905</sb:first-page>
                              <sb:last-page>2913</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0590">B. Vischioni, J.J. Oudejans, W. Vos, J.A. Rodriguez, G. Giaccone, Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients, Molecular cancer therapeutics, 5 (2006) 2905-2913.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib115">
                     <ce:label>[115]</ce:label>
                     <sb:reference id="sref115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nadler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.L.</ce:given-name>
                                 <ce:surname>Camp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Schwartz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Rimm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.M.</ce:given-name>
                                 <ce:surname>Kluger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kluger</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin. Cancer Res. : Off. J. Am. Assoc. Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4455</sb:first-page>
                              <sb:last-page>4462</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0595">Y. Nadler, R.L. Camp, C. Schwartz, D.L. Rimm, H.M. Kluger, Y. Kluger, Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer, Clinical cancer research : an official journal of the American Association for Cancer Research, 14 (2008) 4455-4462.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib116">
                     <ce:label>[116]</ce:label>
                     <sb:reference id="sref116">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ikezoe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Nishioka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Tasaka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Taniguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Kuwayama</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Komatsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bandobashi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Togitani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.P.</ce:given-name>
                                 <ce:surname>Koeffler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Taguchi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1851</sb:first-page>
                              <sb:last-page>1857</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0600">T. Ikezoe, J. Yang, C. Nishioka, T. Tasaka, A. Taniguchi, Y. Kuwayama, N. Komatsu, K. Bandobashi, K. Togitani, H.P. Koeffler, H. Taguchi, A novel treatment strategy targeting Aurora kinases in acute myelogenous leukemia, Molecular cancer therapeutics, 6 (2007) 1851-1857.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib117">
                     <ce:label>[117]</ce:label>
                     <sb:reference id="sref117">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Dar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.W.</ce:given-name>
                                 <ce:surname>Goff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Majid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Berlin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>El-Rifai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Aurora kinase inhibitors--rising stars in cancer therapeutics?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer Ther.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>9</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>268</sb:first-page>
                              <sb:last-page>278</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0605">A.A. Dar, L.W. Goff, S. Majid, J. Berlin, W. El-Rifai, Aurora kinase inhibitors--rising stars in cancer therapeutics?, Molecular cancer therapeutics, 9 (2010) 268-278.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib118">
                     <ce:label>[118]</ce:label>
                     <sb:reference id="sref118">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Lowenberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Muus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Ossenkoppele</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Rousselot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Cahn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ifrah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Martinelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Amadori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Berman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Sonneveld</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Jongen-Lavrencic</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Rigaudeau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Stockman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Goudie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Faderl</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Jabbour</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Kantarjian</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>118</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6030</sb:first-page>
                              <sb:last-page>6036</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0610">B. Lowenberg, P. Muus, G. Ossenkoppele, P. Rousselot, J.Y. Cahn, N. Ifrah, G. Martinelli, S. Amadori, E. Berman, P. Sonneveld, M. Jongen-Lavrencic, S. Rigaudeau, P. Stockman, A. Goudie, S. Faderl, E. Jabbour, H. Kantarjian, Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia, Blood, 118 (2011) 6030-6036.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib119">
                     <ce:label>[119]</ce:label>
                     <sb:reference id="sref119">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Estey</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acute myeloid leukemia and myelodysplastic syndromes in older patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Clin. Oncol. : Off. J. Am. Soc. Clin. Oncol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1908</sb:first-page>
                              <sb:last-page>1915</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0615">E. Estey, Acute myeloid leukemia and myelodysplastic syndromes in older patients, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25 (2007) 1908-1915.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib120">
                     <ce:label>[120]</ce:label>
                     <sb:reference id="sref120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Crumpler</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Avery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faisal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kosmopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Brown</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.W.</ce:given-name>
                                 <ce:surname>Sheldrake</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Bush</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Henley</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Box</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Haven Brandon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bayliss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>55</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8721</sb:first-page>
                              <sb:last-page>8734</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0620">V. Bavetsias, S. Crumpler, C. Sun, S. Avery, B. Atrash, A. Faisal, A.S. Moore, M. Kosmopoulou, N. Brown, P.W. Sheldrake, K. Bush, A. Henley, G. Box, M. Valenti, A. de Haven Brandon, F.I. Raynaud, P. Workman, S.A. Eccles, R. Bayliss, S. Linardopoulos, J. Blagg, Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia, Journal of medicinal chemistry, 55 (2012) 8721-8734.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib121">
                     <ce:label>[121]</ce:label>
                     <sb:reference id="sref121">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Jagtap</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.T.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.B.</ce:given-name>
                                 <ce:surname>Kondekar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.J.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.W.</ce:given-name>
                                 <ce:surname>Tseng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Chern</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur. J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>85</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>268</sb:first-page>
                              <sb:last-page>288</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0625">A.D. Jagtap, P.T. Chang, J.R. Liu, H.C. Wang, N.B. Kondekar, L.J. Shen, H.W. Tseng, G.S. Chen, J.W. Chern, Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia, Eur J Med Chem, 85 (2014) 268-288.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib122">
                     <ce:label>[122]</ce:label>
                     <sb:reference id="sref122">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.G.</ce:given-name>
                                 <ce:surname>Anderson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.A.</ce:given-name>
                                 <ce:surname>Tucker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Shen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.B.</ce:given-name>
                                 <ce:surname>Glaser</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.J.</ce:given-name>
                                 <ce:surname>Shah</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>16</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>498</sb:first-page>
                              <sb:last-page>511</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0630">J. Li, M.G. Anderson, L.A. Tucker, Y. Shen, K.B. Glaser, O.J. Shah, Inhibition of Aurora B kinase sensitizes a subset of human glioma cells to TRAIL concomitant with induction of TRAIL-R2, Cell death and differentiation, 16 (2009) 498-511.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib123">
                     <ce:label>[123]</ce:label>
                     <sb:reference id="sref123">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Ottone</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Zaza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Divona</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Hasan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Lavorgna</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Laterza</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Cicconi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Panetta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Di Giandomenico</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Cittadini</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ciardi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Montefusco</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Franchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Annino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Venditti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Amadori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Lo-Coco</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Br. J. Haematol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>161</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>533</sb:first-page>
                              <sb:last-page>540</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0635">T. Ottone, S. Zaza, M. Divona, S.K. Hasan, S. Lavorgna, S. Laterza, L. Cicconi, P. Panetta, J. Di Giandomenico, M. Cittadini, C. Ciardi, E. Montefusco, A. Franchi, L. Annino, A. Venditti, S. Amadori, F. Lo-Coco, Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin, British journal of haematology, 161 (2013) 533-540.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib124">
                     <ce:label>[124]</ce:label>
                     <sb:reference id="sref124">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.S.</ce:given-name>
                                 <ce:surname>Moore</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faisal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Gonzalez de Castro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Haven Brandon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Avery</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Mair</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Mirabella</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Swansbury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.D.</ce:given-name>
                                 <ce:surname>Pearson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1462</sb:first-page>
                              <sb:last-page>1470</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0640">A.S. Moore, A. Faisal, D. Gonzalez de Castro, V. Bavetsias, C. Sun, B. Atrash, M. Valenti, A. de Haven Brandon, S. Avery, D. Mair, F. Mirabella, J. Swansbury, A.D. Pearson, P. Workman, J. Blagg, F.I. Raynaud, S.A. Eccles, S. Linardopoulos, Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns, Leukemia, 26 (2012) 1462-1470.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib125">
                     <ce:label>[125]</ce:label>
                     <sb:reference id="sref125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Bavetsias</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Large</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Bouloc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Kosmopoulou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Matteucci</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.E.</ce:given-name>
                                 <ce:surname>Wilsher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Martins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Reynisson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Atrash</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Faisal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Urban</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Valenti</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>de Haven Brandon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Box</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.I.</ce:given-name>
                                 <ce:surname>Raynaud</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Workman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.A.</ce:given-name>
                                 <ce:surname>Eccles</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bayliss</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Blagg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Linardopoulos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>McDonald</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>53</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5213</sb:first-page>
                              <sb:last-page>5228</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0645">V. Bavetsias, J.M. Large, C. Sun, N. Bouloc, M. Kosmopoulou, M. Matteucci, N.E. Wilsher, V. Martins, J. Reynisson, B. Atrash, A. Faisal, F. Urban, M. Valenti, A. de Haven Brandon, G. Box, F.I. Raynaud, P. Workman, S.A. Eccles, R. Bayliss, J. Blagg, S. Linardopoulos, E. McDonald, Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate, Journal of medicinal chemistry, 53 (2010) 5213-5228.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib126">
                     <ce:label>[126]</ce:label>
                     <sb:reference id="sref126">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Matsumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kito</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ueda</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J. Biol. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>275</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>21525</sb:first-page>
                              <sb:last-page>21531</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0650">Y. Abe, S. Matsumoto, K. Kito, N. Ueda, Cloning and expression of a novel MAPKK-like protein kinase, lymphokine-activated killer T-cell-originated protein kinase, specifically expressed in the testis and activated lymphoid cells, The Journal of biological chemistry, 275 (2000) 21525-21531.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib127">
                     <ce:label>[127]</ce:label>
                     <sb:reference id="sref127">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.W.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Khosravi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Minden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.Z.</ce:given-name>
                                 <ce:surname>Penn</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>64</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6461</sb:first-page>
                              <sb:last-page>6468</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0655">J. Wu, W.W. Wong, F. Khosravi, M.D. Minden, L.Z. Penn, Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis, Cancer research, 64 (2004) 6461-6468.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib128">
                     <ce:label>[128]</ce:label>
                     <sb:reference id="sref128">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Ayllon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>O'Connor</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>3451</sb:first-page>
                              <sb:last-page>3461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0660">V. Ayllon, R. O'Connor, PBK/TOPK promotes tumour cell proliferation through p38 MAPK activity and regulation of the DNA damage response, Oncogene, 26 (2007) 3451-3461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib129">
                     <ce:label>[129]</ce:label>
                     <sb:reference id="sref129">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Nishidate</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Katagiri</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Res.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>66</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9186</sb:first-page>
                              <sb:last-page>9195</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0665">J.H. Park, M.L. Lin, T. Nishidate, Y. Nakamura, T. Katagiri, PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer, Cancer research, 66 (2006) 9186-9195.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib130">
                     <ce:label>[130]</ce:label>
                     <sb:reference id="sref130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Brown-Clay</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.N.</ce:given-name>
                                 <ce:surname>Shenoy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Timofeeva</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.V.</ce:given-name>
                                 <ce:surname>Kallakury</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.K.</ce:given-name>
                                 <ce:surname>Nandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.P.</ce:given-name>
                                 <ce:surname>Banerjee</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15594</sb:first-page>
                              <sb:last-page>15609</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0670">J.D. Brown-Clay, D.N. Shenoy, O. Timofeeva, B.V. Kallakury, A.K. Nandi, P.P. Banerjee, PBK/TOPK enhances aggressive phenotype in prostate cancer via beta-catenin-TCF/LEF-mediated matrix metalloproteinases production and invasion, Oncotarget, 6 (2015) 15594-15609.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib131">
                     <ce:label>[131]</ce:label>
                     <sb:reference id="sref131">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Joel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.A.</ce:given-name>
                                 <ce:surname>Mughal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Grieg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Murrell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Palmero</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Mikkelsen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Fjerdingstad</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Sandberg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Behnan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Glover</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.A.</ce:given-name>
                                 <ce:surname>Langmoen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Stangeland</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>14</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>121</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0675">M. Joel, A.A. Mughal, Z. Grieg, W. Murrell, S. Palmero, B. Mikkelsen, H.B. Fjerdingstad, C.J. Sandberg, J. Behnan, J.C. Glover, I.A. Langmoen, B. Stangeland, Targeting PBK/TOPK decreases growth and survival of glioma initiating cells in vitro and attenuates tumor growth in vivo, Molecular cancer, 14 (2015) 121.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib132">
                     <ce:label>[132]</ce:label>
                     <sb:reference id="sref132">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.A.</ce:given-name>
                                 <ce:surname>Zykova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.S.</ce:given-name>
                                 <ce:surname>Kang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Ebeling</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Abe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.Y.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Bode</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Gastroenterology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>133</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>219</sb:first-page>
                              <sb:last-page>231</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0680">F. Zhu, T.A. Zykova, B.S. Kang, Z. Wang, M.C. Ebeling, Y. Abe, W.Y. Ma, A.M. Bode, Z. Dong, Bidirectional signals transduced by TOPK-ERK interaction increase tumorigenesis of HCT116 colorectal cancer cells, Gastroenterology, 133 (2007) 219-231.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib133">
                     <ce:label>[133]</ce:label>
                     <sb:reference id="sref133">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Aksamitiene</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.N.</ce:given-name>
                                 <ce:surname>Kholodenko</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Kolch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Hoek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Kiyatkin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell. Signal.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1369</sb:first-page>
                              <sb:last-page>1378</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0685">E. Aksamitiene, B.N. Kholodenko, W. Kolch, J.B. Hoek, A. Kiyatkin, PI3K/Akt-sensitive MEK-independent compensatory circuit of ERK activation in ER-positive PI3K-mutant T47D breast cancer cells, Cellular signalling, 22 (2010) 1369-1378.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib134">
                     <ce:label>[134]</ce:label>
                     <sb:reference id="sref134">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Nandi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Tidwell</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Karp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Rapoport</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells, Blood cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol. Dis.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>240</sb:first-page>
                              <sb:last-page>245</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0690">A. Nandi, M. Tidwell, J. Karp, A.P. Rapoport, Protein expression of PDZ-binding kinase is up-regulated in hematologic malignancies and strongly down-regulated during terminal differentiation of HL-60 leukemic cells, Blood cells, molecules & diseases, 32 (2004) 240-245.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib135">
                     <ce:label>[135]</ce:label>
                     <sb:reference id="sref135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Alachkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mutonga</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Malnassy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Fulton</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Woods</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Meng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kline</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Raca</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Odenike</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Takamatsu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Miyamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Matsuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Stock</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncotarget</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>33410</sb:first-page>
                              <sb:last-page>33425</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0695">H. Alachkar, M. Mutonga, G. Malnassy, J.H. Park, N. Fulton, A. Woods, L. Meng, J. Kline, G. Raca, O. Odenike, N. Takamatsu, T. Miyamoto, Y. Matsuo, W. Stock, Y. Nakamura, T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia, Oncotarget, 6 (2015) 33410-33425.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib136">
                     <ce:label>[136]</ce:label>
                     <sb:reference id="sref136">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Matsuo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.H.</ce:given-name>
                                 <ce:surname>Park</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Miyamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hisada</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Alachkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Nakamura</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci. Transl. Med.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                        </sb:host>
                        <sb:comment>259ra145</sb:comment>
                     </sb:reference>
                     <ce:source-text id="srct0700">Y. Matsuo, J.H. Park, T. Miyamoto, S. Yamamoto, S. Hisada, H. Alachkar, Y. Nakamura, TOPK inhibitor induces complete tumor regression in xenograft models of human cancer through inhibition of cytokinesis, Science translational medicine, 6 (2014) 259ra145.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib137">
                     <ce:label>[137]</ce:label>
                     <sb:reference id="sref137">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dayal</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Opoku-Temeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.E.</ce:given-name>
                                 <ce:surname>Hernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Sooreshjani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.A.</ce:given-name>
                                 <ce:surname>Carter-Cooper</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.G.</ce:given-name>
                                 <ce:surname>Lapidus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.O.</ce:given-name>
                                 <ce:surname>Sintim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Future Med. Chem.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>823</sb:first-page>
                              <sb:last-page>835</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0705">N. Dayal, C. Opoku-Temeng, D.E. Hernandez, M.A. Sooreshjani, B.A. Carter-Cooper, R.G. Lapidus, H.O. Sintim, Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines, Future medicinal chemistry, 10 (2018) 823-835.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib138">
                     <ce:label>[138]</ce:label>
                     <sb:reference id="sref138">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Karin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.M.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The IKK NF-kappa B system: a treasure trove for drug development, Nature reviews</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Drug Discov.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>17</sb:first-page>
                              <sb:last-page>26</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0710">M. Karin, Y. Yamamoto, Q.M. Wang, The IKK NF-kappa B system: a treasure trove for drug development, Nature reviews. Drug discovery, 3 (2004) 17-26.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib139">
                     <ce:label>[139]</ce:label>
                     <sb:reference id="sref139">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Hayden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Signaling to NF-kappaB</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2195</sb:first-page>
                              <sb:last-page>2224</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0715">M.S. Hayden, S. Ghosh, Signaling to NF-kappaB, Genes & development, 18 (2004) 2195-2224.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib140">
                     <ce:label>[140]</ce:label>
                     <sb:reference id="sref140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.A.</ce:given-name>
                                 <ce:surname>Schmid</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Birbach</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cytokine Growth Factor Rev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>157</sb:first-page>
                              <sb:last-page>165</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0720">J.A. Schmid, A. Birbach, IkappaB kinase beta (IKKbeta/IKK2/IKBKB)--a key molecule in signaling to the transcription factor NF-kappaB, Cytokine & growth factor reviews, 19 (2008) 157-165.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib141">
                     <ce:label>[141]</ce:label>
                     <sb:reference id="sref141">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Mettang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.N.</ce:given-name>
                                 <ce:surname>Reichel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Lattke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Palmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Abaei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Rasche</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Huber-Lang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Baumann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wirth</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IKK2/NF-kappaB signaling protects neurons after traumatic brain injury</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>FASEB J. : Off. Publ. Fed. Am. Soc. Exp. Biol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1916</sb:first-page>
                              <sb:last-page>1932</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0725">M. Mettang, S.N. Reichel, M. Lattke, A. Palmer, A. Abaei, V. Rasche, M. Huber-Lang, B. Baumann, T. Wirth, IKK2/NF-kappaB signaling protects neurons after traumatic brain injury, FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 32 (2018) 1916-1932.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib142">
                     <ce:label>[142]</ce:label>
                     <sb:reference id="sref142">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Hayden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NF-kappaB, the first quarter-century: remarkable progress and outstanding questions</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>203</sb:first-page>
                              <sb:last-page>234</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0730">M.S. Hayden, S. Ghosh, NF-kappaB, the first quarter-century: remarkable progress and outstanding questions, Genes & development, 26 (2012) 203-234.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib143">
                     <ce:label>[143]</ce:label>
                     <sb:reference id="sref143">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Oeckinghaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.S.</ce:given-name>
                                 <ce:surname>Hayden</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Ghosh</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crosstalk in NF-kappaB signaling pathways</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat. Immunol.</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>695</sb:first-page>
                              <sb:last-page>708</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0735">A. Oeckinghaus, M.S. Hayden, S. Ghosh, Crosstalk in NF-kappaB signaling pathways, Nature immunology, 12 (2011) 695-708.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib144">
                     <ce:label>[144]</ce:label>
                     <sb:reference id="sref144">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.U.</ce:given-name>
                                 <ce:surname>Birkenkamp</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Geugien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Schepers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Westra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Lemmink</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Vellenga</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>103</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0740">K.U. Birkenkamp, M. Geugien, H. Schepers, J. Westra, H.H. Lemmink, E. Vellenga, Constitutive NF-kappaB DNA-binding activity in AML is frequently mediated by a Ras/PI3-K/PKB-dependent pathway, Leukemia, 18 (2004) 103-112.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib145">
                     <ce:label>[145]</ce:label>
                     <sb:reference id="sref145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.L.</ce:given-name>
                                 <ce:surname>Guzman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Neering</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Upchurch</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Grimes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.S.</ce:given-name>
                                 <ce:surname>Howard</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Rizzieri</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Luger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.T.</ce:given-name>
                                 <ce:surname>Jordan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Blood</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>98</sb:volume-nr>
                              </sb:series>
                              <sb:date>2001</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2301</sb:first-page>
                              <sb:last-page>2307</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0745">M.L. Guzman, S.J. Neering, D. Upchurch, B. Grimes, D.S. Howard, D.A. Rizzieri, S.M. Luger, C.T. Jordan, Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells, Blood, 98 (2001) 2301-2307.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib146">
                     <ce:label>[146]</ce:label>
                     <sb:reference id="sref146">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Griessinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Imbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Lagadec</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Gonthier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dubreuil</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Romanelli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dreano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Peyron</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2007</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>877</sb:first-page>
                              <sb:last-page>885</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0750">E. Griessinger, V. Imbert, P. Lagadec, N. Gonthier, P. Dubreuil, A. Romanelli, M. Dreano, J.F. Peyron, AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells, Leukemia, 21 (2007) 877-885.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib147">
                     <ce:label>[147]</ce:label>
                     <sb:reference id="sref147">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Frelin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Imbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Griessinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Loubat</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dreano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Peyron</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>8187</sb:first-page>
                              <sb:last-page>8194</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0755">C. Frelin, V. Imbert, E. Griessinger, A. Loubat, M. Dreano, J.F. Peyron, AS602868, a pharmacological inhibitor of IKK2, reveals the apoptotic potential of TNF-alpha in Jurkat leukemic cells, Oncogene, 22 (2003) 8187-8194.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib148">
                     <ce:label>[148]</ce:label>
                     <sb:reference id="sref148">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.H.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.P.</ce:given-name>
                                 <ce:surname>Parks</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Oncogene</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2000</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4936</sb:first-page>
                              <sb:last-page>4940</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0760">Q. Cheng, H.H. Lee, Y. Li, T.P. Parks, G. Cheng, Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition, Oncogene, 19 (2000) 4936-4940.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="bib149">
                     <ce:label>[149]</ce:label>
                     <sb:reference id="sref149">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Griessinger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Frelin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Cuburu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Imbert</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Dageville</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hummelsberger</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Sirvent</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Dreano</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Peyron</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1466</sb:first-page>
                              <sb:last-page>1469</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="srct0765">E. Griessinger, C. Frelin, N. Cuburu, V. Imbert, C. Dageville, M. Hummelsberger, N. Sirvent, M. Dreano, J.F. Peyron, Preclinical targeting of NF-kappaB and FLT3 pathways in AML cells, Leukemia, 22 (2008) 1466-1469.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>